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Summary 
A genome-wide, single-cell analysis of vascular smooth muscle cell plasticity            Lina Dobnikar 
Vascular smooth muscle cells (VSMCs) possess a remarkable capacity to change phenotype in 
response to injury or inflammation. In healthy arteries, VSMCs exist in a contractile state, but 
upon vascular inflammation or injury, they can switch into an activated state, in which they 
downregulate the contractile differentiation markers and show increased migration, 
proliferation and secretion of proinflammatory cytokines. This process is termed phenotypic 
switching and can lead to VSMC accumulation within atherosclerotic plaques. Previous 
observations of clonal expansion of a small number of VSMCs in atherosclerosis suggested 
that VSMCs were functionally heterogeneous. I hypothesised that functional heterogeneity of 
VSMCs in disease may originate from VSMC heterogeneity in healthy arteries. 
In the first part of this thesis I explored the regional heterogeneity of VSMCs originating from 
different parts of the mouse aorta, as well as heterogeneity of VSMCs within a vascular bed 
using single-cell and bulk RNA sequencing. VSMCs originating from the atherosclerosis-prone 
aortic arch and atherosclerosis-resistant descending thoracic aorta were found to have 
distinct transcriptional signatures at the single-cell level. Additionally, several disease-relevant 
genes were observed to be heterogeneously expressed within both vascular beds.  
In the second chapter I identified and characterised a rare subset of VSMCs expressing Stem 
cell antigen 1 (SCA1). Single-cell RNA-seq was combined with VSMC-specific lineage tracing to 
profile gene expression in individual VSMCs from healthy mouse arteries and to compare 
SCA1-expressing VSMCs to other cells. SCA1-positive VSMCs were heterogeneous, with many 
of them expressing low levels of contractile VSMC markers. Additionally, a subset of SCA1-
positive VSMCs in healthy arteries expressed transcriptional signatures characteristic of 
activated VSMCs involved in phenotypic switching.  
In the third chapter I investigated the involvement of SCA1-positive VSMCs in phenotypic 
switching. SCA1 upregulation was found to mark the process of VSMC phenotypic switching 
following in vitro culture and in vivo vascular injury. Single-cell RNA-seq profiling of VSMCs in 
atherosclerosis and following vascular injury showed that Ly6a/Sca1-expressing VSMCs were 
present and expressed transcriptional signatures similar to activated SCA1-positive cells 
observed in healthy arteries.  
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Overall the results presented in this thesis highlight the heterogeneous nature of VSMCs in 
healthy arteries, both regionally and within a vascular bed. I identified a rare subset of SCA1-
positive VSMCs with activated transcriptional signatures in healthy arteries. I hypothesised 
that SCA1-positive VSMCs may be responsible for clonal expansion of VSMCs in 
atherosclerosis, which would have clinical implications for earlier detection and specific 
targeting of expanding VSMCs in atherosclerosis in the future. In support of this hypothesis I 
have shown that Ly6a/Sca1 is upregulated in model systems of VSMC phenotypic switching 
and that transcriptional signatures of Ly6a/Sca1-expressing VSMCs in mouse atherosclerosis 
and vascular injury resemble those of healthy activated SCA1-positive VSMCs.  
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1 Introduction 
1.1 The cardiovascular system 
Single-cell organisms uptake oxygen and nutrients and excrete waste products through 
diffusion. As the organisms get larger and more complex, their volume to surface area ratio 
increases and diffusion across the outer surface of the organism becomes too inefficient to 
supply the entire organism with the required nutrients (Monahan-Earley et al. 2013). To 
overcome this problem, complex organisms evolved a circulatory system (Monahan-Earley et 
al. 2013).  
 
In mammals, the cardiovascular system consists of the heart, the blood vessels and the blood. 
The latter acts as a carrier of oxygen, nutrients and waste products and is pumped through 
the blood vessels by the heart. The mammalian cardiovascular system is composed of two 
closed circuits; the pulmonary circuit and the systemic circuit. The role of the pulmonary 
circuit is to re-oxygenate the blood, which has returned from the systemic circuit. The right 
atrium of the heart receives the de-oxygenated blood, which is then pumped to the lungs 
through the pulmonary artery by the right ventricle. The large surface area of the lungs 
enables efficient diffusion of fresh oxygen and waste carbon dioxide between the air and the 
blood. Oxygenated blood returns to the heart through the left atrium and the left ventricle of 
the heart then pumps the freshly oxygenated blood into the systemic circuit. The blood is first 
pumped into the aorta, which branches into progressively narrower arteries and to the 
arterioles. These lead into the capillaries, where the exchange of nutrients, oxygen and waste 
takes place through diffusion. The deoxygenated blood then passes into the venules and 
returns to the right atrium of the heart through the veins (Aaronson et al. 2012).  
 
Overall, the cardiovascular system vastly increases the effective surface area through which 
the diffusion can take place and allows cells throughout the body of complex organisms to 
have a supply of oxygen. Interestingly, the largest blood vessels in human themselves have a 
network of smaller blood vessels within their walls called vasa vasorum. These supply the cells 
within the blood vessel wall with blood as the wall is too thick for sufficient diffusion to take 
place through the lumen (Williams & Heistad 1996).  
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1.2 Artery wall structure 
The large arteries need a strong and elastic wall in order to withstand and regulate the blood 
pressure. The artery wall consists of the intimal, medial and adventitial layers, which surround 
the lumen (Aaronson et al. 2012). The structure of the artery wall is shown in Figure 1.1. The 
intimal layer is the innermost layer of the artery wall. Its inner lining is formed of a single 
continuous layer of endothelial cells, which are supported by a subendothelial layer of 
connective tissue (Palotie et al. 1983). In the larger human arteries, the intimal layer also 
contains VSMCs (Aaronson et al. 2012). Endothelial cells act as a barrier between the blood 
and the rest of the artery wall and regulate the selective transport of molecules into the wall 
(Galley & Webster 2004). In addition, endothelial cells are involved in the regulation of 
vascular tone through production of vasoconstrictors and vasodilators, such as nitric oxide 
(Ignarro et al. 1987; Galley & Webster 2004). Overall, endothelial cells are involved in tissue 
homeostasis and respond to the local environment, such as shear stress induced by blood flow 
(Rajendran et al. 2013). Endothelial dysfunction contributes to many cardiovascular diseases, 
including atherosclerosis (Gimbrone & García-Cardeña 2016). 
 
The medial layer of the aorta is composed of vascular smooth muscle cells (VSMCs) and 
extracellular matrix components and is separated from the intimal layer by the internal elastic 
lamina (Aaronson et al. 2012). Within the medial layer, VSMCs are arranged circumferentially 
in concentric layers around the lumen that are separated by the extracellular matrix (Wolinsky 
& Glagov 1967; Dingemans et al. 2000). The extracellular matrix is an ordered structure 
composed largely of elastin, collagens and proteoglycans and provides strength and flexibility 
to the medial layer (Stegemann et al. 2005). VSMCs are linked to the surrounding extracellular 
matrix via adhesion receptors, such as integrins, syndecans and dystroglycan (Moiseeva 2001). 
In addition to providing structural integrity, the interaction of VSMCs with the surrounding 
extracellular matrix plays a role in maintaining VSMC contractility through mechanical 
interactions (Moiseeva 2001; Stegemann et al. 2005).  
The adventitial layer is the outermost layer of the artery wall and is separated from the medial 
layer by the external elastic lamina (Aaronson et al. 2012). Adventitia is the most 
heterogeneous layer of the vasculature and contains a diverse range of cell types and 
structures, such as fibroblasts, resident immune cells, progenitor cells, nerves as well as vasa 
vasorum in certain large vessels (Stenmark et al. 2013). Given the presence of nerves and the 
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vasa vasorum, the adventitial layer has an important function in transducing signals and 
nutrients to the inner layers of the artery wall (Stenmark et al. 2013). Adventitia has been 
observed to remodel extensively in response to injury or inflammation and is additionally 
thought to be involved in the process of vascular inflammation through resident immune cells, 
such as macrophages and dendritic cells (Maiellaro & Taylor 2007). Adventitia has also been 
identified as a niche for vascular stem cells and progenitor in recent years, which will be 
discussed in more detail in Section 1.7. 
 
 
 
 
Figure 1.1: Artery wall structure.  
Large arteries are composed of concentric intimal, medial and adventitial layers. A layer of endothelial 
cells in the intima surrounds the lumen of the artery and forms direct contact with the blood. The 
intimal layer of large arteries in some organisms also contain VSMCs. The medial layer is separated 
from the intima by the internal elastic lamina and is composed of layers of VSMCs and the extracellular 
matrix. This layer provides structural support to the blood vessel wall. The outermost layer is the 
adventitia, which contains a variety of cells and structures, such as fibroblasts and resident immune 
cells, as well as nerves and vasa vasorum. The figure is from Libby et al. (2011) 
 
1.3 Vascular smooth muscle cells (VSMCs) 
VSMCs are highly specialised cells, which play a key role in the regulation of blood flow and 
pressure through contraction (Owens et al. 2004). In healthy arteries, VSMCs generally exist 
in a so-called contractile state, in which they exhibit an elongated cell shape and contain an 
abundance of contractile filaments (Rensen et al. 2007). In this state, VSMCs express several 
characteristic marker proteins including smooth-muscle myosin heavy chain (MYH11/SM-
MHC), α-smooth muscle actin (ACTA2/α-SMA) and transgelin (TAGLN/SM22α), with MYH11 
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being the most specific VSMC marker throughout development (Miano et al. 1994; Rensen et 
al. 2007). Contractile VSMCs show low levels of proliferation and synthesis of extracellular 
matrix components (Owens 1995). 
 
The remarkable feature of VSMCs is their high degree of plasticity. Upon inflammation or 
injury, contractile VSMCs can transition to a so-called synthetic state during the process 
known as phenotypic switching or modulation (Figure 1.2). As VSMCs transition towards the 
synthetic state, they adopt a more rounded cell shape and show reduced contractile function 
and reduced expression of several VSMC markers proteins (Rensen et al. 2007). Synthetic 
VSMCs show higher levels of proliferation and migration than cells in the contractile state and 
increase the synthesis of extracellular matrix components, such as collagen, proteoglycans 
and elastin (Rensen et al. 2007). Phenotypically modulated VSMCs have been observed to 
express characteristic proteins, such as osteopontin (SPP1/OSTP), vascular cell adhesion 
molecule 1 (VCAM1), matrix Gla protein (MGP), collagen α-1(VIII) chain (COL8A1) and others 
(Rensen et al. 2007; Orr et al. 2010; Allahverdian et al. 2018). VSMC plasticity allows for 
dynamic blood vessel remodelling and injury repair. However it also poses a potential risk of 
misregulation, which may lead to cardiovascular disease (Bennett et al. 2016). 
 
 
 
 
Figure 1.2: Phenotypic modulation of VSMCs.  
In healthy vasculature VSMCs predominantly exist in the contractile state, where they express VSMC 
marker proteins and contain contractile filaments. VSMCs are capable of transitioning to a synthetic 
state after the stimulus of injury or inflammation. In the synthetic state they increase proliferation and 
migration, and decrease VSMC marker protein expression. The figure is based on Davis-Dusenbery et 
al. (2011). 
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1.4 Vascular development and the origins of VSMCs 
The initial formation of the vascular system in the embryo occurs through the process of 
vasculogenesis. This process starts with the formation of blood islands in the extra-embryonic 
mesoderm of the yolk sac, which are lined by endothelial precursors (Ferguson et al. 2005). 
The endothelial precursors throughout the yolk sac subsequently merge to form the vascular 
plexus, which is the foundation for further development of the vascular system in the embryo 
(Coward & Wells 2013; Schmidt et al. 2007). This initial network is then extensively remodelled 
and extended through the process of angiogenesis during development (Ferguson et al. 2005). 
During vascular development, VSMC precursors are recruited to the forming vasculature and 
differentiated to provide structural support (Pfaltzgraff & Bader 2015). The recruitment 
process and the differentiation of VSMCs is mediated by many factors, including secretion of  
platelet-derived growth factor (PDGF)-BB by the endothelial cells (Hellstrom et al. 1999; 
Carmeliet 2000; Yao et al. 2014). PDGF-BB is also thought to be important for the patterning 
of the outer layers of the vascular wall (Greif et al. 2012). During development, VSMCs are 
involved in the maturation of the vascular system through the synthesis of extracellular matrix 
components, proliferation and migration (Owens et al. 2004). 
 
VSMCs recruited to different parts of the vasculature have different embryonic origins 
(Majesky 2007). This observation was first made in experiments using quail and chick chimeras 
(Le Lièvre & Le Douarin 1975; Majesky 2007). In these experiments the neural tube and neural 
crest from one of the organisms were grafted into the embryo of the other and the different 
nuclear staining patterns enabled the tracking of neural cells in the recipient organism. These 
experiments revealed that VSMCs located in parts of the vasculature had neural origins (Le 
Lièvre & Le Douarin 1975). Later lineage tracing studies have confirmed that VSMCs in the 
carotid arteries and the aortic arch are derived from the neural crest (Jiang et al. 2000; 
Nakamura et al. 2006). Jiang et al. (2000) and Nakamura et al. (2006) used a Wnt1-Cre and P0-
Cre dependent reporter systems respectively to trace cells originating from the neural crest in 
mammalian development and observed that VSMCs derived from the neural crest localise to 
the ascending aorta and the aortic arch, as well as the left and right carotid arteries in mature 
vasculature. Somites, which originate from the paraxial mesoderm, have also been shown to 
give rise to VSMCs during development (Pouget et al. 2006). VSMCs derived from the paraxial 
mesoderm have been observed in the aorta after transplantation of paraxial mesoderm to 
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create quail and chick chimeras (Pouget et al. 2006). Wasteson et al. (2008) observed that 
VSMCs can also be derived from somites in mouse embryos, and that somite-derived VSMCs 
localise to the descending thoracic aorta in the mature vasculature. Advances have also been 
made in the understanding of the embryonic origins of VSMCs in several other vascular beds. 
For example it was determined that aortic root VSMCs are derived from the secondary heart 
field and VSMCs located in the abdominal aorta are derived from splanchnic mesoderm 
(Majesky 2007). The embryonic origins of VSMCs located in different part of the vasculature 
are illustrated in Figure 1.3.  
 
 
 
 
Figure 1.3: Embryonic origins of VSMCs.  
VSMCs are recruited from a variety of embryonic sources. VSMCs in the aortic root (red) are derived 
from the secondary heart field, VSMCs in the aortic arch and the carotid arteries (medium blue) are 
derived from the neural crest, the pulmonary artery VSMCs (green) are from the pleural mesothelium, 
VSMCs in coronary arteries (dark blue) originate from the proepicardium, the descending thoracic 
aorta (brown) is composed of VSMCs originating from somites, VSMCs in the abdominal aorta (light 
blue) are derived from splanchnic mesoderm and the VSMCs in renal arteries (purple) originate from 
nephrogenic stromal cells. Figure adapted from Wang et al. (2015). 
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1.5 VSMC heterogeneity 
1.5.1 Regional heterogeneity of VSMCs 
There are regional differences in susceptibility to diseases, such as atherosclerosis, between 
different parts of the vasculature (Haimovici & Maier 1971; DeBakey & Glaeser 2000; Leroux-
Berger et al. 2011). These differences are thought to originate from both the distinct 
embryonic origins of VSMCs located in different parts of the vasculature (section 1.4) and the 
unique environmental factors that various blood vessels are exposed to (Cunningham & 
Gotlieb 2005; Majesky 2007). In particular, lineage tracing studies have revealed that VSMCs 
in the aortic arch (AA) are derived from the neural crest, while VSMCs in the descending 
thoracic aorta (DT) originate from the paraxial mesoderm (Majesky 2007). The AA region is 
known to be more prone to atherosclerosis than the DT region (Van Assche et al. 2011; 
Trigueros-Motos et al. 2013; Sinha et al. 2014). This is likely to be at least partially due to 
environmental factors, with the curvature of the aortic arch and several branch sites creating 
areas of disturbed blood flow (Cunningham & Gotlieb 2005; Chiu & Chien 2011). However, 
intrinsic factors are also thought to influence different atherosclerotic susceptibilities of 
arteries from different parts of the body. VSMCs derived from the neural crest or the 
mesoderm, which were isolated from chick embryos, were observed to respond differently to 
the same culture conditions, particularly to exposure to the transforming growth factor (TGF)-
β (Topouzis & Majesky 1996). Transcriptional differences between the neural crest and 
mesodermal VSMCs isolated from the AA and DT regions respectively were also observed, 
with a number of differentially expressed genes thought to be related to distinct 
developmental origins (Van Assche et al. 2011; Trigueros-Motos et al. 2013). For example, 
several Hox genes are expressed at higher levels in the DT region compared with the AA (Van 
Assche et al. 2011; Trigueros-Motos et al. 2013). Trigueros-Motos et al. (2013) observed an 
inhibitory relationship between HOXA9 and the proinflammatory transcription factor NF-κB 
(encoded by Nfkb1) in VSMCs, which has been previously also described in endothelial cells 
(Trivedi et al. 2007). Higher NF-κB activity in the AA region may provide a possible explanation 
for higher atherosclerosis susceptibility of the AA through increased inflammation (Trigueros-
Motos et al. 2013).  
 
To address the confounding enviromental factors affecting the AA and DT regions, Cheung et 
al. (2012) used in vitro differentiation to model VSMCs with neuroectodermal or mesodermal 
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origins. Several Hox genes, including Hoxa9, were found to be expressed at higher levels in 
mesodermal VSMCs compared with neuroectodermal VSMCs, both of which have been 
derived from human pluripotent stem cells in vitro (Cheung et al. 2012; Trigueros-Motos et al. 
2013). In further support of the hypothesis that intrinsic differences between vascular beds 
party contribute to observed variation in disease susceptibility, a study in which grafts were 
transplanted from the disease-prone abdominal aorta to the disease-resistant jugular vein 
region, showed that grafts from the abdominal aorta retained a higher susceptibility for 
atherosclerosis in a different environment (Haimovici & Maier 1971). However, the 
mechanisms through which the observed intrinsic differences contribute to disease 
susceptibility are not yet fully understood. 
 
1.5.2 VSMC heterogeneity within a vascular bed 
There is also heterogeneity among VSMCs residing in the same vascular bed, despite them 
experiencing similar environmental conditions and sharing the same embryonic origin. VSMCs 
within a vascular bed show considerable cell-to-cell variability in the expression levels of 
contractile VSMC proteins, as well as adhesion molecules (Frid et al. 1994; Moiseeva 2001). 
Studies in a variety of organisms have further suggested that there were subpopulations of 
VSMCs resident in the media, which are characterised by different patterns of VSMC 
contractile marker expression or different responses to in vitro culture (Bochaton-Piallat et al. 
1996; Frid et al. 1997; Li et al. 2001; Hao et al. 2002). These studies also observed that 
individual VSMCs had different propensities for phenotypic modulation, leading to speculation 
that VSMCs which adopt the extreme synthetic state in culture may be the VSMCs involved in 
neointima formation in disease (Bochaton-Piallat et al. 1996; Frid et al. 1997). These 
observations led to the hypothesis that VSMCs may exist on a spectrum between different 
phenotypic states (Rensen et al. 2007). 
 
1.5.3 Functional heterogeneity of VSMCs  
Benditt & Benditt (1973) observed that the entire plaque caps regularly showed inactivation 
of the same X chromosome, which was not observed to be the case in the underlying media. 
This observation led to the hypothesis that VSMCs in the plaque cap may have monoclonal 
origins (Benditt & Benditt 1973). However, a later study reported that larger patches of cells 
with the same inactivated X-chromosome can also exist in the media, which could explain the 
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previous observation without the implication of monoclonal origin of the plaque cap (Murry 
et al. 1997; Schwartz & Murry 1998). Recent advances in VSMC-specific lineage tracing 
approaches support the hypothesis that a small subset of VSMCs proliferate during plaque 
development, as well as during neointima formation following injury (Feil et al. 2014; Chappell 
et al. 2016; Jacobsen et al. 2017). Using a multi-colour lineage labelling strategy to study VSMC 
proliferation after injury in mice, Chappell et al. (2016) observed that the neointima induced 
by carotid ligation was composed of monochrome patches derived from a single VSMC. 
Furthermore, atherosclerotic plaques were observed to be composed of either single 
monochrome patches or a small number of monochrome patches, suggesting that only a 
fraction of VSMCs proliferated extensively during plaque formation (Chappell et al. 2016; 
Jacobsen et al. 2017). These observations suggest that VSMCs within a vascular bed may be 
functionally heterogeneous, with only a small subset of VSMCs responding to stimuli through 
extensive proliferation and accumulation in the lesion.  
 
1.6 VSMC response to stimulus 
In healthy arteries, VSMCs predominantly exist in the contractile state. As described in Section 
1.3, certain stimuli such as inflammation, mechanical injury, or biochemical factors, can induce 
VSMC phenotypic modulation. This process occurs, for example, during in vitro culture as well 
as in vivo following vascular injury or development of atherosclerosis (Rensen et al. 2007).  
 
1.6.1 Mechanisms of VSMC phenotypic switching 
The process of VSMC phenotypic switching is regulated through a complex network of factors, 
many of which are not yet fully understood. Environmental factors, such as the surrounding 
extracellular matrix (ECM) components, biochemical factors and mechanical forces play an 
important role in influencing the phenotypic modulation of VSMCs (Rensen et al. 2007). Some 
of these factors promote the maintenance of the differentiated contractile VSMC phenotype, 
while others stimulate phenotypic modulation towards the synthetic state. The effect of the 
majority of studied ECM components on VSMC phenotype is to promote the contractile state 
(Rensen et al. 2007). For example, the deletion of heparan-sulfate side chains from the 
proteoglycan perlecan lead to increased VSMC proliferation in vitro as well as after carotid 
ligation injury in vivo (Tran et al. 2004). Collagen type IV and laminin are also thought to 
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promote the contractile state and lead to increased expression of contractile VSMC marker 
proteins when applied to cultured VSMCs (Thyberg & Hultgårdh-Nilsson 1994). There are also 
ECM components, however, which have been shown to promote the synthetic phenotype. For 
example, fibronectin and hyaluronan have both been shown to induce VSMC proliferation 
(Hedin et al. 1988; Evanko et al. 1999). Biochemical factors also influence the phenotypic state 
of VSMCs, with the most extensively studied examples being PDGF-BB and TGF-β. These two 
growth factors have diverging effects, with PDFG-BB promoting VSMC proliferation, while 
TGF-β promotes the contractile state of VSMCs (Rensen et al. 2007). Some effects of 
mechanical forces on the VSMC state are mediated through the endothelium, such as shear 
stress (Zhao et al. 2015). Mechanical stress can also act on VSMCs directly when the vessel 
wall is stretched periodically due to blood pressure. Mechanical stress has generally been 
observed to promote the contractile phenotype, with reduced mechanical stress levels, such 
as during culture, promoting phenotypic modulation towards the synthetic state (Rensen et 
al. 2007). Another environmental factor affecting VSMC phenotypic switching is vascular 
inflammation. NF-κB is one of the key inflammatory regulators in the vasculature (Brasier 
2010), and a VSMC-specific inhibition of NF-κB has been shown to result in decreased 
neointima formation following injury (Yoshida et al. 2013). 
 
Advances have also been made in the understanding of how transcriptional and epigenetic 
regulation impacts the phenotypic state of VSMCs. Transcription factors myocardin, SRF and 
KLF4 have so far been identified as central to transcriptional regulation of VSMC modulation 
(Allahverdian et al. 2018). One of the most extensively characterised models of transcriptional 
regulation in VSMCs is the SRF/myocardin regulation through CArG elements. Myocardin is 
expressed specifically in cardiac and smooth muscle cells during development and has been 
described as the master regulator of VSMC contractile phenotype (Yoshida et al. 2003; Wang 
et al. 2003). It acts by forming a complex with transcription factor SRF and promotes the 
expression of contractile VSMC genes through CArG regulatory elements (Yoshida et al. 2003; 
Wang et al. 2003). In contrast, KLF4 has been observed to be key in the process of de-
differentiation of VSMCs during phenotypic switching (Yoshida et al. 2008; Shankman et al. 
2015). KLF4 is thought to influence de-differentiation of VSMCs through multiple mechanisms, 
including disruption of the SRF/myocardin complex association with contractile gene 
promoters, repression of myocardin expression and mediation of chromatin modification (Liu 
et al. 2005; McDonald et al. 2006). The epigenetic regulation of VSMC phenotypic modulation 
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has also been investigated in recent years. For example, it has been observed that induction 
of VSMC phenotypic switching through PDGF-BB in culture resulted in increased repressive 
methylation (H3K9me3) and reduced activating histone acetylation at contractile gene 
promoters, with recruitment of histone deacetylases mediated by KLF4 (McDonald et al. 2006; 
Yoshida et al. 2007; Gomez et al. 2015). Interestingly, studies of epigenetic regulation of VSMC 
modulation have identified H3K4me2 at the contractile gene promoters as a possible lineage 
mark of VSMCs, which is retained following phenotypic switching (Gomez et al. 2015). 
Additionally, microRNAs have also been implicated in the regulation of VSMC phenotypic 
switching, with both pro-contractile and pro-synthetic effects. microRNA from cluster 143/145 
promotes the contractile state (Cordes et al. 2009), whereas several other microRNAs have 
been observed to decrease VSMC differentiation and increase proliferation (Maegdefessel et 
al. 2015). 
 
1.6.2 VSMCs in culture 
In vitro culture is a commonly used model system for studying VSMC response to stimulus and 
subsequent phenotypic modulation. In vitro culture replicates some of the hallmarks of VSMC 
phenotypic switching, such as downregulation of contractile proteins, increased proliferation 
and a change in cell shape (Chamley-Campbell et al. 1979). It provides a practical way of 
mimicking and investigating the response of VSMC to stimuli, which are thought to influence 
their involvement in disease and vascular injury repair. Culture of VSMCs has provided 
numerous important insights into the biology of VSMC phenotypic modulation, several of 
which have also been verified in vivo (Rensen et al. 2007). However, in the absence of in vivo 
validation, findings from cultured VSMCs must be interpreted with caution, since culture 
conditions do not accurately represent the physiological conditions under which VSMCs are 
phenotypically modulated. For example, mechanical forces and ECM interactions occurring in 
intact arteries generally promote the contractile phenotype (discussed in the previous section, 
Rensen et al. 2007), therefore the process of phenotypic modulation in vivo is likely influenced 
by a complex set of opposing factors, some of which promote the contractile and some the 
synthetic state.  
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1.6.3 VSMCs in atherosclerosis 
Atherosclerosis is an inflammatory disease, in which a number of different cell types are 
involved, including endothelial cells, VSMCs and immune cells (Aaronson et al. 2012). During 
atherosclerosis, plaques form in the blood vessel wall, which protrude into the lumen and may 
obstruct blood flow when advanced (Figure 1.4). The rupture of an atherosclerotic plaque can 
lead to a heart attack or a stroke (Aaronson et al. 2012). The endothelial layer plays an 
important role in mediating early development of atherosclerosis. It is thought that high lipid 
levels and disturbed blood flow in areas of increased atherosclerosis susceptibility, such as 
artery branch points, trigger atherosclerosis-promoting changes in endothelial cells (Chiu & 
Chien 2011; Libby et al. 2011). This includes increased lipid and monocyte infiltration into the 
artery wall and secretion of PDGFs, which induces increased proliferation in the endothelium 
and VSMCs (Chiu & Chien 2011; Libby et al. 2011).  
 
Phenotypic switching and proliferation of VSMCs has long been thought to play an important 
part in the development of atherosclerotic plaques (Ross & Glomset 1973). VSMCs are known 
to be involved in different processes within the plaque, such as formation of the stabilising 
plaque cap, vascular calcification and accumulation within the necrotic core of the plaque 
(Bennett et al. 2016). However, the loss of VSMC contractile markers in many plaque VSMCs 
can make unambiguous identification and characterisation of VSMC-derived plaque cells 
difficult. To overcome this problem, VSMC-specific genetic lineage tracing approaches have 
been developed in animal models of atherosclerosis, which have shed light on the widespread 
presence and diversity of VSMCs within atherosclerotic lesions (Bennett et al. 2016). 
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Figure 1.4: Development of the atherosclerotic plaque.  
a) In the early stage of atherosclerosis circulating immune cells adhere to endothelial cells (green) and 
infiltrate into the blood vessel wall, alongside lipid deposits. b) VSMCs (red) migrate into the plaque 
where they form the fibrous cap. Plaque increases in size and protrudes into the lumen. c) Advanced 
atherosclerotic plaque have a lipid core and may rupture, which leads to thrombus formation. Figure 
from Libby et al. (2011) 
 
 
The most commonly used model organism for studying atherosclerosis is the mouse, despite 
wild-type mice being relatively resistant to the development of atherosclerosis (Getz & 
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Reardon 2012). However, genetic modification led to the establishment of the ApoE-/- (Plump 
et al. 1992; Zhang et al. 1992) and Ldlr-/- models (Ishibashi et al. 1993) of atherosclerosis. The 
ApoE-/- model has been shown to develop progressive lesions, which are more similar in 
development to human atherosclerotic plaques and is the most widely used mouse model of 
atherosclerosis (Nakashima et al. 1994; Getz & Reardon 2012). Apart from enabling the use of 
genetic modifications to study progression of the disease, mouse models have the advantage 
of faster plaque development. In human, atherosclerotic plaques typically develop over many 
years, whereas in the ApoE-/- model plaques develop within 8 weeks of high fat diet, with 
advance lesions present after 15 weeks (Nakashima et al. 1994). There are, however, 
important limitations to the use of mouse models for studying atherosclerosis, which need to 
be considered when extrapolating the findings to human disease. For example, there are some 
differences in artery wall structure, such as thinner medial layer in mouse arteries and the 
absence of intimal VSMC and vasa vasorum in the mouse (Getz & Reardon 2012). Additionally, 
there are differences in atherosclerotic plaque distribution in different areas of the 
vasculature in the ApoE-/- model and in human (Nakashima et al. 1994; Getz & Reardon 2012). 
Despite these limitations, mouse models of atherosclerosis have greatly contributed to the 
understanding of this disease and have enabled investigations, such as VSMC-specific lineage 
tracing, which would not have been possible in human.  
 
Studies using VSMC-specific lineage tracing in mice have suggested that 30-70% of cells within 
atherosclerotic plaques originate from VSMCs and that the majority of VSMC-derived cells lose 
VSMC marker proteins in the plaque (Gomez et al. 2013; Shankman et al. 2015; Chappell et al. 
2016). In addition, recent studies have revealed that some macrophage-like cells within the 
atherosclerotic plaque could be derived from VSMCs as VSMC lineage-labelled cells were 
observed to express macrophage markers, such as LGALS3 and CD68 (Feil et al. 2014; 
Shankman et al. 2015; Chappell et al. 2016; Jacobsen et al. 2017).  
 
On the whole, VSMCs within the plaque are thought to play both beneficial and harmful roles 
in the development of atherosclerotic plaques. For example, VSMCs in the fibrous cap 
synthesise extracellular matrix components and their proliferation in the event of initial 
plaque rupture can lead to repair and restoration of plaque stability (Bennett et al. 2016). 
Conversely, phenotypic switching of VSMCs to a macrophage-like state is thought to 
negatively contribute to the development of atherosclerosis (Shankman et al. 2015), as VSMC-
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derived macrophages have been observed to clear lipids and apoptotic cells less efficiently 
than bone-marrow derived macrophages (Vengrenyuk et al. 2015). 
 
The current view is that VSMCs can adopt multiple phenotypes within the atherosclerotic 
plaque, such as macrophage-like cells, fibroblast-like cells in the plaque cap, mesenchymal 
stem cell-like cells, as well as calcifying-like cells contributing to vascular calcification (Figure 
1.5, Naik et al. 2012; Nguyen et al. 2013; Feil et al. 2014; Shankman et al. 2015; Chappell et al. 
2016; Jacobsen et al. 2017). Observations of the clonal nature of VSMC-derived cells within 
the plaque and the wide range of phenotypes that VSMCs are thought to adopt in the plaque 
suggest that VSMCs involved in atherosclerosis have high levels of phenotypic plasticity and 
that a single VSMC can be phenotypically modulated and proliferate to form different 
subpopulations of VSMC-derived cells within the plaque (Chappell et al. 2016).  
 
 
 
 
Figure 1.5: Phenotypic modulation of VSMCs in atherosclerosis.  
Phenotypically modulated VSMCs migrate out of the media and proliferate during plaque 
development. VSMCs can undergo extensive phenotypic changes and transition to mesenchymal stem 
cell-like cells, macrophage-like cells, foam cells or osteochondrogenic-like cells involved in vascular 
calcification (not shown) among others. Figure from Bennett et al. (2016).  
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1.6.4 VSMCs in carotid ligation injury 
Carotid ligation is a vascular injury model, which provides an acute and reproducible 
environment for studying VSMC phenotypic switching (Kumar & Lindner 1997). During carotid 
ligation surgery, the left carotid artery is mechanically tied to stop blood flow. Cessation of 
blood flow then triggers endothelial dysfunction, which induces vascular remodelling and 
VSMC response (Kumar & Lindner 1997). Alternative vascular injury models also exist, for 
example the wire injury model, where the endothelial layer is surgically removed (Lindner et 
al. 1993). However, the extent of VSMC proliferation and participation in the neointima 
formation appears to be greater in the carotid ligation model (Kumar & Lindner 1997).  
 
The model of vascular injury provides an alternative setting for the investigation of VSMC 
plasticity to the atherosclerotic plaque. Studies have shown that VSMCs are extensively 
involved in the formation of neointima following carotid ligation injury and that neointimal 
VSMCs are derived from VSMC, which were in a differentiated state prior to injury (Herring et 
al. 2014; Chappell et al. 2016). Vascular injury models also provide a suitable setting for 
investigations of VSMC heterogeneity. Clonal or oligoclonal expansion of VSMCs (discussed in 
Section 1.5.3) is also observed following carotid ligation injury, which suggests that VSMCs are 
functionally heterogeneous in their response to injury (Chappell et al. 2016).  
 
1.7 Origins of phenotypically switched VSMCs 
The origin of VSMCs involved in the atherosclerotic plaque and neointima formation has been 
extensively debated in recent years. Several studies have asked whether VSMCs within lesions 
arise from previously differentiated VSMCs, from cells migrating from other vascular layers, 
or from alternative vascular progenitor populations. In support of the latter possibility, Sata 
et al. (2002) reported that the majority of VSMCs within the atherosclerotic plaque were 
derived from circulating hematopoietic stem cells derived from the bone marrow. However, 
a later report contradicted this observation and claimed that plaque VSMCs were derived 
exclusively from the local vasculature (Bentzon et al. 2006), although ACTA2 expression has 
since been observed in some bone-marrow-derived monocytes located in the neointima 
following wire injury (Iwata et al. 2010). Alternative origins of de-differentiated VSMCs from 
within the vasculature have also been proposed. VSMCs in the neointima of a pulmonary 
17 
 
hypertension model were proposed to originate from endothelial cells based on the 
observation that Tie2-Cre lineage traced cells upregulated ACTA2 and MYH11 (Qiao et al. 
2014). Hu et al. (2004) suggested that adventitial progenitors could give rise to VSMCs within 
atherosclerotic plaques. These adventitial progenitors expressed Stem cell antigen 1 (SCA1) 
and were observed to migrate to the plaque and express VSMC markers after isolated and 
labelled adventitial SCA1+ cells were transplanted into the adventitia (Hu et al. 2004). 
Furthermore, Passman et al. (2008) reported that SCA1, CD34 and PDGFRB expressing 
adventitial cells were capable of differentiation into VSMCs in vitro. In addition, Klein et al. 
reported vascular-wall resident stem cells expressing CD44, CD90 and CD73, but not CD34 and 
CD45 markers in the adventitial layer (Klein et al. 2011). These vascular-wall resident stem 
cells upregulated VSMC markers following culture with TGF-β and were observed to 
contribute to neovascularisation after being grafted with endothelial cells in vivo (Klein et al. 
2011). More recently, Kramann et al. (2016) used an inducible lineage tracing strategy to trace 
Gli1+ cells (adventitial location in healthy arteries) following vascular wire injury. Under these 
conditions, lineage labelled cells were observed to express VSMCs marker genes (Kramann et 
al. 2016). Given that Gli1+ cells also expressed Sca1, Cd34 and Pdgfrb, these cells may overlap 
with previously reported adventitial progenitor populations (Kramann et al. 2016; Passman et 
al. 2008; Hu et al. 2004).  
 
Vascular progenitor populations have also been proposed to exist in the medial layer. Sainz et 
al. (2006) reported a SCA1-positive subpopulation of medial cells, which were capable of 
differentiating into endothelial cells and VSMCs in vitro. Additionally, Tang et al. (2012) 
suggested that mature VSMCs do not contribute to neointima formation and that a resident 
progenitor population in the medial layer gives rise to phenotypically modulated VSMCs. 
However, the findings of Tang et al. have proven controversial and were questioned by experts 
in the field (Nguyen et al. 2013). Examples of raised concerns include the severity of the 
vascular injury model, which may have killed the medial VSMCs, and a lack of definitive lineage 
tracing approaches showing that the neointimal VSMCs originate from the proposed 
progenitor population (Nguyen et al. 2013). 
 
Recent studies using inducible lineage tracing strategies have suggested that cells expressing 
differentiated VSMC markers prior to injury or atherosclerosis give rise to neointimal VSMCs. 
Nemenoff et al. (2011) used a tamoxifen-inducible Myh11-Cre lineage tracing strategy and 
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observed that VSMCs, which expressed contractile VSMC markers and thus the lineage label 
prior to injury, contributed to neointima formation. Differentiated VSMCs have also been 
reported to contribute to atherosclerotic plaques using a similar inducible lineage tracing 
strategy (Gomez et al. 2013). In addition, Gomez et al. (2013) reported that the contribution 
of VSMCs to the atherosclerotic plaque has likely been underestimated previously, as several 
VSMC-derived cells no longer expressed VSMC markers. Further studies using inducible and 
VSMC-specific lineage tracing approaches have confirmed these observations (Feil et al. 2014; 
Shankman et al. 2015; Chappell et al. 2016; Jacobsen et al. 2017). 
A recent study, which investigated the origins of neointimal cells in vascular injury models of 
different severities, may provide a partial explanation for the contradicting observations 
about the origins of neointimal VSMCs reported in the literature (Roostalu et al. 2018). 
Roostalu et al. (2018) observed that VSMC-derived cells gave rise to the neointima in a limited 
wire injury model, but that adventitial cells contributed to repair following a more severe 
microanastomosis injury. Overall, there is strong evidence that cells of the VSMC lineage can 
expand to give rise to neointimal and plaque VSMCs. Further studies are required to 
determine whether the rare expanding VSMCs possess any special characteristics and to 
determine whether they are the sole contributor to lesional VSMCs, or whether multiple 
origins may contribute to the VSMC pool in disease simultaneously. 
 
1.8 Stem cell antigen 1 (SCA1): a marker of stem/progenitor populations 
expressed by a subset of vascular cells 
Stem cell antigen 1 (SCA1) is part of the Ly6 family and is a cell surface protein encoded by the 
gene Ly6a in mice (Holmes & Stanford 2007). SCA1 is used as a marker protein for the 
enrichment of hematopoietic stem cells (Spangrude et al. 1988) and is expressed in 
stem/progenitor populations in a wide range of tissues in the mouse (Holmes & Stanford 
2007). For example, the precursor cells in adult skin tissue express SCA1 (Fernandes et al. 
2004). Skin-derived precursor cells have been shown to be capable of in vitro differentiation 
into a variety of cell types, such as adipocytes and neural cells (Toma et al. 2001; Fernandes 
et al. 2004), vascular smooth muscle cells (Steinbach et al. 2011) and hepatocytes (Rodrigues 
et al. 2014). SCA1-positive progenitors have also been observed in the cardiovascular system, 
both in the vasculature (discussed in Section 1.7) and in the heart (Oh et al. 2003; Matsuura 
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et al. 2004). SCA1-positive cardiac progenitors were observed to have the capacity to 
differentiate into cardiomyocytes in vitro (Oh et al. 2003; Matsuura et al. 2004) and an 
increase in SCA1-positive cells was observed following myocardial infarction (Wang et al. 
2006). However, recent studies suggested that SCA1-positive cells do not contribute to 
cardiomyocytes in vivo and are instead part of the endothelial cell population (Vagnozzi et al. 
2018; Zhang et al. 2018).  
 
SCA1 has no known human orthologue and its function in mice is not yet fully understood 
(Holmes & Stanford 2007). However, the relevance of SCA1 extends beyond being a marker 
of stem/progenitor populations, as demonstrated by the alterations observed in SCA1 
knockout mice in several tissues (Holmes & Stanford 2007). For example, studies carried out 
in SCA1 knockout mice suggested an impact of this gene on haematopoiesis (Ito et al. 2003; 
Bradfute et al. 2005), T-cell proliferation (Stanford et al. 1997), osteoporosis (Bonyadi et al. 
2003), as well as on cardiac function (Bailey et al. 2012). At the molecular level, SCA1 is thought 
to be involved in cell signalling, however its mechanism of action is poorly understood (Holmes 
& Stanford 2007). Better understanding of SCA1 function in mice may aid in the identification 
of its human orthologue, which may help in translating findings observed in mice to human in 
the future (Holmes & Stanford 2007).  
 
1.9 Single-cell transcriptomics as a tool for studying cell heterogeneity and 
plasticity 
Single-cell transcriptomics enables genome-wide measurements of mRNAs at the single-cell 
level, and as such can offer several advantages over the conventional population-level RNA-
seq. For example, cell-to-cell heterogeneity at a global transcriptome-wide level can be 
addressed using single-cell RNA-seq (scRNA-seq) (Stegle et al. 2015). Transcriptome-wide 
analysis of cell-to-cell heterogeneity allows for the identification and characterisation of rare 
subpopulations of cells (Stegle et al. 2015), whereas such signals are typically lost in 
conventional RNA-seq analyses of heterogeneous cell populations. Single-cell analysis also 
allows for any contaminating cells to be identified and excluded from the analysis, while this 
is not possible in population-level approaches (Kaur et al. 2017).  
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1.9.1 Approaches for scRNA-seq library generation 
scRNA-seq was first developed by Tang et al. (2009) to enable transcriptome-wide profiling in 
applications where only low amounts of biological material were available. Since then, several 
protocols for scRNA-seq have been developed and used extensively to profile tissue 
heterogeneity, characterise cell differentiation and identify new subpopulations of cells 
(Stegle et al. 2015). Several challenges needed to be addressed during the development of 
experimental protocols for wider application of scRNA-seq to become possible. These 
included the development of efficient methods for capturing single cells, and increasing the 
sensitivity of protocols to handle low amounts of mRNA present in individual cells 
(Kolodziejczyk et al. 2015).  
 
The first step in scRNA-seq protocols is the capture of single cells (Figure 1.6). Several 
approaches for single-cell capture have been developed, each of which has certain advantages 
and disadvantages. Early studies used manual isolation of cells, which was low throughput but 
enabled the inspection of each captured cell to ensure viability and that only one cell was 
captured (Tang et al. 2009). To increase throughput, automated capture methods were also 
developed and used. For example, flow cytometry has been used to sort single cells into the 
wells of a plate, which additionally allows for the enrichment of desired populations of cells 
(Jaitin et al. 2014). However, subsequent library generation may be expensive due to relatively 
large volumes of reagents required in a 96-well plate format (Kolodziejczyk et al. 2015). Single 
cells can also be captured using microfluidic approaches. The commercial Fluidigm C1 platform 
captures single-cells on a microfluidics chip and enables subsequent processing to be carried 
out in small reaction volumes. The disadvantage of this method is that cells of different sizes 
cannot be captured on one chip (Kolodziejczyk et al. 2015), and that the number of captured 
cells per chip is limited. Droplet-based microfluidic approaches, which enable extremely high 
throughput of single-cell capture, have also been developed (Macosko et al. 2015; Klein et al. 
2015). Droplet-based approaches tend to be cost effective for large numbers of profiled cells 
due to a small reaction volume and the high number of cells captured per experiment 
(Macosko et al. 2015; Klein et al. 2015). However, both the chip-based and droplet-based 
microfluidic approaches have relatively low capture efficiencies, and may not be suitable 
when the amount of starting material is the limiting factor (Kolodziejczyk et al. 2015).  
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Once single cells are captured, they are lysed and their mRNA is reverse-transcribed to 
generate cDNA (Figure 1.6). In most protocols this is achieved by exploiting the fact that most 
cellular mRNAs have poly(A) tails and efficient reverse transcription is an important step for 
the overall sensitivity of the protocol (Kolodziejczyk et al. 2015). Due to the low amounts of 
mRNA present in single-cells, resulting cDNA needs to be amplified prior to generation of 
sequencing libraries (Tang et al. 2009). Possible approaches for cDNA amplification are either 
in vitro transcription or PCR (Figure 1.6), with each method presenting certain advantages and 
disadvantages. PCR is an exponential amplification approach where amplification efficiencies 
may vary depending on sequence, while in vitro transcription is a linear amplification method 
but an additional round of reverse transcription could introduce additional 3’ coverage biases 
(Kolodziejczyk et al. 2015). In vitro transcription is used in the CEL-seq (Hashimshony et al. 
2012), CEL-seq2 (Hashimshony et al. 2016), MARS-seq (Jaitin et al. 2014) and inDrop (Klein et 
al. 2015) protocols. PCR is also used in several protocols, including the original Tang et al. 
(2009) protocol, Smart-seq (Ramsköld et al. 2012) , Smart-seq2 (Picelli et al. 2013; Picelli et al. 
2014), STRT-seq (Islam et al. 2011), Drop-seq (Macosko et al. 2015) and the commercial 10X 
Genomics Chromium (Zheng et al. 2017) protocols. During PCR amplification, adapter 
sequences are incorporated into the cDNA to enable untargeted cDNA amplification (Tang et 
al. 2009). The first adapter is typically added during the reverse transcription to the poly(T) 
primer. The second adapter can be incorporated by different methods, for example through 
addition of a poly-A tail to the reverse-transcribed cDNA (Tang et al. 2009), or through 
template switching (Islam et al. 2011) (Figure 1.6). Template switching has the advantage of 
amplifying the full length of the transcript, therefore allowing the full transcript to be 
sequenced (Ramsköld et al. 2012; Picelli et al. 2013).  
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Figure 1.6: Experimental protocols for scRNA-seq.  
The first step in scRNA-seq protocols is single-cell capture. This can be achieved using several different 
methods, including manual isolation by micropipetting, FACS, or microfluidics approaches where cells 
are captured in droplets or on a chip. After cell lysis, cellular mRNA is reverse-transcribed. Poly(A) 
tailing or template switching approaches can be used to insert barcodes into the cDNA. Resulting cDNA 
is amplified using either PCR or in vitro transcription (IVT), after which libraries are prepared for 
sequencing. Figure adapted from Kolodziejczyk et al. (2015). 
 
 
An important part of scRNA-seq protocols, which has been crucial for increasing throughput 
and reducing the cost of scRNA-seq, is multiplexing (Svensson et al. 2018). Multiplexing 
enables libraries of many single cells to be sequenced together, and can reduce labour if 
introduced early in the protocol (Svensson et al. 2018). However, early introduction of 
multiplexing prevents the full length of the transcript from being sequenced. For the full 
transcript to be analysed, multiplexing needs to take place after cDNA amplification, as each 
fragment is required to contain the cellular barcode (Ramsköld et al. 2012). Examples of 
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protocols, which sequence the full-length transcript, are the Smart-seq (Ramsköld et al. 2012) 
and Smart-seq2 (Picelli et al. 2013; Picelli et al. 2014). The downside of multiplexing following 
cDNA amplification is that library preparation may be more labour intensive (Svensson et al. 
2018). However, sequencing the full transcript can be advantageous in certain applications, 
such as when investigating alternative splicing (Ramsköld et al. 2012). Multiplexing can also 
be carried out prior to cDNA amplification, with cellular barcodes added during reverse 
transcription (Islam et al. 2011). cDNA can then be pooled for amplification. Early barcoding 
approaches also enable the addition of unique molecular identifiers (UMIs) to transcripts 
alongside the cellular barcode (Islam et al. 2014; Fu et al. 2011; Hug & Schuler 2003). Biases 
can be introduced during cDNA amplification and UMIs can be used to correct for uneven 
cDNA amplification (Islam et al. 2014). The disadvantage of this approach is that early 
barcoding is not compatible with the sequencing of full-length transcripts, as mentioned 
above. Every sequencing read needs to contain the cellular barcode to enable demultiplexing, 
therefore only the 3’ or 5’ tags of the transcript can be sequenced with early barcoding 
approaches (Svensson et al. 2018). Despite this limitation, early barcoding approaches are 
widely used and have enabled a remarkable increase in the numbers of profiled cells when 
combined with high-throughput capture methods (Svensson et al. 2018). Examples of 
protocols using early barcoding are STRT-seq (Islam et al. 2011), MARS-seq (Jaitin et al. 2014), 
CEL-seq2 (Hashimshony et al. 2016), inDrop (Klein et al. 2015), Drop-seq (Macosko et al. 2015) 
and the 10X Genomics Chromium platform (Zheng et al. 2017). 
 
With so many different scRNA-seq protocols available, the key question is which one is best 
suited to answer a particular research question. It is challenging to directly compare the 
performance of protocols, due to different cell types and varying sequencing depths used in 
published studies. A benchmarking study by Svensson et al. (2017) attempted to overcome 
this challenge by using ERCC controls, which are a panel of artificial RNA molecules frequently 
added to single cells during library preparation for quality control purposes. By comparing 
reported numbers of added ERCCs with their read counts following sequencing, Svensson et 
al. (2017) estimated the accuracies and sensitivities of several scRNA-seq protocols. When 
varying sequencing depth was accounted for, the top performing protocols were CEL-seq2, 
STRT-seq and SMARTer protocols carried out on the Fluidigm C1 platform (Svensson et al. 
2017). Droplet-based approaches, such as inDrop, Drop-seq and 10X Genomics Chromium, 
performed relatively well given their high throughput nature, particularly when varying 
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sequencing depth was accounted for (Svensson et al. 2017). However, there are differences 
between artificial ERCC controls and endogenous mRNAs, which may have impacted the 
performance of the protocols to different degrees (Svensson et al. 2017). Additionally, ERCCs 
can degrade during handling, which may have introduced technical noise to benchmarking 
(Svensson et al. 2017). Ziegenhain et al. (2017) used a different approach to benchmark the 
performance of a selection of scRNA-seq protocols. scRNA-seq libraries of mouse embryonic 
stem cells were generated for all six benchmarked protocols, which included Smart-seq2, 
Drop-seq and MARS-seq protocols (Ziegenhain et al. 2017). Smart-seq2 protocol was 
determined to have the highest sensitivity and captured the largest number of genes per cell 
(Ziegenhain et al. 2017).  
 
Overall, different protocols for scRNA-seq library generation have various advantages and 
disadvantages. The most suitable protocol depends on the research question and any practical 
limitations, such as limited biological material. There is generally also a trade-off between the 
number of cells included in the study and the sequencing depth per cell due to the cost of 
sequencing. The droplet-based 10X Genomics Chromium platform has become widely used 
for single-cell transcriptome profiling in recent years, likely due to the practical convenience 
of an optimised commercial product and relatively high data quality (Zheng et al. 2017).  
 
1.9.2 scRNA-seq data analysis approaches 
The analysis of scRNA-seq data presents several challenges, which largely originate from the 
technical noise resulting from low amounts of cellular mRNA and the resulting sparsity of the 
data (Brennecke et al. 2013). A particular problem in scRNA-seq data are dropout events, 
which occur when a transcript was present in the cell at the time of reverse transcription, but 
was not included in the resulting library due to incomplete mRNA capture, or was not 
sequenced due to a low sequencing depth (Kharchenko et al. 2014). Technical challenges of 
noise and dropouts, alongside the large number of single cells included in most studies, mean 
that analysis approaches devised for bulk RNA-seq are not always applicable to scRNA-seq 
data. Since the development of high throughput scRNA-seq protocols, numerous analysis 
methods tailored specifically to scRNA-seq data have been developed instead (Stegle et al. 
2015; Wagner et al. 2016; Kiselev et al. 2019).  
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An important early step in data analysis is quality control, as inclusion of low quality cells could 
skew the biological interpretation of the data (McCarthy et al. 2017). Quality control is 
typically carried out by filtering out cells with particularly high or low total read count, number 
of detected genes and proportion of mitochondrial reads. ERCC spike-in controls can also be 
used to eliminate poor quality cells (McCarthy et al. 2017). Good quality cells then need to be 
normalised to account for the differences in sequencing depths of individual cells and several 
different normalisation methods have been developed. Read counts of detected genes can be 
adjusted for sequencing depth based on the total library size or by additionally correcting for 
gene length using transcripts per million (TPM, Li et al. 2010), reads per kilobase million 
(RPKM, Mortazavi et al. 2008) or fragments per kilobase million (FPKM, Trapnell et al. 2010) 
approaches. Bulk RNA-seq normalisation approaches may not be well suited to scRNA-seq 
data, as the proportion of genes with zero counts is drastically higher in scRNA-seq (Vallejos 
et al. 2017). For example, the DESeq2 normalisation method (Love et al. 2014) developed for 
bulk RNA-seq estimates size factors for each sample based on the geometric mean of 
expressed genes. However, as a large proportion of genes are not detected consistently in 
scRNA-seq assays, this approach does not accurately reflect the sequencing depth in such 
sparse settings (Vallejos et al. 2017). Alternative approaches tailored specifically to sparser 
scRNA-seq datasets have been developed, for example the pooling normalisation approach, 
where size factors are estimated based on pools of single cell and subsequent deconvolution 
(Lun et al. 2016).  
 
To address the problem of dropouts in scRNA-seq data, several imputation methods have 
been developed, such as MAGIC (van Dijk et al. 2018) and scImpute (Li & Li 2018). The goal of 
imputation methods is to determine whether a zero is a technical dropout or a true biological 
readout and to correct for dropouts arising due to technical effects. However, it may not be 
straightforward to distinguish between true and false negatives, which can lead to the 
introduction of false-positive values (Tallulah S. Andrews & Hemberg 2019). Any technical 
effects resulting from different batches of scRNA-seq libraries may also need to be accounted 
for prior to biological interpretation of the data (Stegle et al. 2015). Several approaches for 
batch correction have been developed for bulk RNA-seq, such as remove unwanted variation 
(RUV) (Risso et al. 2014) or limma (Ritchie et al. 2015) workflows. However, these approaches 
may remove interesting biological variation, which could result from varying cell types present 
in different batches or varying proportion of cell types sampled in each batch (Haghverdi et 
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al. 2018). scRNA-seq specific methods have been developed to address this problem, such as 
the mnnCorrect (Haghverdi et al. 2018), which is applicable if batches contain at least one 
overlapping subpopulation of cells. An alternative approach to comparing different scRNA-seq 
datasets is to use cell projection methods, which aim to map the transcriptional profiles onto 
a reference dataset and identify which cells originate from the same biological populations. 
For example, scmap (Kiselev et al. 2018) maps the cells in a dataset to the most similar cell or 
cluster of cells within a reference dataset. Another such tool for assessing similarities between 
cell populations profiled in different datasets is MetaNeighbour (Crow et al. 2018), which is 
tailored to assessing how reliable cell type annotations are across different datasets. Cell 
projection approaches are becoming particularly powerful with the development of large-
scale reference datasets, such as the Human Cell Atlas (Regev et al. 2017) and the Tabula Muris 
(The Tabula Muris Consortium 2018). When reliable reference datasets are available, 
projection methods have the ability to assess whether cell types have been consistently 
annotated across datasets generated and analysed in different laboratories, as well as to assist 
with the assignment of cell types in newly generated datasets. Further analysis of scRNA-seq 
datasets is dependent on the biological question, but frequently includes dimensionality 
reduction to visualise the transcriptomes of profiled cells in a two or three dimensional space, 
clustering to identify subpopulations of cells, and differential expression analysis between 
identified subpopulations.  
 
To visualise the highly dimensional scRNA-seq profiles, dimensionality reduction techniques 
can be employed. Various methods have been applied to scRNA-seq data analysis, such as the 
linear principal component analysis (PCA) and independent component analysis (ICA, 
Hyvärinen & Oja 2000; Trapnell et al. 2014), as well as non-linear t-distributed stochastic 
neighbour embedding (t-SNE, Maaten & Hinton 2008), diffusion maps (Coifman et al. 2005; 
Haghverdi et al. 2015) and uniform manifold approximation and projection (UMAP, McInnes 
et al. 2018; Becht et al. 2019). Recent benchmarking of different dimensionality reduction 
approaches for scRNA-seq data suggested that PCA may be best suited for applications where 
a low number of cells has been profiled, and t-SNE may give better results in datasets with 
larger numbers of cells (Li & Li 2019). However, diffusion maps and UMAP methods have not 
been included in this comparison (Li & Li 2019). Dimensionality reduction is frequently 
performed on a set of highly variable genes, which reduces the initial high dimensionality of 
scRNA-seq data. Highly variable genes can be estimated using several approaches, for example 
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based on their variance between cells, their squared coefficient of variation (Brennecke et al. 
2013) or based on the relationship between their log mean expression and variance (Lun et 
al. 2016).  
 
An important question arising during the analysis of heterogeneous datasets is which 
populations of cells have been profiled. Unsupervised clustering is a useful tool for answering 
such questions, and can be used for characterising the heterogeneity of the dataset and for 
identifying new subpopulations of cells. Numerous approaches for clustering have been 
developed and applied to scRNA-seq, with the majority of these approaches based on 
hierarchical, k-means or graph-based clustering (Kiselev et al. 2019). Several clustering 
approaches have been specifically adapted for scRNA-seq data to take the high dimensionality 
and sparsity of the data into account. These include CIDR (Lin et al. 2017) based on hierarchical 
clustering, SC3 (Kiselev et al. 2017) and RaceID (Grün et al. 2015) based on k-means clustering 
and PhenoGraph (Levine et al. 2015) and a graph-based clustering approach implemented in 
the Seurat package (Macosko et al. 2015; Butler et al. 2018) for graph-based clustering. 
Evaluating the results of clustering algorithms often requires a degree of biological knowledge 
about profiled cells. For example, known cell type markers are frequently used for interpreting 
identified clusters (Kolodziejczyk et al. 2015). Direct comparison of different clustering 
algorithms is therefore challenging, as there is a lack of gold standard ground truth datasets, 
and different clustering algorithms may specialise in certain applications, such as rare cell 
populations or large datasets (Kiselev et al. 2019). Due to these challenges, unsupervised 
clustering of scRNA-seq data is still an active area of research. Benchmarking of developed 
approaches on a variety of real and simulated datasets suggested that SC3 clustering and 
Seurat’s graph-based clustering overall performed best, with the latter approach being faster 
and thus more applicable to larger datasets (Duò et al. 2018).  
 
Differential gene expression analysis between clusters of cells is a common technique for 
investigating the characteristics and potential function of identified subpopulations of cells. 
Due to the sparsity of scRNA-seq data and the large numbers of cells profiled, approaches 
developed for bulk RNA-seq are not widely applicable. Several tailored approaches for 
differential gene expression analysis in scRNA-seq data have been developed, such as scde 
(Kharchenko et al. 2014) and MAST (Finak et al. 2015). Several standard statistical tests, such 
as the Wilcoxon rank sum test and the student’s t-test, have also been shown to perform well 
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in identifying differentially expressed genes in scRNA-seq data (Soneson & Robinson 2018). 
Since scRNA-seq data profiles gene expression levels in individual cells, it is also possible to 
assess the relative variability in gene expression between groups of cells (Vallejos et al. 2015; 
Eling et al. 2018).  
 
With increased throughput of scRNA-seq and advances in computational analyses, unbiased 
profiling of cellular heterogeneity in many different tissues became possible. scRNA-seq 
studies revealed that the transcriptional heterogeneity within many tissues is greater than 
previously thought. For example, Jaitin et al. (2014) profiled over a thousand spleen cells and 
characterised different subpopulations of dendritic cells, and the transcriptional 
heterogeneity of cells within a tumour was highlighted by Patel et al. (2014). The extent of 
heterogeneity of cell types in the mouse cortex and hippocampus was revealed using scRNA-
seq by Zeisel et al. (2015), where several subtypes of oligodendrocytes were observed among 
what was previously thought to be a homogeneous cell population (Zeisel et al. 2015). Since 
then, many more scRNA-seq studies have been published and made their data publicly 
available, which created unprecedented resources for investigating the heterogeneity of 
different tissues and organs. 
 
scRNA-seq is also a valuable tool for investigating continuous transitions between cell states 
or cell types, such as differentiation trajectories. Several analytical approaches for modelling 
differentiation trajectories tailored to scRNA-seq data have been developed, including 
Monocle (Trapnell et al. 2014), TSCAN (Ji & Ji 2016), diffusion pseudotime (Haghverdi et al. 
2016) and Slingshot (Street et al. 2018). These analytical approaches have been applied to 
various biological systems. For example, Trapnell et al. (2014) gained insight into the 
transcriptional regulation of myoblast differentiation by constructing a differentiation 
trajectory of profiled cells and investigating the transcriptional changes along the resulting 
trajectory. Important insights using similar approaches have also been made in other systems, 
such as haematopoiesis (Paul et al. 2015). Paul et al. observed that there was a higher level of 
heterogeneity among myeloid progenitors than was previously known and that different 
progenitor populations were primed towards certain lineages, while retaining a degree of 
plasticity when the system was perturbed. Advancements in the understanding of 
differentiation and cell state transitions have also been made in many other biological 
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processes, including dendritic cell differentiation, T cell commitment and lymphoid 
differentiation (Papalexi & Satija 2018).  
 
Computational analysis of scRNA-seq data is an area of active research and significant 
advances in performance and usability of the tools have been made in recent years. 
Comprehensive and user-friendly workflows, such as Seurat (Butler et al. 2018), scanpy (Wolf 
et al. 2018) and ASAP (Gardeux et al. 2017) have been developed, with Seurat in particular 
becoming widely used in scRNA-seq data analysis. Overall, single-cell transcriptomics is an 
exciting and rapidly developing field and the advances in the experimental and analytical 
approaches have enabled unprecedented resolution, coverage and scale in transcriptional 
profiling studies.  
 
1.10 Aims and hypotheses 
In this thesis I focused on the heterogeneity and plasticity of VSMC, both in healthy arteries, 
as well as during their response to injury and disease. I have taken advantage of scRNA-seq 
and lineage labelling approaches to investigate these questions at the single-cell level. 
Specifically, the aims of this thesis are: 
 
1) Investigate the regional heterogeneity of VSMCs between the atherosclerosis-prone 
AA and atherosclerosis-resistant DT regions of the aorta, and to establish whether the 
observed population-level differences are detectable at the single-cell level. 
 
2) Characterise the transcriptional heterogeneity of VSMCs within a vascular bed, with 
the aim of identifying potential sources of functional heterogeneity, which has been 
observed in VSMC response to injury and atherosclerosis. I hypothesised that the 
observed functional heterogeneity may stem from VSMC heterogeneity in healthy 
arteries. 
 
3) Investigate the heterogeneity of VSMCs during phenotypic switching in the 
atherosclerotic plaque and following vascular injury.  
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2 Methods 
2.1 Animal models and tissue processing 
Animal work and tissue processing was carried out by H.F. Jørgensen, A.L. Taylor, J.L. Harman 
and J. Chappell. For VSMC-specific lineage tracing, both single-colour ROSA26-eYFP and multi-
colour ROSA26-Confetti systems were used in combination with the tamoxifen-inducible 
Myh11-CreERt2 in C57Bl/6 mice (Wirth et al. 2008; Gomez et al. 2013; Chappell et al. 2016). 
To create a Myh11-CreERt2 construct, CreERt2 was inserted into the ATG codon of a bacterial 
artificial chromosome (BAC) carrying the Myh11 gene (Wirth et al. 2008). The construct was 
injected into mouse oocytes, where it integrated into the Y chromosome (Wirth et al. 2008). 
Studies have suggested that CreERt2 expression is confined to mature VSMCs in healthy 
animals (Wirth et al. 2008; Nemenoff et al. 2011), however since CreERt2 is not under the 
control of the endogenous Myh11 promoter, it should be noted that there may be differences 
in the activities of the endogenous and transgenic Myh11 promoters (Chakraborty et al. 2019). 
CreERt2 has been mutated to bind tamoxifen, after which it is translocated to the nucleus, 
where recombination at the reporter allele takes place (Feil et al. 1996; Feil et al. 1997). Since 
CreERt2 is expressed selectively in VSMCs, reporter expression following induction of lineage 
labelling by tamoxifen is VSMC-specific.  
 
For the analysis of VSMCs within atherosclerotic plaques, the Myh11-CreERt2/Confetti lineage 
tracing system was crossed with ApoE-/- mice, which has been described (Chappell et al. 2016). 
Carotid ligation experiments were carried out using Myh11-CreERt2/eYFP lineage traced mice 
containing the Ki67-RFP reporter (Basak et al. 2014). Sca1-GFP animals used have been 
described previously (Ma et al. 2002). As the Myh11-CreERt2 transgene is Y-linked, only male 
mice were used in this study. Tamoxifen (10 mg/animal) was administered intraperitoneally 
at 6-8 weeks of age over a 10 day period to induce recombination for lineage labelling. For 
analysis of VSMCs in atherosclerotic arteries, Myh11-CreERt2/Confetti/ApoE-/- mice were 
tamoxifen labelled as described and subsequently fed a high-fat diet (21% fat, 0.2% 
cholesterol) for 14-18 weeks (Chappell et al. 2016). For analysis of VSMCs following carotid 
ligation (Kumar & Lindner 1997), tamoxifen-treated Myh11-CreERt2/eYFP/Ki67-RFP mice 
underwent carotid ligation surgery, during which the left carotid artery was tied with a 6-0 silk 
suture to cease blood flow (Chappell et al. 2016). Prior to surgery the mice received analgesic 
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(Temgesic) and were anaesthetised using 2.5-3% isofluorane inhalation (Chappell et al. 2016). 
Prior to analysis, aortas or carotid arteries were isolated by dissection and the surrounding 
fatty tissue was removed.  
 
2.2 Bulk RNA-seq analysis 
2.2.1 Experimental protocol 
Generation of bulk RNA-seq libraries was carried out by J.L. Harman. Dissected aortas were 
incubated in RNAlater, separated into the AA and DT sections and the adventitial and 
endothelial layers were removed. Medial layers from 3-5 animals were lysed in Trizol and 
RNeasy column (Qiagen) was used to clean the isolated RNA. 550 ng of total RNA was used to 
prepare sequencing libraries (TruSeq Stranded mRNA Library Prep Kit, Illumina), which were 
sequenced on the MiSeq sequencer (Illumina). Three independent libraries were generated 
from the medial layers of each of the AA and DT regions. 
 
2.2.2 Data processing and analysis 
Raw reads were processed through the Babraham Institute Bioinformatics pipeline, during 
which they were aligned to the GRCm38 mouse genome using TopHat aligner v2.1 (Trapnell 
et al. 2009). SeqMonk software was used to count the number of aligned reads per gene 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk, SeqMonk analysis was 
performed by P. Oldach). I used the R statistical environment for subsequent analysis. 
Differential gene expression analysis was carried out using the DESeq2 Bioconductor R 
package v1.12 (Love et al. 2014). Specifically, functions DESeqDataSetFromMatrix (with design 
corresponding to the AA or DT origin of the samples) and DESeq (with default parameters) 
were used for the analysis. Genes were considered differentially expressed if their log2 fold 
change between regions was > 1 and their FDR-adjusted p-value was < 0.01 (Benjamini-
Hochberg multiple testing correction).  
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2.3 Flow cytometry analysis and scRNA-seq experimental methods 
Experimental work was carried out by H.F. Jørgensen, A.L. Taylor, J.L. Harman and J. Chappell, 
unless otherwise stated. In case of the carotid arteries and the whole aorta 10X Genomics 
Chromium experiments, the entire artery was dissociated to a single-cell suspension by 
incubation with collagenase type IV (2.5 mg/ml) and porcine pancreatic elastase (2.5 U/ml) for 
1-2h, followed by filtering through a 40 µm cell strainer to remove any remaining clumps of 
cells. In other experiments, the adventitial and endothelial layers were removed prior to 
dissociation of medial cells to a single-cell suspension as described above. 
 
For SCA1 antibody staining, single-cells were incubated with TruStain FcX (1:100, BioLegend) 
prior to staining with the APC-conjugated isotype control antibody (1:10 Miltenyi 130-102-
655) or the anti-SCA1 antibody (1:10 Miltenyi 130-120-343). SCA1 antibody staining was 
analysed using an Accuri C6 (wild type and the single-colour reporter) or a Fortessa (multi-
colour reporter) flow cytometer.  
 
2.3.1 Fluidigm C1 platform 
Medial layers of the AA and DT aortic sections from 5-7 male C57Bl/6 mice were isolated and 
dissociated to a single-cell suspension, as described above. Samples (100 cells/µl) were 
processed using the Fluidigm C1 Auto Prep Arrays system with medium-sized chips (17-25 µm) 
in line with manufacturer’s instructions. Visual inspection of the chips was performed to select 
successfully captured single-cells. SMARTer Ultra Low RNA Kit (Clontech) was used to generate 
amplified cDNA. Sequencing libraries were then prepared using the Nextera Library Prep Kit 
(Illumina) and sequenced on a HiSeq 2500 sequencer (Illumina) using the 50bp paired-end 
sequencing protocol. Single cells from both the AA and DT regions were analysed in two 
independent experiments.  
 
For the pooled VSMC and adventitial samples, single-cell suspension was prepared from the 
medial and adventitial layers of the aorta, as described above. Total RNA from 2000-4000 cells 
was then extracted with the RNeasy Plus Micro Kit (Qiagen). Amplified cDNA was generated 
using the SMARTer Ultra Low RNA Kit (Clontech) according to the tube control protocol. 
Nextera Library Prep Kit (Illumina) was used to prepare sequencing libraries from the amplified 
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cDNA. Libraries were then sequenced on a HiSeq 2500 sequencer (Illumina) using the 50bp 
paired-end sequencing protocol. 
 
2.3.2 Smart-seq2 platform 
Medial layers of 5-7 Myh11-CreERt2/Confetti male mice were dissociated to a single-cell 
suspension and stained for SCA1 as described above. Cells were additionally stained with 
Zombie-NIR (1:100, BioLegend) to identify dead cells. Aria-Fusion flow cytometer (BD 
Bioscience) was used to sort live single cells, which were lineage-labelled and/or SCA1-
positive, into individual wells of a 96-well plate. Lineage-labelled cells were required to 
express only one of the four confetti colours to reduce the chances of profiling doublets of 
cells. Amplified cDNA was generated using the Smart-seq2 protocol (Picelli et al. 2014), with 
these modifications: for the reverse transcription Primescript (Clontech) was used, cDNA was 
amplified in 24 PCR cycles and ERCC controls (Invitrogen) were added at 1:40,000,000 or 
1:80,000,000 dilution into the reverse transcription (RT) mix. Sequencing libraries were 
prepared with the Nextera Library Prep Kit (Illumina) and sequenced on a HiSeq 2500 
sequencer (Illumina) through the 50bp paired-end sequencing. Analysed cells were from 3 
independent experiments, with SCA1-positive, lineage-labelled cells included in all three 
experiments and cells, which were only positive for either SCA1 or the lineage label, included 
in two of the experiments.  
 
2.3.3 10X Genomics Chromium platform 
The 10X Genomics Chromium platform with the Gene Expression v2 kit was used to generate 
the datasets described in this section.  
 
2.3.3.1 VSMCs in healthy aorta and whole aorta analysis 
For both the whole aorta and VSMC-only samples, aortas of three tamoxifen-labelled Myh11-
CreERt2/Confetti males were processed to a single-cell suspension as described above and 
stained with Zombie-NIR (1:100, BioLegend). Aria-Fusion flow cytometer (BD Bioscience) was 
used to isolate 20,000 live single cells for both samples. In case of the whole aorta sample, 
selection based on lineage label expression was not performed, while expression of one of the 
four fluorescent proteins was required for the VSMC-only sample to reduce the chances of 
profiling doublets. Samples were then processed through the 10X Genomics Chromium 
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platform. Sequencing libraries were sequenced on a HiSeq4000 instrument (Illumina) using 
paired-end sequencing. 
 
2.3.3.2 Carotid ligation injury 
The carotid ligation surgery has been performed on the left carotid artery as described 
previously and above (Kumar & Lindner 1997; Chappell et al. 2016). Left carotid arteries from 
5 male tamoxifen-labelled Myh11-CreERt2/eYFP/Ki67-RFP mice were dissected 7 days 
following carotid ligation and dissociated to a single-cell suspension as described above. An 
Aria-Fusion flow cytometer (BD Bioscience) was used to isolate 20,000 live single eYFP+ cells. 
Due to the rare nature of RFP+ cells, the sample was enriched for about 100 eYFP+RFP+ cells. 
Isolated cells were processed through the 10X Genomics Chromium system and their libraries 
were sequenced on a HiSeq4000 sequencer (Illumina) using paired-end sequencing.  
 
2.3.3.3 VSMCs in atherosclerotic arteries  
Myh11-CreERt2/Confetti/ApoE-/- tamoxifen-labelled male mice were fed a high fat diet for 
either 14 or 18 weeks as described above. Aortas of 2-3 mice per time point were used, with 
atherosclerotic plaques manually isolated, dissociated essentially as described previously 
(Butcher et al. 2011), with the addition of porcine pancreatic elastase (2.5 U/ml) to the 
digestion cocktail, and passed through a 40 µm cell strainer to remove clumps. 20,000 single 
lineage-labelled cells, which expressed only one of the four fluorescent proteins, were isolated 
from each time point using an Aria-Fusion flow cytometer (BD Bioscience). Samples were 
processed through the 10X Genomics Chromium platform and sequenced using pair-end 
sequencing on a HiSeq4000 machine (Illumina). Experiment performed jointly with H.F. 
Jørgensen.  
 
 
2.4 Processing, quality control and normalisation of scRNA-seq data 
2.4.1 Fluidigm C1 and Smart-seq2 platforms 
Raw reads were processed through the Babraham Institute Bioinformatics pipeline, during 
which they were aligned to the GRCm38 mouse genome using TopHat aligner v2.1 (Trapnell 
et al. 2009). Htseq-count v0.8 (Anders et al. 2015) was used to count the number of read 
alignments per gene in the resulting bam files. The idattr parameter was set to “gene_id” and 
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the stranded parameter to “no”. Single cells processed through the Fluidigm C1 platform were 
considered of good quality if their total read count was over 1 million and less than 3.5 million, 
the number of genes detected in the cell was between 5000 and 9500 and the proportion of 
mitochondrial reads was less than 20%. Additionally, over 80% of reads were required to map 
to genes and over 50% to exons. The percentage of reads mapping to genes and exons was 
calculated using the SeqMonk software v1.42 from the aligned bam files 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk). Single cells processed using 
the Smart-seq2 protocol (Picelli et al. 2014) were considered of good quality if the total read 
count per cell exceeded 100,000, the number of genes detected exceeded 1500 and the 
percentage of ERCC control reads did not exceed 30%.  
 
Prior to normalisation, the genes with mean expression levels below 1 count per cell were 
filtered out to reduce noise. The function computeSumFactors from the Bioconductor R 
package scran (Lun et al. 2016) was then used to compute the normalisation factors for 
individual cells (scran v1.2 for Fluidigm C1 data and v1.8 for Smart-seq2 data). For the PCA 
comparison of single VSMC transcriptomes with the pooled adventitial and VSMC samples, 
the normalisation method estimateSizeFactorsForMatrix from the R Bioconductor package 
DESeq2 v1.12 was used, with the method locfunc = “shorth” from the genefilter R 
Bioconductor package v1.6.  
 
Batch correction methods were not applied to Fluidigm C1 profiles of AA and DT VSMCs due 
to unbalanced experimental design, despite batch effects being noticeable for DT VSMCs. 
Batch correction could have introduced artificial differences between the AA and DT VSMC 
profiles, since individual batches contained transcriptional profiles from a single region. 
Instead, these technical issues were considered during downstream analyses to ensure that 
any conclusions drawn from the analyses were supported by all batches. 
 
2.4.2 10X Genomics Chromium platform 
10X Genomics cellranger pipeline (v2.0 for atherosclerosis samples and v2.1 for healthy aorta 
and carotid ligation samples) was used to demultiplex the raw BCL files, align the reads to the 
GRCm38 mouse genome using the STAR aligner (Dobin et al. 2013) and count the UMIs 
detected per gene (cellranger pipeline run by F. Krueger). I imported the gene-count matrices 
into R using the Seurat v2.3 package function Read10X (Butler et al. 2018).  
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Cells isolated from healthy arteries were considered of good quality if their total UMI count 
was between 1000 and 8000, the number of genes detected was between 500 and 2500 and 
the cell contained less than 8% of mitochondrial reads. VSMCs isolated from carotid arteries 
following ligation surgery were required to have at least 5000 UMIs and 2000 genes detected 
and to not exceed 6% of mitochondrial reads. VSMCs isolated from atherosclerotic plaques 
were required to have 5000-20,000 UMIs, 1000-5000 genes and less than 9% of mitochondrial 
reads detected. The remaining good quality cells were then normalised using the 
NormalizeData (method = “LogNormalize”, scale.factor = 10,000) and ScaleData functions 
from the Seurat R package v2.3 (Butler et al. 2018). 
 
2.5 Processing and analysis of publicly available cultured VSMC transcriptomes 
Fastq files were downloaded from the Gene Expression Omnibus (GSE79436, Adhikari et al. 
2015). Downloaded data was processed using the Babraham Institute Bioinformatics pipeline, 
which included alignment using TopHat v2.1 (Trapnell et al. 2009). Htseq-count v0.8 (same 
parameters as decribed above for the Fluidigm C1 and Smart-seq2 profiles) was then used to 
count the number of reads per gene. Transcriptomes from cultured and ex vivo VSMCs were 
normalised together using the computeSumFactors function from the Bioconductor R package 
scran v1.2 (Lun et al. 2016). 
 
2.6 Log transformation and PCA dimensionality reduction 
Normalised read counts were log2-transformed and a pseudocount of 1 was added to all 
counts to avoid log-transforming 0 counts. Principal component analysis of the Fluidigm C1 
and Smart-seq2 profiles was carried out using the plotPCA function from the scater R 
Bioconductor package v1.8 (McCarthy et al. 2017) with the underlying prcomp R method. The 
features were scaled and the top 500 most variable genes were used for the analysis, apart 
from PCA based on the random forest predictors, where the 30 random forest predictor genes 
were used. For the 10X Genomics Chromium data PCA was carried out using the Seurat R 
package v2.3 (Butler et al. 2018). Specifically the function RunPCA was used and the JackStraw 
function (num.replicate = 100) was used to estimate whether PCs explained more variance 
than expected at random.  
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2.7 Random forest analysis 
AA and DT cells were first split into the training (75% or 108 cells) and test (25% or 35 cells) 
sets randomly using the createDataPartition function from the CRAN R package caret v6.0. 
Recursive feature elimination was carried out on the training dataset using the rfe function 
from the caret R package with 10-fold cross validation. Performance of the random forest 
model based on the top 25, 30, 35, 40, 45, 50 features identified during recursive feature 
elimination was evaluated, with 30 predictor genes selected for further model training. The 
random forest model based on the identified 30 top predictor genes (1000 trees) was trained 
using the train function from the caret R package with the “rf” method from the randomForest 
R package v4.6. Following grid search optimisation the mtry parameter was set at 2. Repeated 
10-fold cross-validation (10 repeats) was used during training. The performance of the final 
model on the test data was evaluated using the predict function from the stats R package. ROC 
plot was generated using the ROCR R package v1.0.  
 
2.8 Highly variable gene and co-expression analysis 
Highly variable gene analysis was performed using the highly variable gene identification 
workflow in the R Bioconductor package scran (Lun et al. 2016) v1.2 for Fluidigm C1 data and 
v1.8 for Smart-seq2 data. Analysis was carried out separately for the AA, DT and SCA1-positive, 
lineage-labelled (S+L+) cells. The design parameter in the trendVar and decomposeVar 
functions was used to account for differences between the batches. For the AA and DT VSMCs 
the technical variance for a given mean log expression level was estimated using the trendVar 
(method = “loess”) function based on all genes under the assumption that the majority of the 
genes were not highly variable. For highly variable gene identification in S+L+ cells, ERCC 
controls were available and were used to estimate the technical variance using the trendVar 
(method = “loess”) function. Based on the estimated relationship between technical variance 
and the mean log expression levels of a gene, the variance of each gene was then decomposed 
into the technical and biological components using the decomposeVar function. A gene was 
identified as highly variable if the biological component of variance was significantly greater 
than zero (FDR-adjusted p-value < 0.05, Benjamini-Hochberg correction for multiple testing) 
and greater than 0.5.  
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For increased stringency in highly variable gene identification, I repeated the highly variable 
gene analysis in S+L+ cells 1000 times using 90% of randomly selected cells during each 
iteration. To combine the p-values from the iterations, a method based on the work of Licht 
and Rubin (Licht 2010) was implemented by M. Spivakov. In this method, p-values from each 
sample were transformed into z-scores using the quantile function of the normal distribution. 
The combined z-score for each gene was computed as the mean z-score for this gene across 
iterations divided by the total variance of the gene’s z-scores across the iterations. The 
probability density function of the normal distribution was then used to compute the p-values, 
which were adjusted for multiple testing using the Benjamini-Hochberg method. A gene was 
considered highly variable if the adjusted p-value was below 0.05.  
 
Gene correlations within the cVSMC network of S+L+ cells from healthy arteries, as well as 
Ly6a/Sca1 co-expressed genes in VSMCs post carotid ligation surgery, were identified using 
an approach based on the Spearman’s rho implemented in the R Bioconductor package scran 
v1.8 (Lun et al. 2016). Function correlatePairs was used to assess the pairwise correlations 
either among the genes within the cVSMC network (S+L+ cells) or between Ly6a/Sca1 and the 
remaining profiled genes (VSMC in injury). Gene pairs with Benjamini-Hochberg FDR-adjusted 
p-value < 0.05 (cVSMC network) or < 0.01 (VSMC in injury) and a positive rho value were 
considered to be positively correlated.  
 
2.9 Network analysis and visualisation 
Network analysis and visualisation of the resulting modules was performed by M. Spivakov. 
Network analysis was used to identify co-expressed modules of highly variable genes in S+L+ 
cells and was carried out using the blockwiseModules (power = 3, TOMType = “unsigned”, 
minModuleSize = 5, reassignThreshold = 0, mergeCutHeight = 0.25) function of the R package 
WGCNA v1.63 (Langfelder & Horvath 2008). The soft-thresholding power was chosen using 
the pickSoftThreshold function. Resulting ME1 (cVSMC module) and ME2 modules were 
visualised using Cytoscape v2.6.1 (Shannon et al. 2003). The WGCNA co-expression weight of 
gene pairs is encoded by the edge thickness in visualised modules.  
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2.10 Summarising expression levels of gene signatures using PC1 scores 
To summarise the overall expression levels of gene signatures, PC1 scores were used. Firstly, 
PCA was performed based on the genes contained in the gene signature using the prcomp 
(center = TRUE, scale. = TRUE) function from the R package stats. Since the sign of the PC 
values is arbitrary, PC1 values of individual cells were multiplied by -1 if the PC1 values 
correlated negatively with the total expression levels the gene signature.  
 
2.11 Identification of the cVSMCneg and cVSMCpos signatures 
Identification of genes that were positively or negatively correlated with the cVSMC score 
(summarised expression of module ME1) of S+L+ cells was carried out by M. Spivakov. A 
modified version of the approach for identification of trajectory associated genes from the 
monocle R Bioconductor package (Trapnell et al. 2014) was used. The loess (family = 
“symmetric”) R function was used to estimate the mean-variance relationship of mean log 
expression levels and the log squared coefficient of variation. Negative binomial regression 
implemented in the VGAM R package v1.0 was then used to model the dependence of the 
expression level of a gene and the cell’s cVSMC score. The size parameter of the negative 
binomial distribution was assumed to be the inverse fitted squared coefficient of variation 
described above. Likelihood-ratio test was used to assess the significance of the binomial 
regression fit compared with the intercept-only model. P-values were adjusted for multiple 
testing using the Benjamini-Hochberg procedure. Genes were considered significantly 
positively or negatively correlated if their adjusted p-values were below 0.05.  
 
2.12 Clustering analysis and t-distributed Stochastic Neighbour Embedding (t-
SNE) visualisation 
Clustering analysis and t-SNE visualisation were performed using the R package Seurat v2.3 
(Butler et al. 2018; Maaten & Hinton 2008). The dimensionality of the dataset was first 
reduced using PCA as described above. The principal components included in further analysis 
were chosen based on the elbow plot showing the standard deviations of calculated principal 
components, whether they explained biologically meaningful variation among the profiled 
cells, or whether they explained significantly more variance than expected at random (as 
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described above). Graph-based clustering implemented in the FindClusters function was used 
for the analysis. The resolution parameter was set based on the biologically meaningful 
outcomes of identified clusters as follows: at 0.6 for the analysis of the whole aorta and VSMC-
only datasets and the initial analysis of plaque VSMCs; at 0.8 for re-analysis of plaque VSMCs 
following the removal of low quality cells (initial cluster 4) and for analysis of VSMCs following 
carotid ligation injury. t-SNE analysis implemented in the RunTSNE function was used to 
visualise profiled cells and the results of the clustering analysis. The same number of principal 
components was used to calculate t-SNE scores as for the clustering analysis in each dataset.  
 
2.13 Differential gene expression analysis 
Differential gene expression analysis between the identified clusters of cells in the 10X 
Genomics Chromium datasets was carried out using functions FindMarkers and 
FindAllMarkers of the R package Seurat (Butler et al. 2018), using the method “wilcox”. For 
the analysis of differentially expressed genes between the VSMC clusters of the whole aorta 
and VSMC-only datasets from healthy arteries, each VSMC cluster was compared with the 
remaining VSMC clusters using the FindMarkers function. Genes expressed in at least 10% of 
the cells in either population and showing log2-fold change > 0.5 between populations were 
included in the analysis. Function FindAllMarkers was used for identifying cluster markers in 
the vascular injury and atherosclerosis datasets with log2 fold change required to be at least 
0.5 between the compared populations of cells. Genes were required to be expressed in either 
of the compared populations in at least 10% of the cells. In all cases tested genes were 
considered differentially expressed if the Bonferroni adjusted p-value was < 0.05 according to 
the Wilcoxon rank sum test.  
 
Differential gene expression analysis between cultured and ex vivo VSMCs was carried out 
using the R package scde (Kharchenko et al. 2014). Genes with greater than 10 read counts in 
at least 5 cells were included in the analysis. scde.error.models and scde.expression.prior 
functions were used to compute the error models and expression priors and the function 
scde.expression.difference (n.randomisations = 100) was used to analyse differential 
expression of genes between conditions. Genes were considered differentially expressed if 
their log fold change between conditions was greater than 1 and their absolute corrected Z 
score was greater than 1.96.  
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2.14 Gene ontology analysis  
Gene ontology analysis of the differentially expressed genes between the AA and DT regions 
according to bulk RNA-seq, as well as of the identified highly variable genes within the AA and 
DT regions, was performed using the PANTHER overrepresentation test, with the gene 
ontology database released on 1/1/2019 (Mi et al. 2019). Gene ontology analysis of genes 
differentially expressed in the VSMC cluster 6 of the whole aorta and VSMC-only datasets and 
between cultured and ex vivo VSMCs was also performed using the PANTHER 
overrepresentation test, but with gene ontology databases released on 3/7/2019 and 
8/10/2019 respectively. Gene ontology “biological process complete” was used for all 
analyses and the gene lists were analysed against the Mus musculus genome-wide 
background, unless otherwise stated. Fisher’s exact test and the Bonferroni correction for 
multiple testing were used for determining whether a gene ontology term was significantly 
overrepresented (adjusted p-value < 0.05). Gene ontology analysis of cVSMCpos and 
cVSMCneg signatures was carried out by M. Spivakov based on the “biological process” gene 
ontology using the clusterProfiler R package v3.8 (Yu et al. 2012).  
 
2.15 Fisher’s exact test 
Fisher’s exact test was used to determine whether prediction of only AA regional identities 
would be expected at random, given the bias towards AA predictions when the random forest 
model was applied to the 10X Genomics Chromium profiles of VSMCs. The fisher.test function 
in the R package stats was used, with the contingency table constructed based on the number 
of predicted AA or DT cells in cluster 6 (136 and 0 respectively) and the number of predicted 
DT or AA cells in other VSMC clusters (690 and 4343 respectively).  
 
2.16 Data availability 
Next generation sequencing datasets used in this thesis are publicly available (GSE117963, 
GSE79436), with the exception of the VSMCs in carotid ligation injury dataset, which is 
unpublished.  
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3 Regional differences between the aortic arch (AA) and 
descending thoracic aorta (DT) VSMCs 
3.1 Introduction 
In this chapter I focused on exploring the regional heterogeneity of VSMCs. Regional 
heterogeneity among VSMCs is thought to stem partly from the environmental differences 
experienced by the different areas of the vasculature, as well as from diverse embryonic 
origins of VSMCs located in different parts of the organism (Cunningham & Gotlieb 2005; 
Majesky 2007). For example, VSMCs located in the AA are derived from the neural crest, while 
VSMCs in the neighbouring DT region of the aorta have mesodermal origins (Majesky 2007). 
In addition, the environmental factors related to the curvature of the AA section and branch 
sites of the aorta are thought to impact VSMC heterogeneity (Cunningham & Gotlieb 2005; 
Chiu & Chien 2011). Together, these factors likely underpin the observations that the AA and 
DT sections of the aorta have different susceptibilities for atherosclerosis, with AA being more 
susceptible to atherosclerotic plaque development (Van Assche et al. 2011; Trigueros-Motos 
et al. 2013; Sinha et al. 2014). 
 
This chapter compares VSMCs from the AA and DT regions at the single-cell as well as at the 
population-wide level. The transcriptional differences between VSMCs derived from the AA 
and DT regions have been previously investigated at the population level (Van Assche et al. 
2011; Trigueros-Motos et al. 2013). In this chapter I extended the understanding of regional 
VSMC heterogeneity in the aorta by showing that the transcriptional differences are 
consistently expressed at the level of single cells. Additionally, I explored the heterogeneity of 
VSMCs within both vascular regions and observed heterogeneous expression of several 
disease-relevant genes. 
 
3.2 Results 
3.2.1 Single-cell analysis of VSMCs from the AA and DT aortic regions  
In collaboration with H.F. Jørgensen and M. Spivakov, we profiled individual ex vivo VSMCs 
from the AA and DT aortic regions of healthy mice using scRNA-seq. This approach allowed us 
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to address the differences between VSMCs from two regions of the aorta, as well as VSMC 
heterogeneity within a vascular bed. To obtain single ex vivo VSMCs, the aortas were first 
dissected from healthy mice and the endothelial cells were removed. The aorta was then 
separated into the AA and DT regions and the adventitial layer was removed from both 
regions. VSMCs resident in the medial layer were then dissociated to a single-cell suspension 
using enzymatic digestion separately for each region. We then used the Fluidigm C1 platform 
to capture single cells and to prepare the amplified cDNA for subsequent sequencing library 
preparation and sequencing (Figure 3.1).  
 
 
 
 
Figure 3.1: Schematic of the approach.  
To obtain a single-cell suspension of VSMCs, the medial layer of the aorta from the AA and DT regions 
was dissected and enzymatically digested. Single cells were then captured and cDNA libraries were 
prepared followed by sequencing and data analysis. Microscopy images were prepared by H.F. 
Jørgensen. Experimental work was carried out by M. Spivakov and H.F. Jørgensen and the figure was 
adapted from Dobnikar and Taylor et al. 2018. 
 
 
We obtained single-cell profiles of 173 cells. Raw sequencing reads were processed through 
the Babraham Institute pipeline and aligned to the GRCm38 mouse genome (details in 
Methods). I then generated the raw read count matrix and performed quality control to 
ensure that low quality cells do not affect the results of the analysis. Cells with very low or 
very high total read count (< 1,000,000 and > 3,500,000) and number of genes detected per 
cell (< 5000 and > 9500) were filtered out. This excluded the cells which may have burst and 
lost cytoplasmic mRNA, or were not sequenced to sufficient depth (low values) or could be 
doublets (high values). In addition, cells considered to be good quality had > 80% of reads 
mapping to genes, > 50% of reads mapping to exons and < 20% of mitochondrial reads (Figure 
3.2). In total, 143 cells (79 AA and 64 DT) passed the quality control filters.  
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Figure 3.2: Quality control of scRNA-seq data of ex vivo VSMCs.  
Violin plots showing distributions of total read count, number of genes detected, and the percentage 
of reads in genes, exons and mitochondria for the profiled AA and DT single cells. Red lines indicate 
quality control filtering thresholds. The figure is from Dobnikar and Taylor et al. 2018. 
 
 
The transcriptional profiles of good-quality cells were normalised, with only genes showing 
mean expression > 1 read included in the normalised dataset to reduce noise. All profiled cells 
expressed key VSMC marker genes Myh11, Acta2 and Tagln at high levels. Myocd, Smtn, Vcl 
and Cnn1, which were expressed at lower levels, were also detected in most cells (Figure 3.3, 
top panel). The fact that a few of the cells were negative for some of the VSMC marker genes 
may be due to dropout events, which are more frequent for lowly expressed genes. Dropout 
events can occur when a transcript is present in the cell, however it is not detected due to 
insufficient sequencing depth or imperfect mRNA capture and low amounts of starting 
material in single cells (Kharchenko et al. 2014). In agreement with this notion, detection rates 
of VSMC marker genes were comparable to housekeeping genes of similar expression levels 
(Figure 3.3, bottom panel). 
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Figure 3.3: Profiled AA and DT single cells express VSMC contractile marker genes.  
Violin plots showing the log2-transformed normalised read count distributions of VSMC marker genes 
Myh11, Acta2, Tagln, Myocd, Smtn, Vcl and Cnn1 (blue) and housekeeping genes Actb, Ppia, Eef2, 
Rpl13a, Gapdh (purple) in profiled AA and DT single cells. The figure is from Dobnikar and Taylor et al. 
2018. 
 
 
To further verify that all of the profiled single cells were VSMCs, I compared the scRNA-seq 
transcriptomes with profiles generated from pooled medial and adventitial cells. Pooled 
samples were prepared by H.F. Jørgensen and involved pooling 2000-4000 cells prior to library 
preparation (details in Methods). Principal component analysis and unsupervised k-means 
clustering showed that all single VSMCs clustered with the pooled medial samples, suggesting 
a similarity of their transcriptomes, and away from pooled adventitial cell samples (Figure 3.4a 
and b). This suggested that none of the profiled single cells were likely contaminants from the 
neighbouring adventitial tissue. I additionally compared the averaged scRNA-seq 
transcriptomes with conventional bulk RNA-seq measurements of VSMCs from the AA and DT 
regions of the aorta. Although there were some discrepancies among lowly expressed genes, 
averaged scRNA-seq transcriptomes generally correlated with averaged bulk RNA-seq 
measurements (R2 = 0.56, genes with mean expression greater than 3 log-transformed counts 
were included in the calculation, Figure 3.4c). 
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Figure 3.4: Profiled AA and DT single cells are distinct from pooled adventitial samples and share 
similarities with bulk RNA-seq VSMC profiles.  
a) Principal component analysis comparing single-cell transcriptomes (yellow and red circles) to pooled 
medial (green squares), adventitial SCA1+ (dark blue squares) and adventitial SCA1-- (light blue 
squares) samples. PC1 explained 9% and PC2 explained 5% of the variance. b) Results of k-means 
clustering (k=2) of the pooled and single-cell samples presented in panel a. Pooled samples are 
represented by squares and single-cell samples by circles. c) A scatterplot showing the correlation 
between averaged scRNA-seq profiles and averaged bulk RNA-seq profiles from ex vivo AA and DT 
regions (R2 = 0.56, where genes with mean expression greater than 3 log-transformed counts were 
included in the calculation).  
 
 
Having established that the profiled single-cells were VSMCs, I next investigated whether the 
processing of the ex vivo samples had significant effect on the transcriptional profile of the 
cells. During culture, VSMCs acquire characteristics of the synthetic state and cultured VSMCs 
are frequently used as a model for phenotypic switching (Rensen et al. 2007). To assess 
whether VSMCs profiled in our study retained their contractile phenotype during sample 
preparation, I compared the transcriptional profiles of ex vivo single VSMCs with publicly 
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available transcriptional profiles of single cultured VSMCs (GEO accession GSE79436, Adhikari 
et al. 2015). Both the ex vivo and cultured datasets were generated using the Fluidigm C1 
platform and the sequencing data was processed in an analogous way (details in Methods). 
The read counts were normalised jointly to account for differences in sequencing depth. 
Principal component analysis showed that transcriptional profiles of ex vivo and cultured 
VSMCs were clearly different, as the two populations clustered separately (Figure 3.5). 
Separate clustering of the cultured and ex vivo VSMCs may also be due to batch effects, as the 
two datasets were prepared in different laboratories. Although care has been taken to ensure 
that the data processing steps, such as alignment, counting the number of reads in genes and 
normalisation were carried out in the same way, batch effects cannot be ruled out. 
 
 
 
 
Figure 3.5: Transcriptional profiles of AA and DT ex vivo single cells are distinct from those of cultured 
VSMCs.  
PCA comparing ex vivo VSMCs (blue) with cultured VSMCs (green). Colour-coded circles represent 
individual cells and PCA was carried out based on 500 most variable genes. PC1 explained 25% of the 
variance and PC2 explained 4%. Transcriptional profiles of cultured VSMCs are publicly available at the 
Gene Expression Omnibus (GSE79436, Adhikari et al. 2015). The figure is adapted from Dobnikar and 
Taylor et al. 2018. 
 
 
To address this, I compared the expression of contractile marker genes as well as 
housekeeping genes between the ex vivo and cultured datasets. Cultured VSMCs showed 
reduced VSMC marker gene expression levels compared to ex vivo VSMCs (Figure 3.6a), while 
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the expression levels of all assessed housekeeping genes were comparable (Figure 3.6b). 
Differential gene expression analysis between the cultured and ex vivo cells identified 1278 
genes as upregulated in cultured VSMCs and 2647 genes as upregulated in ex vivo VSMCs 
(details in Methods). Gene ontology analysis of the 200 most upregulated genes for each 
condition identified “muscle structure development”, “muscle tissue development” and 
“potassium ion transport” as the three most overrepresented gene ontology terms for the ex 
vivo upregulated genes and “mitotic cell cycle”, “mitotic cell cycle process” and “cell division” 
as the three most overrepresented gene ontology terms for the genes upregulated in cultured 
cells. This suggests that the differences between the samples are likely driven by biological 
rather than technical factors and that VSMCs profiled in our study retained their contractile 
phenotype and did not undergo significant phenotypic switching during experimental 
procedures. Overall, the results presented in this section show that profiled AA and DT single 
cells are of good quality and have the characteristics expected of contractile VSMCs.  
 
 
 
 
Figure 3.6: Ex vivo VSMCs retained higher levels of VSMC contractile marker gene expression than 
cultured VSMCs.  
Boxplots show the log2-transformed normalised read count levels of VSMC marker genes (a) and 
housekeeping genes (b) in ex vivo (blue) and cultured (green) VSMCs. Transcriptional profiles of 
cultured VSMCs are publicly available at the Gene Expression Omnibus (GSE79436, Adhikari et al. 
2015). The figure is from Dobnikar and Taylor et al. 2018. 
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3.2.2 Population-level differences in gene expression between the AA and DT regions 
Given the low amounts of starting material and dropout events in single-cell data, bulk RNA-
seq can give a clearer picture of the average gene expression differences between two regions 
and can be a useful resource to guide scRNA-seq data analysis. We therefore performed 
conventional bulk RNA-seq of the two regions to obtain a robust set of genes, which are 
differentially expressed between the AA and the DT regions (collaboration with J. L. Harman). 
I performed the differential gene expression analysis, which revealed 442 differentially 
expressed genes (adjusted p-value < 0.01, log2 fold change > 1), of which 386 were 
upregulated in the AA and 56 upregulated in the DT region (Figure 3.7a). Among the genes 
upregulated in the AA were Pde1c and Spp1, which have been associated with the synthetic 
state of VSMCs (Lesauskaite et al. 2001; Cai et al. 2015, Figure 3.7a). Gene expression 
differences between the two regions were validated using RT-qPCR in independent samples 
for Dcn, Lum, Pde1c, Gpc3, Hoxa7 and 3632451O06Rik, with RT-qPCR showing consistent 
changes in expression between regions with RNA-seq for all tested genes (Figure 3.7b, 
collaboration with A.L. Taylor).  
 
 
 
 
Figure 3.7: Differentially expressed genes between the AA and DT regions.  
a) Volcano plot showing the –log10(p-value) versus log2 fold change for all genes detected using bulk 
RNA-seq. Genes identified as upregulated in the AA are shown in red and genes upregulated in DT are 
shown in yellow. Names of selected genes are indicated. b) Bar chart showing log2 fold change 
between the DT and AA as determined RT-qPCR (grey) compared with bulk RNA-seq (white).  A.L. 
Taylor performed the RT-qPCR analysis and the figure was adapted from Dobnikar and Taylor et al. 
2018. 
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Gene ontology (GO) analysis of genes upregulated in the DT region showed enrichment for 
GO terms related to regionalization and patterns specification, which was driven by higher 
expression levels of several Hox genes (Figure 3.8). Genes upregulated in the AA region 
showed enrichment for GO terms “regulation of cell population proliferation” and 
“inflammatory response” among others (Figure 3.8). This is consistent with previous reports 
of neural crest derived VSMCs (AA) being more responsive to treatment with inflammatory 
cytokines compared with mesoderm-derived (DT) VSMCs (Owens et al. 2010; Topouzis & 
Majesky 1996; Gadson et al. 1997; Cheung et al. 2012).  
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Figure 3.8: Enrichment for gene ontology terms (biological process) among genes upregulated in the 
AA and DT regions.  
Bar plots show the top 15 gene ontology terms, for which there was the strongest enrichment among 
the genes upregulated in the AA (a) and DT (b) regions. Shown gene ontology terms are ranked 
according to their adjusted p-values (details in Methods). 
 
 
Gene expression differences between the AA and DT regions were previously explored using 
microarrays (Trigueros-Motos et al. 2013). Consistent with previous findings (Trigueros-Motos 
et al. 2013), several Hox genes were found to be upregulated in the DT region (Figure 3.7a). 
Overall, the overlap between differentially expressed genes identified with microarrays and 
RNA-seq was relatively low, with 88 genes identified with both methods out of 442 and 246 
genes identified as differentially expressed with RNA-seq and microarrays respectively (Figure 
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3.9a). This could be due to a large proportion of genes identified as differentially expressed 
only using microarrays showing low expression levels, with 70% of these genes showing log2-
transformed read count < 4 in RNA-seq data (Figure 3.9b). Cross-hybridization and non-
specific background hybridization of probes limit the accuracy of transcript detection with 
microarrays (Zhao et al. 2014). This is particularly problematic for lowly expressed genes, 
which could explain the discrepancy between the RNA-seq and microarray measurements for 
the genes expressed at low levels.  
 
 
 
 
Figure 3.9: Comparison of the genes identified as differentially expressed using microarrays in a 
previous study (Trigueros-Motos et al. 2013) and bulk RNA-seq in our study.  
a) Scatterplot showing log2 fold change in expression between the AA and DT versus log2-transformed 
mean expression levels for all genes detected using RNA-seq. Genes identified as differentially 
expressed using RNA-seq only (red), microarrays only (green) and with both methods (blue) are 
indicated. b) Bar plot showing the percentages of differentially expressed genes detected using 
microarrays only (green), RNA-seq only (red) or both methods (blue) for different expression level 
thresholds. The figure is from Dobnikar and Taylor et al. 2018.  
 
 
In summary, I identified a refined list of differentially expressed genes between the AA and DT 
regions using bulk RNA-seq. I next explored how the region-specific gene expression is 
reflected at the single-cell level. 
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3.2.3 Transcriptional signatures of AA and DT regions are detectable at the single-cell 
level 
Genes identified as differentially expressed using bulk RNA-seq had a variety of expression 
profiles at the single-cell level. For example, some genes showed almost exclusive expression 
in one region only (Figure 3.10, top panel), whereas others were expressed in different 
proportions of AA and DT cells (Figure 3.10, bottom panel). This led us to question whether 
each individual cell expressed a regional signature or whether population level differences 
might be reflected in different proportion of cells expressing the observed gene signatures 
associated with each region.  
 
 
 
 
Figure 3.10: Examples of expression patterns of genes identified as differentially expressed in bulk 
RNA-seq at the single-cell level.  
Boxplots showing log2-transformed normalised read counts for single VSMCs from the AA (red) and 
the DT (yellow). Top panel shows examples of genes, where only one of the regions shows appreciable 
expression. Examples of genes, which are expressed by different proportions of AA and DT cells, are 
shown in the bottom panel. The figure is from Dobnikar and Taylor et al. 2018. 
 
 
To address this question, I assessed whether regional identity of VSMCs could be predicted 
with machine learning based on the transcriptomes of single cells. If a reliable predictive 
model could be built, this would suggest that each individual cell bears a signature of regional 
identity. I used a random forest model to classify each VSMC as either belonging to the AA or 
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the DT region. I chose to use a random forest approach as it provided insight into which genes 
were important for classification, in addition to the high performance of the random forest 
model in this setting. Firstly, single cells were randomly assigned to the training (75% of the 
cells) and test (25% of the cells) datasets (Figure 3.11). The test dataset was withheld during 
model construction and optimisation, and was only used to test the final model.  
 
 
 
 
Figure 3.11: Schematic of the random forest approach.  
A schematic showing the proportions of cells included in the training (75%) and test (25%) datasets 
during random forest model construction. The figure is adapted from Dobnikar and Taylor et al. 2018. 
 
 
Due to a limited number of samples available for model training, it was necessary to select a 
reduced set of genes, on which the model would be based. This step removed redundant 
genes and ensured that the model was interpretable and not overly complex. I started with 
the list of genes identified as differentially expressed using bulk RNA-seq and then used the 
recursive feature elimination algorithm to reduce the number of genes further. Recursive 
feature elimination first constructs a random forest model and ranks the genes based on their 
importance for model accuracy. Further random forest models are then constructed based on 
a series of predetermined numbers of genes found to be most important for model accuracy. 
The performance of these models is then evaluated to assess which sets of genes lead to good 
performance. Using this approach, I identified a set of 30 genes with a strong predictive power 
and constructed the final random forest model based on the training data. Several of the 30 
top predictive genes were among the most differentially expressed genes in bulk RNA-seq 
data (for example Pde1c, Hand2, Hoxa7, Gpc3 and 22104C18Rik), however the selection of 
other genes by recursive feature elimination was less obvious. This is likely due to gene 
expression differences between the bulk and single-cell datasets and the non-linear nature of 
the random forest algorithm, where performance is dependent on the whole set of genes used 
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in training rather than individual genes. The importance of the top 30 predictive genes for the 
accuracy of the final model is shown in Figure 3.12a.  
 
Next, the cells initially withheld for model testing were used to evaluate the performance of 
the model on unseen data. The model showed high levels of accuracy, correctly predicting 
17/18 AA cells and 14/15 DT cells from the test set. The accuracy of the random forest model 
is also demonstrated in Figure 3.12b, which shows that high levels of correct predictions are 
achieved while maintaining low levels of false positives. Consistent with the observation that 
the 30 genes used for random forest construction have the predictive power to classify cells 
as originating from the AA or DT regions, principal component analysis based on these genes 
showed a separation of the AA and DT cells (Figure 3.12c). Furthermore, Figure 3.12c shows 
that VSMCs from the test set (highlighted with black circles) were evenly distributed along the 
principal components 1 and 2 and thus form a representative test set. To examine whether 
the random forest model may be overfitting I performed an additional negative control. The 
regional labels of AA and DT single cells were randomly permuted and split into training and 
test datasets. An equivalent random forest model was than trained and tested on the 
transcriptomes with randomised regional labels. The performance of the random forest model 
on randomised data was markedly reduced compared with the original random forest model, 
and was only marginally better than random (Figure 3.12d), suggesting that significant 
overfitting during model training did not occur. 
 
Ex vivo VSMCs from the both of the AA and DT regions were profiled in two separate 
experiments. VSMCs from both of the batches were present in both the training and test 
datasets and were accurately classified as originating from the AA or DT regions. However, for 
VSMCs originating from the DT region, batch effects were apparent on the PCA plot based on 
the 30 random forest predictor genes (Figure 3.13). I have chosen not to apply batch 
correction to single-cell transcriptomes to ensure that any technical factors, which have likely 
affected one of the DT batches, would not introduce artificial differences between the AA and 
DT profiles. Instead I have ensured that VSMCs from both experiments were accurately 
predicted in the test dataset before making conclusions about the effectiveness of the random 
forest model and kept the technical issues in mind during further analysis.  
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Figure 3.12: Random forest analysis distinguishes ex vivo VSMCs from the AA and DT regions at the 
single-cell level.  
a) Bar plot showing the importance for model accuracy of genes used to construct the random forest 
model. b) Receiver operating characteristics curve showing the level of true positive rate of 
classification for a given level of false positive rate. The area under the curve (AUC) is indicated. c) PCA 
based on the 30 genes used for random forest construction. VSMCs from the AA are shown in red and 
VSMCs from the DT are shown in yellow. VSMCs assigned to the test set are circled in black. PC1 
explained 17% and PC2 8% of the variance. d) Results of a randomised negative control, where the AA 
and DT regional labels of transcriptional profiles were randomly permuted for both the training (left) 
and test (right) datasets. Panels a-c are from Dobnikar and Taylor et al. 2018. 
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Figure 3.13: Examination of batch effects in ex vivo VSMCs profiled in separate AA and DT 
experiments.  
PCA is based on the 30 predictor genes used in the random forest model. VSMCs from the AA are 
shown in dark red (batch 1) and pink (batch 2) and VSMCs from the DT are shown in orange (batch 1) 
or yellow (batch 2). PC1 explained 17% and PC2 8% of the variance. 
 
 
Overall, high performance of the random forest classifier suggested that each individual cell 
within the AA and DT region could be assigned to the region of origin based on its 
transcriptional profile. If population level differences in gene expression profiles between the 
AA and DT regions were due to different proportions of cell populations present in each 
region, an accurate classification model would not be expected. These results therefore 
suggest that the regional identity signature is expressed at the level of individual cells.  
 
3.2.4 Heterogeneity of VSMCs within the AA and DT vascular beds 
My next objective was to explore whether VSMCs from the AA and DT regions showed 
heterogeneity within each vascular bed and if so, which genes were highly variable. Variability 
in observed gene expression levels between cells from the same vascular bed is due to both 
technical and biological effects. Low amount of starting material is one of the main technical 
factors contributing to the resulting cell-cell variability (Brennecke et al. 2013). Such technical 
variability is dependent on the mean expression level of a gene and decreases for highly 
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expressed genes as higher transcript levels are captured more consistently across cells and 
dropout effects become less dominant. I was interested in the genes, which showed variability 
in expression levels beyond the technical noise, given their mean expression level.  
 
To assess which genes were expressed heterogeneously, I adopted an approach for identifying 
highly variable genes (Lun et al. 2016) based on the relationship between variance and mean 
log expression of profiled genes. To estimate the background technical variation I fitted a 
parametric trend to the variance of log expression levels versus mean log expression levels of 
all genes. The assumption of this method was that a large majority of genes were not variably 
expressed between the cells, therefore the minority of genes that were expressed 
heterogeneously should not skew the background estimation. Technical background variation 
was then subtracted from the total variance of each gene. A gene was identified as highly 
variable if the remaining biological component of variance was significantly greater than zero 
(adjusted p-value < 0.05, details in Methods, Lun et al. 2016). This resulted in 176 genes being 
identified as highly variable in the AA region and 120 in the DT region (Figure 3.14), with 65 of 
them common to both regions. Interestingly, only two of the genes identified as highly 
variable in at least one region (Wif1 and Lum) were also identified as differentially expressed 
between AA and DT (Section 3.2.2), suggesting that heterogeneity within each vascular region 
is largely driven by factors independent of regional identity.  
 
 
 
Figure 3.14: Highly variable genes in AA and DT regions. 
Scatterplots showing the variance of log2-transformed normalised read counts versus mean log2-
transformed normalised read counts, with each black dot representing a gene. Genes identified as 
highly variable in the AA (red, left) and the DT (yellow, right) are indicated. Blue line represents the 
estimation of technical variance. The figure is from Dobnikar and Taylor et al. 2018. 
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To assess the nature of the genes, which were identified as highly variable, I used gene 
ontology analysis. Highly variable genes within the AA region showed enrichment for “positive 
regulation of vasculature development” (genes Pdgfd, Hspb6, Nras, Hk2, Efnb2, Adm, Anxa1, 
F3, Rapgef2, Myocd) and “regulation of cell growth” (genes Cd44, Thrb, Fn1, Rab11a, Rtn4, 
Ddx3x, Tram1, Rbbp7, Gja1, Sdcbp, Sgk1, Myocd, Efna5, Rgs4) among enriched gene ontology 
terms (Figure 3.15). Highly variable genes within the DT region showed enrichment for gene 
ontology term “regulation of cell population proliferation” (genes Cd44, Thrb, Itga1, Stat1, 
Tes, Wisp2, Pdgfd, Atf3, Rtn4, Anxa2, Dsp, Gpx1, Nfkbia, Fth1, Rgs5, Efnb2, Nupr1, Ctnnb1, 
Asph, Cdh13, Anxa1, Gja1, Cnbp, Hipk1, Rps6kb1). In addition, a number of genes identified as 
highly variable were involved in processes which play an important role in VSMC biology in 
disease, such as proliferation and migration. While gene ontology terms “regulation of cell 
proliferation” and “regulation of cell migration” were not significantly enriched among the 
highly variable genes in the AA or DT regions, a number of highly variable genes were 
associated with these gene ontology terms. Forty of the genes identified as highly variable 
were associated with the gene ontology term “regulation of cell proliferation”, including Rgs5, 
Gja1, Pdgfd, Irf1, Anxa1, Anxa2, Myocd, Fn1 and Nfkbia. 21 of the highly variable genes in 
either region mapped to the go term “regulation of cell migration”, including Pdgfd, Anxa1, 
Anxa3, Myocd, Fn1, Adamts1, Gja1 and Postn among others. Expression profiles for some of 
the highly variable genes are shown in Figure 3.16. 
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Figure 3.15: Gene ontology analysis of highly variable genes in the AA and DT regions.  
Enrichment for gene ontology terms (biological process) among genes identified as highly variable in 
the AA (a) and DT (b) regions. Bar plots show the significantly enriched gene ontology terms, ranked 
by their adjusted p-values (details in Methods). 
 
 
Several of the genes identified as highly variable within the AA or DT regions were previously 
investigated in the context of cardiovascular disease. For example, Anxa1 has been observed 
to be expressed at lower levels in VSMCs isolated from asymptomatic compared with 
symptomatic human plaques (Viiri et al. 2013). Pdgfd is an activator of the PDGF receptor β 
and overexpression of Pdgfd in transgenic mice was observed to lead to increased VSMC 
proliferation and vascular remodelling (Pontén et al. 2005). Rgs5 was observed to promote 
atherosclerotic plaque formation and its expression was found to be increased during arterial 
remodelling (Arnold et al. 2014). Rgs5 is also involved in the regulation of blood pressure and 
VSMC contraction (Gunaje et al. 2011). Overall, this analysis shows that VSMCs from the same 
vascular region show heterogeneous expression of a range of genes related to biological 
functions, which are important for VSMC biology in healthy arteries as well as in disease. 
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Figure 3.16: Expression levels of highly variable genes in profiled VSMCs.  
Violin plots showing the distribution of log2-transformed normalised read counts of selected highly 
variable genes across the cells from the AA (red) and the DT (yellow). The median is marked with a 
grey line.  
 
 
3.2.5 Highly variable gene expression in independent VSMC profiles 
Highly variable gene analysis in Section 3.2.4 identified individual genes which showed 
heterogeneity in expression levels among VSMCs. I was next interested in examining whether 
subsets of highly variable genes showed coordinated variability between individual VSMCs. 
However, the number of cells profiled using the Fluidigm C1 platform was too low to detect 
clear co-expression patterns. Instead, I examined the expression patterns of highly variable 
genes in independent VSMC profiles. To this end, I used two scRNA-seq datasets of thousands 
of aortic cells generated using the 10X Genomics Chromium platform in collaboration with A.L. 
Taylor. Both datasets were generated using aortas of mice on a VSMC lineage traced 
background (details in Methods). The first dataset was generated only from medial cells FACS-
sorted for VSMC-lineage label expression. The second dataset was generated from the whole 
aorta and contains adventitial and endothelial cells alongside VSMCs. 
 
3.2.6 Processing of the 10X Genomics Chromium VSMC transcriptomes 
Sequencing data of single-cell transcriptomes generated using the 10X Genomics Chromium 
platform was processed through the 10X Genomics pipeline (details in Methods). I then 
filtered the transcriptomes based on the number of UMIs detected per cell, the number of 
genes detected and the proportion of mitochondrial reads (Figure 3.17, details in Methods) 
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and normalised the profiles of the remaining 5686 cells. I then used principal component 
analysis to identify the major sources of variability between the cells. To reduce noise and 
dimensionality, clustering analysis was based on the results of principal component analysis, 
rather than on the expression levels of individual genes. It is desired to exclude non-
informative principal components from the analysis to reduce noise and overfitting, however 
care needs to be taken that important aspects of heterogeneity are not excluded from the 
analysis. The standard deviation of identified principal components and the clusters of cells 
they delineate are shown in Figure 3.18. The first 15 principal components, all of which 
explained significantly more variance between the cells than would be expected at random, 
were included in the final clustering analysis (details in Methods). In total, 9 clusters were 
identified. Clusters 0, 1, 2, 3, 5 and 6 expressed VSMC marker genes, such as Myh11, and all 
contained cells from both the whole aorta and the VSMC-only datasets (Figure 3.19). Cells 
within clusters 4 and 7 expressed adventitial marker gene Pdgfra or the endothelial marker 
gene Cdh5 and were assigned adventitial and endothelial identities respectively (Figure 3.19).  
 
 
 
 
Figure 3.17: Quality control of the VSMCs only (red) and whole aorta (blue) 10X Genomics Chromium 
datasets.  
Violin plots show the distribution of values for total UMI count, number of genes detected and 
proportion of mitochondrial reads. Black dots represent individual cells and red lines indicate the 
quality control thresholds. Cells were considered to be of good quality if total UMI count was between 
1000 and 8000, number of genes detected was between 500 and 2500 and the percentage of 
mitochondrial reads was below 8%. 
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Figure 3.18: Principal component analysis and selection of principal components for further analysis.  
Top left plot shows the standard deviation of principal components 1-20. The higher the standard 
deviation, the more variance is explained by that component. The other plots show the values of 
principal components 1-16 for profiled cells. Each cell is represented by a circle and is coloured-coded 
by cluster membership. PC1 separated VSMCs (clusters 0, 1, 2, 3, 5 and 6) from other profiled cells, 
PC2 separated the endothelial cells (cluster 7), P3 further separated endothelial cells as well profiles 
likely originating from resident immune cells (cluster 8), while PCs 4 and 5 further separated cluster 8.  
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Figure 3.19: Clustering analysis and identification of cell types within the VSMC-only and whole aorta 
10X Genomics Chromium datasets.  
a) Results of clustering analysis (details in Methods) with adventitial, endothelial and VSMC clusters 
indicated on a t-SNE plot. b) Distribution of cells from the VSMC-only and whole aorta datasets, which 
confirmed assignemnt of VSMC cluster identities. Cells from the VSMCs-only dataset are shown in red 
and whole aorta dataset cells in blue. (c-d) Expression levels of VSMC marker Myh11, adventitial 
marker Pdgfra and endothelial marker Cdh5 are colour coded on a t-SNE plot, with darker gray 
representing higher expression levels.  
 
 
3.2.7 Highly variable genes show co-expression in VSMCs profiled using the 10X 
Genomics Chromium platform  
Next I investigated whether highly variable genes identified in the Fluidigm C1 dataset showed 
differential expression in specific clusters of VSMCs. I performed differential expression 
analysis for each VSMC cluster relative to the remaining VSMCs (log2 fold change > 0.5 and 
adjusted p-value < 0.05, details in Methods) and examined the overlap of upregulated and 
downregulated genes in each cluster with previously identified highly variable genes (Table 
3.1).  
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 Cluster 
0 
Cluster 
1 
Cluster 
2 
Cluster 
3 
Cluster 
5 
Cluster 
6 
Total upregulated genes 0 0 64 19 3 62 
Of which highly variable 
genes 
0 0 17 1 0 3 
Total downregulated genes 55 3 1 0 0 42 
Of which highly variable 
genes 
13 0 1 0 0 5 
 
Table 3.1: Table shows the numbers of upregulated and downregulated genes within each of the VSMC 
clusters (details in Methods), which overlap with highly variable genes identified in either the AA or DT 
region.  
 
 
One of the most highly variable genes in the Fluidigm C1 dataset Rgs5, was found to be 
upregulated in cluster 6 and downregulated in cluster 2 (Figure 3.20a). Several genes were 
identified as differentially upregulated or downregulated in Cluster 6, suggesting that its 
expression profiles differed more substantially than the remaining VSMC clusters (Table 3.1). 
Clusters 1 and 5 did not differentially express any of the highly variable genes and the only 
highly variable gene upregulated in cluster 3 was Gnb1 (Table 3.1). VSMCs in cluster 2 
expressed 17 highly variable genes at higher levels and 13 highly variable genes were 
downregulated in cluster 0 (Table 3.1). Notably, 12 of the highly variable genes upregulated 
in cluster 2 were also downregulated in cluster 0 (Figure 3.20b). Expression patterns of the 
most strongly upregulated genes in cluster 2 (Nfkbia, Wsb1 and Ppp1r15a) and downregulated 
genes in cluster 0 (Nfkbia, Gadd45b and Ppp1r15a) are shown in Figure 3.20c. Observed 
differences in expression levels of highly variable genes between clusters 0 and 2 are not 
explained by quality control parameters, such as the total normalised log-transformed 
expression levels or the number of genes detected per cell (Figure 3.20d). Overall, this analysis 
suggests that a subset of highly variable genes is co-expressed in VSMCs from healthy arteries.  
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Figure 3.20: Highly variable gene expression in VSMC profiled as part of the 10X Genomics Chromium 
whole aorta and VSMCs-only datasets.  
a, c) Expression levels of highly variable genes Rgs5 (a), Nfkbia, Wsb1, Gadd45b and Ppp1r15a (c) are 
colour coded on a t-SNE plot, with darker gray representing higher expression levels. b) Barplots 
showing the highly variable genes, which are upregulated in cluster 2 (left, green) and downregulated 
in cluster 0 (right, left). The log2 fold change of each gene within clusters 2 and 0 is shown. d) Violin 
plots representing the quality control parameters of total normalised log expression and the number 
of genes detected per cell, shown separately for each cluster, as defined in Figure 3.19a. Black dots 
represent individual cells.  
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3.2.8 Application of the random forest model to independent VSMC profiles  
I was next interested in how generalizable the findings from the random forest analysis were 
to independent datasets. While the random forest model achieved high accuracy for 
predicting regional identity of aortic VSMCs within the Fluidigm C1 dataset, I wanted to 
explore how versatile the model was for predicting regional identity in sparser datasets. I used 
the scRNA-seq datasets of aortic cells generated using the 10X Genomics Chromium described 
in Section 3.2.6, to explore the predictive power of the random forest classifier. It is important 
to note that the AA and DT regional identity of the cells in these datasets was not known in 
advance, therefore they could not be used as a formal validation of the random forest 
classifier. Instead, I applied the classifier to these datasets to learn whether it has any 
predicative power based on expression levels of known differentially expressed genes.  
 
I first checked the expression of random forest predictor genes in VSMCs profiled using the 
10X Genomics Chromium platform. While all 30 predictor genes were expressed at 
appreciable levels in the Fluidigm C1 dataset, expression was much sparser in the 10X 
Genomics Chromium dataset, with 11 out of 30 genes expressed in less than 1% of VSMCs. 
The median percentage of VSMCs expressing a particular predictor gene was 56% for Fluidigm 
C1 cells and 4% for 10X VSMCs (Figure 3.21a). Additionally, the number of random forest 
predictor genes expressed per cell was drastically lower in the 10X Genomics Chromium 
dataset compared with the Fluidigm C1 dataset (Figure 3.21b). Such sparsity in random forest 
predictor genes’ expression is expected to affect the classifier performance. This was 
particularly problematic for DT cells, as there were only 9 predictor genes, which were 
upregulated in the DT region according to bulk RNA-seq, as opposed to 21 AA predictors.  
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Figure 3.21: Random forest predictor genes are expressed sparsly in VSMCs-only and whole aorta 
10X Genomics Chromium datasets.  
a) Violin plot showing the proportion of cells that express a random forest predictior, with dots 
representing individual predictor genes. Median levels for 10X Genomics Chromium (light grey) and 
Fluidigm C1 (dark grey) are indicated with a black bar. b) Barplots showing the distribution of the 
number of random forest predictors expressed in an individual cell in the 10X Genomics Chromium 
(top) and Fluidigm C1 (bottom) datasets. 
 
 
The random forest classifier predicted that 690 VSMCs were of DT origin and 4479 VSMCs 
from the AA. The outcome was likely biased towards AA predictions due to a higher number 
of random forest predictor genes identified as upregulated in the AA with bulk RNA-seq. As 
an initial check of the regional predictions, I examined the expression levels of random forest 
predictor genes Hand2, Sfrp2, Hoxa7 and Ccdc3 (Figure 3.22a). As expected, Hand2 and Sfrp2 
were overall expressed at higher levels in VSMCs predicted to be of the AA origin, while Hoxa7 
and Ccdc3 showed higher expression levels in VSMCs predicted to originate from the DT 
region. Since Hand2, Sfrp2, Hoxa7 and Ccdc3 were part of the random forest model, the fact 
that higher expression of these genes was observed in the appropriate region was not 
verification of whether the regional identity predictions were sensible. To partially overcome 
the limitation of not knowing the regional identity of VSMCs in advance, I examined the 
expression levels of all genes, which were identified as differentially expressed in either the 
AA or DT regions according to bulk RNA-seq. Figure 3.22b shows that overall single cells with 
predicted AA identity showed higher expression levels of genes upregulated in the AA region 
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than DT-predicted cells. Similarly, cells predicted to originate from the DT showed overall 
higher expression levels of genes upregulated in the DT region.  
 
 
 
 
Figure 3.22: Random forest model applied to 10X Genomics Chromium datasets.  
a) Boxplots showing the expression levels of AA-upregulated random forest predictors Hand2 and 
Sfrp2 and DT-upregulated predictors Hoxa7 and Ccdc3 in 10X profiled VSMCs, which were predicted to 
originate from either the AA or DT region. b) Boxplots showing the PC1 score in VSMCs segregated 
based on their predicted regional identity. Principal component analysis is based on all genes identified 
as upregulated in either AA (left) or DT (right) using bulk RNA-seq. Higher PC1 score represents higher 
overall expression in a cell (details in Methods). c) t-SNE plot colour coded by the random forest 
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prediction for each VSMC. AA predictions are shown in red and DT predictions in blue. d) Barplot 
showing the log2 fold change in expression between cluster 6 and other VSMCs for genes differentially 
expressed in cluster 6 as well as in bulk RNA-seq. Genes included in the random forest model are 
indicated in grey. e, f) Barplots showing the top 10 overrepresented gene ontology terms ranked by 
adjusted p-value, which were found to be significantly enriched among the genes upregulated (e) or 
downregulated (f) in cluster 6 relative to other VSMCs.  
 
 
The majority of VSMC clusters contained cells which were predicted as originating from both 
the AA and the DT regions. Cluster 6, however, contained only cells predicted to originate from 
the AA region (Figure 3.22c). Despite the fact that more VSMCs were predicted as originating 
from the AA than the DT region, observing 0% of DT predictions in cluster 6 and 16% of DT 
predictions in other VSMCs would not be expected at random (Fisher’s exact test, p = 4e-9, 
details in Methods). Differential gene expression analysis discussed in Section 3.2.7 identified 
62 genes as upregulated and 42 genes as downregulated in cluster 6 relative to other VSMC 
clusters. Of the 62 genes identified as upregulated in cluster 6, 16 were upregulated in the AA 
bulk RNA-seq profiles, while none of the 62 genes were expressed at significantly higher levels 
in the DT bulk RNA-seq profiles. Additionally, one of the genes downregulated in cluster 6 was 
found to be upregulated in the DT region in bulk RNA-seq (Figure 3.22d). Importantly, 11 of 
the 16 AA genes upregulated in cluster 6 and in bulk AA profiles were not part of the random 
forest model, which supported the assignment of AA identities to VSMCs in this cluster by the 
classifier (Figure 3.22d). Gene ontology analysis of genes upregulated in cluster 6 showed 
overrepresentation of genes involved in extracellular matrix organisation, regulation of cell 
population proliferation and regulation of ossification, among other functions (Figure 3.22e). 
Downregulated genes showed overrepresentation for genes involved in positive regulation of 
cell migration and cell adhesion, as well as other gene ontology terms (Figure 3.22f). These 
functions are relevant for VSMC biology, suggesting that cluster 6 may have a functional role 
within the AA region. Since VSMCs within cluster 6 comprise only 3% percent of all VSMCs 
profiled using the 10X Genomics Chromium platform, this subpopulation of cells was likely to 
rare to have been detected in the Fluidigm C1 dataset, where only 79 AA cells were profiled.  
 
In conclusion, this analysis suggested that the random forest model may be able to identify 
the AA or DT affiliation of cells in the 10X Genomics Chromium dataset, however the sparsity 
of the data is likely a limiting factor for the performance of the model. Overall, further 
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validation where the regional identities of VSMCs are known in advance is required to form 
concrete conclusions about the performance of the model in this setting. Two separate 10X 
Genomics Chromium datasets of the AA and DT VSMCs would also enable the validation of 
the observation that VSMCs in cluster 6 appear to originate only from the neural crest-derived 
AA region. Interestingly, a similar cluster of VSMCs was observed after carotid ligation injury 
in carotid arteries, which are also derived from the neural crest (Section 5.2.2). 
 
3.3 Discussion 
In this chapter I used single-cell transcriptomics to probe the heterogeneity of VSMCs. In 
particular, I focused on the regional heterogeneity between parts of the aorta with distinct 
developmental origins, as well as on the heterogeneity within an aortic region. All profiled 
VSMCs shared common features, such as expression of VSMC marker genes. However, 
consistent differences in gene expression profiles were observed between individual VSMCs 
originating from the AA or DT aortic regions. Moreover, I observed significant cell-to-cell 
heterogeneity with respect to genes involved in VSMC biology and disease within a vascular 
bed. This suggests that VSMC heterogeneity in the healthy state may contribute to differential 
responses to stimuli of VSMCs.  
 
3.3.1 Regional heterogeneity of VSMCs 
Several studies have described the regional differences in susceptibility to vascular disease, 
such as atherosclerosis and vascular calcification (Haimovici & Maier 1971; DeBakey & Glaeser 
2000; Leroux-Berger et al. 2011). In this section I studied the transcriptional differences 
between the atherosclerosis-susceptible AA and atherosclerosis-resistant DT regions, in which 
the VSMC populations are of distinct embryonic origins (Trigueros-Motos et al. 2013; Majesky 
2007). Transcriptional variation between the AA and DT regions has been previously 
investigated using microarrays (Trigueros-Motos et al. 2013; Van Assche et al. 2011). Bulk 
RNA-seq analysis replicated the key findings of higher levels of Hox gene expression in VSMCs 
from the DT region. Among the genes identified as upregulated in the DT region according to 
bulk RNA-seq and previous microarray experiments was Hoxa9, which has been previously 
reported to reciprocally inhibit the proinflammatory transcription factor Nfkb1 in VSMCs 
(Trigueros-Motos et al. 2013). Trigueros-Motos et al. (2013) further reported higher levels of 
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Nfkb1 activity in the AA, which provides a possible explanation of higher susceptibility for 
atherosclerosis through increased inflammation. In agreement with this, gene ontology 
analysis of AA upregulated genes according to bulk RNA-seq revealed enrichment for genes 
involved in the inflammatory response.  
 
Distinct embryonic origins of the neuroectoderm-derived AA and mesoderm-derived DT 
VSMCs are one of the factors affecting the transcriptional differences between the two 
regions. However, there are other factors which could be underpinning the observed 
differences. For example, environmental factors including the local hemodynamic forces and 
the levels of mechanical stress experienced in a given vascular bed may play a role. For 
instance, atherosclerotic plaques frequently develop at branching sites or in areas 
experiencing high mechanical forces (Cunningham & Gotlieb 2005; Chiu & Chien 2011). In this 
analysis it was not possible to separate the confounding effects of differing local environments 
and distinct embryonic origins. To isolate the effects of embryonic origin on the susceptibility 
to atherosclerosis, grafts from the atherosclerosis-susceptible canine abdominal aorta have 
been transplanted into the jugular vein in a previous study (Haimovici & Maier 1971). The 
grafts retained higher susceptibility for atherosclerosis in the lower pressure environment of 
the jugular vein, suggesting an intrinsic difference in disease susceptibility (Haimovici & Maier 
1971). More specifically, the transcriptional differences between VSMCs from the AA and DT 
regions have previously been addressed in the context of environmental factors. Advances in 
in vitro programming of pluripotent stem cells have enabled in vitro differentiation of VSMCs 
of the neuroectodermal or the mesodermal lineages (Cheung et al. 2012). Higher expression 
levels of several Hox genes, including Hoxa9, have been observed in VSMCs of mesodermal 
lineage compared to neuroectodermal VSMCs, both of which have been derived from human 
pluripotent stem cells in vitro (Cheung et al. 2012; Trigueros-Motos et al. 2013). This finding 
suggests that differences in expression between the two regions are not entirely due to 
environmental factors, and indicates that observed transcriptional differences between the 
VSMCs from the AA and DT regions may apply in human VSMCs.  
 
Bulk RNA-seq analysis has provided a refined list of differentially expressed genes between 
the two regions. However, population-level profiling approaches are unable to determine 
whether the observed differences are uniformly present in individual cells or whether they 
are due to differential composition of VSMCs in the two regions. The work in this chapter, 
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enabled by recent advances in single-cell transcriptomics, has looked at regional 
heterogeneity of aortic VSMCs at the single-cell level. The fact that it was possible to construct 
an accurate classifier suggests that the transcriptional signatures of the AA and DT regions are 
present at the level of individual cells, as reliable classification would not be possible 
otherwise. 
 
The application of the random forest model to aortic VSMCs profiled using the 10X Genomics 
Chromium platform indicates that the random forest has some discerning power between the 
AA and DT VSMCs in sparse datasets. This suggests that such an approach could be useful for 
assigning regional identities to VSMCs within larger datasets such as the mouse single-cell 
atlas (The Tabula Muris Consortium 2018), where AA and DT regions were not profiled 
separately. Interestingly, the application of the random forest classifier to the whole aorta and 
VSMC-only datasets profiled using the 10X Genomics Chromium platform highlighted a subset 
of VSMCs, which were predicted to originate exclusively from the AA region and expressed 
Rgs5 at higher levels than average for VSMCs. However, further validation in settings where 
the AA and DT identities of VSMCs are known in advance is required to test the performance 
of the model in sparser datasets, and to validate whether the subset of cells with increased 
Rgs5 expression is present exclusively in the AA region.  
 
3.3.2 Highly variable genes 
High variability in levels of VSMC marker proteins between VSMCs resident in the same 
vascular bed has been previously observed during response to injury (Frid et al. 1994; Rensen 
et al. 2007). Rensen et al. (2007) proposed that VSMCs exist in a spectrum of phenotypes 
ranging from contractile to synthetic within healthy tissue. I hypothesised that variability in 
the healthy state may underpin this differential response of VSMCs to stimulus. Despite the 
uniform expression of regional signatures in single cells, I observed significant cell-to-cell 
heterogeneity within each vascular bed. Several genes identified as highly variable within a 
vascular bed are known to be involved in VSMC biology and disease. Interestingly, there was 
a low overlap between genes identified as highly variable and those identified as differentially 
expressed between the AA and DT regions using bulk RNA-seq. This suggests that cell-to-cell 
heterogeneity within a vascular bed is largely driven by factors independent of the regional 
identity. 
74 
 
The approach taken to identify highly variable genes in this chapter relies on the estimation 
of the background technical variation level and identifying genes with significantly higher 
variability. This approach does not exclude genes which may show true cell-to-cell variation at 
the time of profiling, but where such variation does not necessarily have functional 
implications. Such examples of stochastic variation include transcriptional bursts (Raj & van 
Oudenaarden 2008). Additionally, variable expression of a gene does not necessarily reflect 
variable activity levels of the corresponding protein product. There is potential for post-
transcriptional regulation, which is not captured with the single-cell RNA-seq approach. Since 
the variability of expression of individual genes could be driven by factors which do not 
influence the functional activity levels of the resulting protein, it would be informative to look 
for coordinated variability within a set of highly variable genes. The numbers of cells profiled 
using the Fluidigm C1 method were too low to detect co-expression patterns within highly 
variable genes. However, examining the VSMCs profiled using the 10X Genomics Chromium 
platform revealed that a subset of highly variable genes are co-expressed.  
 
Heterogeneity between single VSMCs at the transcriptional level is in agreement with previous 
observations that several G-protein coupled receptor genes are heterogeneously expressed 
in different vascular regions as well as among aortic VSMCs (Kaur et al. 2017). This study was 
based on single-cell RT-qPCR and further investigated the differences between aortic VSMCs 
from healthy vessels and atherosclerotic arteries. The authors observed that the 
transcriptional profiles of a subset of healthy VSMCs matched the profiles of atherosclerotic 
VSMCs. This subset of healthy VSMCs showed upregulation of a number of G-protein coupled 
receptor genes, including Gprc5b, and was reported to be localised at the inner curvature of 
the AA, which is at increased risk of plaque development due to disturbed blood flow in the 
region (Kaur et al. 2017; Chiu & Chien 2011). No clear segregation of VSMCs with analogous 
expression profiles was observed in either the 10X Genomics Chromium or the Fluidigm C1 
datasets, possibly due to lower sensitivity of the method compared to the RT-qPCR approach 
taken by Kaur et al. (2017). Gprc5b was only detected at low levels in a small numbers of cells, 
and its expression levels may be too low to reliably detect it with scRNA-seq.  
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3.3.3 Conclusion 
In conclusion, the work in this chapter delineated the transcriptional heterogeneity of VSMCs 
between different regions, as well as between individual VSMCs from the same vascular bed. 
I have shown that reliable regional classification of individual VSMC transcriptomes is possible, 
and identified a putative population of cells present only in the AA by applying the classifier 
to an independent dataset. The analysis of highly variable genes within each vascular bed 
revealed significant cell-to-cell heterogeneity of many disease-relevant genes. Furthermore, a 
subset of highly variable genes was co-expressed within the 10X dataset. In the future, it 
would be interesting to investigate the spatial positioning of VSMCs expressing highly variable 
genes at different levels. Single-molecule fluorescence in situ hybridisation or immunostaining 
for a subset of co-expressed highly variable genes could reveal whether there are any areas of 
the aorta, where consistently higher signal is observed. In particular, it would be informative 
to explore whether areas of disturbed flow, such as the branch sites, express increased levels 
of disease-relevant highly variable genes in healthy arteries. This may aid in the investigation 
of the early transcriptional changes in VSMCs, which are involved in atherosclerosis and 
provide direction for future investigations into early targeting of VSMCs involved in disease. 
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4 Rare subpopulation of SCA1-positive VSMCs detected in 
healthy arteries 
4.1 Introduction 
VSMCs possess a remarkable capacity to switch from a contractile muscle phenotype to a 
proliferative synthetic state in response to injury or inflammation (Rensen et al. 2007). 
However, recent studies have challenged the assumption that the majority of VSMCs generate 
the phenotypically modulated VSMC populations under these conditions. For example, it has 
been found that only very few VSMCs undergo extensive proliferation in atherosclerosis, 
which results in clonal or oligoclonal VSMC patches in atherosclerotic plaques (Chappell et al. 
2016; Jacobsen et al. 2017).  
 
There have been previous reports of progenitor populations within the vasculature, which 
have been proposed to differentiate towards VSMCs and to contribute to atherosclerotic 
plaque formation and blood vessel calcification (Hu et al. 2004; Passman et al. 2008; Kramann 
et al. 2016). However, several studies showed that VSMCs within the atherosclerotic plaque 
originated from VSMCs, which expressed contractile differentiation markers prior to 
atherosclerosis plaque development (Nemenoff et al. 2011; Gomez et al. 2013; Feil et al. 2014; 
Shankman et al. 2015; Chappell et al. 2016; Jacobsen et al. 2017).  
 
Jointly, these findings have suggested that VSMCs are functionally heterogeneous with 
respect to their response in atherosclerosis. In collaboration with H.F. Jørgensen’s group, we 
pursued the hypothesis that the differential VSMC response to injury and inflammation may 
be underpinned by the heterogeneity of VSMCs already present in healthy arteries. To 
characterise this heterogeneity, we combined scRNA-seq with a VSMC-specific lineage 
labelling system and profiled the transcriptomes of single VSMC-lineage cells isolated from 
healthy arteries. The analysis revealed a rare subpopulation of VSMCs expressing the 
progenitor marker SCA1, which expressed transcriptional signatures characteristic of the 
synthetic VSMC state.  
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4.2 Results 
4.2.1 Detection of SCA1-positive cells of VSMC lineage in healthy arteries 
Analysis of the transcriptomes of ex vivo VSMCs from the AA and DT regions revealed that one 
of the DT cells co-expressed VSMC marker genes as well as the Ly6a transcript (Ly6a/Sca1) at 
high levels, which encodes the SCA1 protein (Figure 4.1a). Subsequent flow cytometry analysis 
of medial aortic cells stained using the anti-SCA1 antibody showed that 0.5-1% of medial cells 
were SCA1-positive (Figure 4.1b, collaboration with H.F. Jørgensen). SCA1 is a progenitor 
marker (Holmes & Stanford 2007) and was previously found to be expressed in progenitor cell 
populations within the vasculature (Hu et al. 2004; Passman et al. 2008). This prompted us to 
explore the subpopulation of medial SCA1-positive cells further.  
 
 
 
 
Figure 4.1: Ly6a/Sca1 transcript and SCA1 protein is expressed in a small number of medial cells.  
a) Violin plots showing log2-transformed normalised read counts of Myh11, Acta2, Myocd and 
Ly6a/Sca1 in ex vivo VSMCs from the AA and DT regions profiled using the Fluidigm C1 platform. The 
cell co-expressing VSMC marker genes and Ly6a/Sca1 is shown in red. b) Flow cytometry analysis of 
SCA1 protein expression in medial cells. Medial cells were stained either with allophycocyanin (APC) 
conjugated to IgG control (left) or the SCA1 antibody (right). Flow cytometry was carried out by H.F. 
Jørgensen and all panels are from Dobnikar and Taylor et al. 2018. 
 
 
We next used a VSMC-specific lineage tracing system to establish whether SCA1-positive 
medial cells are of the VSMC lineage. We used Myh11-CreERt2 transgenic animals in 
combination with the eYFP single-colour or the R26-Confetti multi-colour reporter (Chappell 
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et al. 2016) to induce permanent fluorescent protein expression in VSMCs after tamoxifen 
injection (Figure 4.2, details in Methods). As Myh11 is a specific marker of VSMCs, tamoxifen 
exposure lead to Cre expression and subsequent recombination at the R26-Confetti/eYFP 
locus in VSMC.  
 
 
 
 
Figure 4.2: Schematic representation of the single-colour (top) and multi-colour (bottom) VSMC 
lineage labelling approaches.  
Upon Myh11 expression Cre-mediated recombination at the Rosa26 locus occurs. This results in stable 
expression of eYFP in the single-colour reporter or of one of the fluorescent proteins (GFP, YFP, RFP or 
CFP) in the multi-colour reporter. Resulting fluorescent label is passed on during cell proliferation and 
is retained if expression of Myh11 is subsequently lost, for example during phenotypic switching. 
Figure adapted from Dobnikar and Taylor et al. 2018. 
 
 
Flow cytometry analysis of medial cells from the aortas of mice on single-colour VSMC lineage 
tracing background revealed that 7.4% of medial SCA1-positive cells express the VSMC lineage 
label (Figure 4.3, collaboration with A.L. Taylor and H.F. Jørgensen). Since the VSMC lineage 
labelling efficiency has been estimated to be at 40-90% for the eYFP reporter, the proportion 
of SCA1-positive cells of VSMC lineage in the media may be higher.  
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Figure 4.3: A proportion of medial SCA1-positive cells express the VSMC lineage label.  
Scatterplots show the forward scatter (FSC) of analysed medial aortic cells from mice on single-colour 
VSMC lineage tracing background against their eYFP VSMC lineage label expression. All medial cells 
(left) or SCA1-positive medial cells only (right) are shown. Rectangular boxes represent the eYFP-
positive cells. Flow cytometry analysis was carried out by A.L. Taylor and H.F. Jørgensen and the figure 
was adapted from Dobnikar and Taylor et al. 2018. 
 
 
To further validate the existence of a VSMC-lineage SCA1-positive subpopulation within the 
medial layer we analysed the medial cells of transgenic Sca1-GFP mice (Ma et al. 2002). Flow 
cytometry analysis showed that 0.2-1.6% of medial cells were GFP-positive (Figure 4.4a, 
collaboration with A.L Taylor), which is in agreement with SCA1 immunostaining analysis 
(Figure 4.1b). To verify that GFP-positive medial cells have a VSMC identity we sorted GFP-
positive medial as well as GFP-positive adventitial cells and immunostained them for the 
contractile VSMC marker ACTA2. As expected, none of the adventitial GFP-positive cells 
expressed ACTA2, whereas 25-86% of medial GFP-positive stained positive for ACTA2 (Figure 
4.4b, collaboration with A.L Taylor). Overall, this approach has provided complementary 
evidence for the existence of a rare medial subpopulation of VSMCs, which express SCA1.  
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Figure 4.4: A subset of medial cells from transgenic Sca1-GFP animals co-express GFP and VSMC 
marker ACTA2.  
a) Medial cells from wild-type as well as transgenic Sca1-GFP animals were analysed for the expression 
of GFP using flow cytometry. None of the wild-type medial cells were positive for GFP, whereas 0.2-
1.6% of medial cells from Sca1-GFP animals expressed GFP across four experiments. The average GFP 
expression in adventitial cells pooled from four animals is shown for reference. b) Plot showing the 
percentage of sorted GFP-positive medial and adventitial cells, which stained positive for ACTA2. GFP-
positive adventitial samples are represented by red circles and GFP-positive medial samples by green 
squares. Flow cytometry analysis and ACTA2 immunostaining was carried out by A.L. Taylor and the 
panels are from Dobnikar and Taylor et al. 2018. 
 
 
To investigate whether the transcriptional signatures of SCA1-positive VSMCs showed 
increased potential for phenotypic switching, we next profiled cells from the whole aorta as 
well as only the cells positive for the VSMC lineage label (L+) using the 10X Genomics 
Chromium platform (Zheng et al. 2017, collaboration with A.L. Taylor). This approach allowed 
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us to profile thousands of cells and enabled us to capture the rare SCA1-positive 
subpopulation of VSMCs. The transcriptomes of profiled cells in the whole aorta and L+ only 
datasets have been processed and analysed jointly as described in Chapter 3, Section 3.2.6. 
This analysis identified three main populations of cells; the VSMCs, adventitial and endothelial 
cells. I observed several Ly6a/Sca1 expressing cells within the VSMC cluster of the whole aorta 
dataset (Figure 4.5a), which further confirmed the existence of SCA1-positive VSMCs. Within 
the L+ only dataset I observed a total of five cells expressing low levels of Ly6a/Sca1 (Figure 
4.5b). Three of these cells were located in the core VSMC cluster with the remaining two cells 
showing different transcriptional profiles. One of these cells was located within the 
endothelial cluster otherwise composed of endothelial cells profiled as part of the whole aorta 
dataset. Plasticity between the mesenchymal and endothelial cells has been proposed to 
occur both in vitro and in vivo (Sainz et al. 2006; Ubil et al. 2014; Evrard et al. 2016; Chen et 
al. 2016), however the VSMC lineage cell located in the endothelial cluster is more likely to be 
a contamination from the neighbouring endothelial layer. This could either be as a result of 
imperfect flow cytometry sorting or due to unspecific VSMC-lineage label expression. 
Microscopy analysis of 72 aortic sections carried out by A.L. Taylor showed a total of seven 
VSMC lineage-positive cells in the adventitial layer and one VSMC lineage-positive cell in the 
endothelial layer. This shows that the VSMC lineage label generally shows high specificity, 
however there are rare cases of lineage-labelled cells located in the neighbouring adventitial 
and endothelial layers. 
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Figure 4.5: Ly6a/Sca1 transcript is expressed in a subset of VSMCs.  
Expression levels of Ly6a/Sca1 in the whole aorta (a) and the VSMC lineage-labelled (L+) cells only (b) 
datasets generated using the 10X Genomics Chromium platform are colour coded on t-SNE plots, with 
darker gray representing higher expression levels. VSMC, adventitial and endothelial clusters were 
defined in Chapter 3, Figure 3.19. 
 
 
Overall we have detected a rare subpopulation of VSMCs, which expressed Ly6a/Sca1. 
However, due to the rarity of these cells, the numbers of Ly6a/Sca1-expressing L+ cells 
captured with the unbiased 10X Genomics Chromium platform were too low to robustly 
investigate their characteristics and heterogeneity. Additionally, the low number of transcripts 
detected per cell in these experiments may pose challenges in detecting differences in 
expression, particularly for lowly expressed genes (Figure 3.17).  
 
4.2.2 Targeted profiling of the medial SCA1-positive subpopulation 
To obtain sufficient numbers of cells for in-depth analysis of the characteristics of SCA1-
positive VSMCs, we decided to use a targeted approach. We selected cells based on the 
expression of the VSMC lineage label and/or SCA1 using flow cytometry and used the Smart-
seq2 protocol (Picelli et al. 2014) to profile their transcriptomes. Typically, aortas from 5-6 
mice needed to be pooled to obtain 100 SCA1-positive and VSMC-lineage positive cells for 
scRNA-seq analysis. Since the number of SCA1-positive VSMCs recovered from primary tissue 
was the limiting factor in this experiment, we decided to use a lower throughput approach, 
83 
 
which can generate higher coverage transcriptomes. We used the Smart-seq2 protocol, rather 
than the Fluidigm C1 technology, as it can be combined with index-sorting by flow cytometry. 
Information on whether each individual cell expressed VSMC lineage label/SCA1 could be used 
later to guide the data analysis. In addition, this protocol enabled different subpopulations of 
cells to be combined on a single 96-well plate during index-sorting, which reduced the impact 
of batch effects on differences between subpopulations.  
 
We isolated the following three subsets of cells from the medial layer of aortas, in which 
VSMCs were labelled using the multi-coloured VSMC lineage tracing strategy: (1) cells 
expressing the VSMC lineage label and SCA1 protein (S+L+); (2) cells that expressed SCA1 
protein, but were negative for the VSMC lineage label (S+L-); as well as (3) cells that were 
VSMC lineage-positive and SCA1-negative (S-L+). To reduce the chances of profiling doublets 
of cells, expression of only one of the four fluorescent labels was required in index-sorted 
cells. After preparation of cDNA libraries using the Smart-seq2 protocol (Picelli et al. 2014), 
the samples were sequenced and processed through the Babraham Institute pipeline (Figure 
4.6, details in Methods, experimental work including flow cytometry analysis and Smart-seq2 
profiling was a collaboration with J. Chappell, A.L. Taylor and H.F. Jørgensen). 
 
 
 
 
Figure 4.6: Schematic representation of the approach used for profiling medial VSMC-lineage (L) 
and/or SCA1 (S) positive subpopulations of cells.  
Medial cells from mice on multi-colour VSMC lineage tracing background were dissociated to a single-
cell suspension. After SCA1 staining, flow cytometry index-sorting was used to isolate individual cells. 
Their transcriptomes were profiled using the Smart-seq2 protocol (Picelli et al. 2014). Microscopy 
image was prepared by A.L. Taylor and the schematic is adapted from Dobnikar and Taylor et al. 2018. 
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4.2.3 Processing and quality control of Smart-seq2 transcriptional profiles 
In total, we profiled 187 single cells in three experiments, of which 109 were S+L+, 40 were S-
L+ and 38 were S+L-. To exclude low-quality cells, I filtered the single-cell transcriptomes based 
on the total reads detected (>100,000), total number of genes detected (>1500) and the 
percentage of reads mapping to ERCC controls (< 30%, Figure 4.7). In this analysis, I decided 
to retain the cells with high total read count and high number of genes detected. This was 
because expression of only one of the four fluorescent proteins from the multi-colour lineage 
labelling system was required during flow cytometry index-sorting, which reduced the chances 
of profiling doublets. At the same time, the subpopulations of cells profiled in this experiment 
could show large differences in gene expression profiles and such filters could exclude 
interesting cells from the analysis. In total, 155 cells passed quality control (92 S+L+, 36 S-L+ 
and 27 S+L-).  
 
Genes which were expressed below the mean expression level of 1 count per cell were filtered 
out of further analysis to reduce noise. Transcriptional profiles were then normalised using 
the pooling normalisation method (Lun et al. 2016, details in Methods) to account for different 
sequencing depths of individual cells.  
 
 
 
 
Figure 4.7: Quality control of scRNA-seq profiles generated using the Smart-seq2 protocol.  
Violin plots show the distributions of total read count, number of genes detected, and the percentage 
of reads mapping to ERCC controls. Red lines indicate the quality control filter thresholds. The figure is 
from Dobnikar and Taylor et al. 2018. 
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I next assessed the expression of Myh11 and Ly6a/Sca1 in the profiled subpopulations of cells. 
I observed that all S-L+ cells expressed Myh11, as did most of the S+L+ cells (Figure 4.8). The 
majority of S+L- cells expressed Myh11 at low levels, with a handful of cells showing high 
Myh11 expression (Figure 4.8). VSMC lineage labelling efficiency of the multi-colour reporter 
system has been estimated to be 70-95% in our study and in a previous study from the 
Jørgensen lab (Chappell et al. 2016), so there is a possibility that the S+L- cells showing high 
Myh11 expression were of the VSMC lineage, but did not express the VSMC lineage label. The 
majority of S+L- cells expressed Ly6a/Sca1, as did several S+L+ cells, although overall, the 
Ly6a/Sca1 expression levels in this category were lower. A small number of the S-L+ cells 
showed low levels of Ly6a/Sca1, but none of these cells expressed high levels of Ly6a/Sca1 
(Figure 4.8a). Overall, Ly6a/Sca1 mRNA expression was detected in only 34% of the cells which 
were identified as Sca1-positive during flow cytometry index-sorting. This may be due to 
dropout events of Ly6a/Sca1, which would be particularly probable in cells where Ly6a/Sca1 
expression is low. Alternatively, although the profiled cells expressed SCA1 protein, the mRNA 
transcript may not have been present at the time of profiling. Ly6a/Sca1 showed a higher 
percentage of zero read counts among the profiled cells than expected according to a linear 
relationship between the percentage of zeroes and mean expression levels on a log scale 
(Figure 4.8b). This likely reflects the fact that Sca1 is expressed at differing levels among 
profiled subpopulations of cells. However, the percentage of zero counts of Ly6a/Sca1 did not 
stand out as unusually high and therefore suggests that Ly6a/Sca1 does not show 
unexpectedly high dropout levels compared with other profiled genes (Figure 4.8b). 
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Figure 4.8: Myh11 and Ly6a/Sca1 expression levels in profiled cells.  
a) Boxplots show the log2-transformed normalised read counts of Myh11 and Ly6a/Sca1 transcripts 
across profiled S+L+ (orange), S+L- (cyan) and S-L+ (magenta) cells. Dots represent individual cells and 
the median expression level is indicated by the thick black line. The first and third quartiles are 
represented by the box boundaries and the whiskers show 1.5 of the interquartile range. b) Scatterplot 
shows the relationship between the log2 percentage of zero read counts and the mean log2 expression 
levels of profiled genes. Individual genes are represented by black dots and Ly6a/Sca1 is highlighted in 
red. Blue line shows the results of linear regression (R2 = 0.78). The analysis is based on the feature 
selection approach developed in the M3Drop and scmap tools (Tallulah S Andrews & Hemberg 2019; 
Kiselev et al. 2018).  Panel a is from Dobnikar and Taylor et al. 2018. 
 
4.2.4 Heterogeneity of the medial SCA1-positive subpopulation of cells 
To further explore the transcriptional differences between the profiled subpopulations of 
medial cells, I performed principal component analysis (PCA, Figure 4.9a). PCA based on 500 
most variable genes resulted in a main cluster of cells expressing high levels of VSMC marker 
genes, including Myh11 (Figure 4.9b). The main cluster contained most of the S-L+ cells, a 
proportion of S+L+ cells, as well as a small number of S+L- cells. S+L- cells located within the 
main cluster expressed Myh11 and the lack of VSMC lineage label expression may be due to 
incomplete recombination of the multi-colour reporter. The majority of the remaining S+L- 
cells clustered at the opposite end of the principal component analysis plot, showing low 
Myh11 expression and higher Ly6a/Sca1 expression levels (Figure 4.9b and c). The S+L+ 
subpopulation showed a large degree of heterogeneity, with cells located both in the main 
cluster of cells as well as spreading out towards the S+L- cluster (Figure 4.9a).  
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As the cells presented in this Chapter were profiled in three independent experiments, I next 
examined whether there were any differences between the experiments that may be driving 
the observed heterogeneity. All three subpopulations of cells were profiled in the first 
experiment, S+L+ and S-L+ were included in the second, and S+L+ and S+L- in the third 
experiment. Figure 4.9d shows the distribution of profiled subpopulations of cells along the 
first two principal components. 
 
 
 
 
Figure 4.9: Principal component analysis of profiled subpopulations of cells.  
Scatterplots show the PC1 and PC2 values for individual cells, based on the 500 most variable genes. 
PC1 explained 10% of the variance and PC2 explained 6%. a) Cells are colour-coded based on the 
presence of the VSMC lineage label (L) and/or SCA1 (S), as identified by flow cytometry. S+L- cells are 
represented by cyan circles, S-L+ cells by red triangles and S+L+ cells by yellow squares. b, c) Log2-
transformed normalised expression levels of Myh11 (b) and Ly6a/Sca1 (c) are colour coded on the PCA 
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plot, with darker grey representing higher expression levels. d) Cells profiled in experiment 1 (red), 
experiment 2 (green) and experiment 3 (blue) are indicated on the PCA plot. Experiment 1 contained 
cells from all three subpopulations, experiment 2 contained cells from the S-L+ and S+L+ 
subpopulations, and experiment 3 contained cells from the S+L- and S+L+ subpopulations. Panel a is 
adapted from Dobnikar and Taylor et al. 2018. 
 
 
Overall, PCA highlighted the heterogeneity of the S+L+ subpopulation of medial cells. I next 
examined which genes were expressed heterogeneously among the S+L+ subpopulation. I 
used an approach which examines the relationship between the variance and mean log 
expression of genes, and decomposes the variance into the technical and biological 
components (Lun et al. 2016, similar to Chapter 3, section 3.2.4). To estimate the technical 
component of variation I used the ERCC controls, which were added to profiled single cells. I 
first fitted a parametric trend to the variance versus mean expression levels of normalised log-
transformed counts of the ERCC controls. I then subtracted the estimated technical variation 
form the total variance of each gene, and identified a gene as highly variable if the resulting 
estimated biological variance was significantly greater than zero (adjusted p-value < 0.05, 
details in Methods, Lun et al. 2016). This approach identified 424 genes as highly variable 
among the S+L+ cells (Figure 4.10a).  
 
Figure 4.10a shows that while most of the ERCCs agreed with the background technical 
variance estimation, two of the ERCC controls showed higher variability than expected at their 
mean expression level, and overlapped with a portion of the genes identified as highly 
variable. This suggested that the identification criteria for highly variable genes may not have 
been stringent enough, as no biological variability is expected for ERCC controls. To address 
this problem, I modified the approach for the identification of highly variable genes. I 
randomly selected 90% of the S+L+ cells at a time and preformed the highly variable gene 
expression analysis as described above. I repeated this approach 1000 times and collected a 
distribution of p-values for individual genes as determined in each iteration. I then used a 
method implemented by M. Spivakov (details in Methods) to combine the collected p-values. 
Performing iterative analysis on a subset of cells increased the robustness of the approach, as 
a gene was required to be consistently highly variable across the majority of the iterations. 
This excluded the genes showing large variation in a small number of cells, which was more 
likely to be observed due to technical factors. The limitation of this approach was that the 
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heterogeneity due to rare subpopulations of cells may have been missed. This approach 
resulted in a more stringent set of 52 highly variable genes (Figure 4.10b). Figure 4.10c shows 
the expression profiles of the top 6 highly variable genes. 
 
 
 
 
Figure 4.10: Highly variable genes among the S+L+ cells.  
a, b) Scatterplots show the mean log expression of genes versus their variance. The blue line represents 
the estimated technical component of variance at a given mean log expression level. ERCC controls are 
highlighted in red and the identified highly variable genes are shown in green. a) Highly variable genes 
were identified as such if their biological component of variance was significantly greater than zero 
(adjusted p-value < 0.05, details in Methods). b) Iterative validation of highly variable genes was 
performed 1000 times with 90% of the cells randomly selected at each iteration. p-values for a given 
gene from individual iterations were then combined using a method devised by M. Spivakov (Dobnikar 
and Taylor et al. 2018). Genes were then identified as highly variable if their adjusted p-value was 
below 0.05 (details in Methods). c) Violin plots showing the log2-transformed normalised expression 
levels of the most highly variable genes. Dots represent individual cells and the black bars indicate the 
median expression levels. Panels b and c are adapted from Dobnikar and Taylor et al. 2018. 
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I next investigated whether any of the identified highly variable genes show coordinated 
variability across the S+L+ cells. Co-expression analysis based on the Spearman’s rank 
correlation coefficient (Lun et al. 2016) revealed high levels of correlation between identified 
highly variable genes. I identified 281 pairs of positively and 25 pairs of negatively correlated 
genes, with all of the highly variable genes identified as significantly correlated with at least 
one other highly variable gene. Myh11, Acta2 and Tagln showed the highest number of 
correlations with other highly variable genes (23, 25 and 25 respectively), with the majority of 
the genes correlated with all three of these VSMC contractile markers. This indicated that 
there may be a contractile VSMC signature which is expressed heterogeneously among the 
profiled cells.  
 
To assess the overall expression levels of the contractile signature, I performed PCA based on 
the 29 genes correlated with either Myh11, Acta2 or Tagln. I used the PC1 scores of each cell, 
oriented such that higher PC1 score generally aligned with higher expression of the genes, as 
a measure of the summarised expression levels of this signature in individual cells. Figure 
4.11a shows that overall the PC1 score of individual cells correlated strongly with the total 
sum of normalised read counts of the genes identified as co-expressed with Myh11, Acta2 and 
Tagln (R2 = 0.96). As expected, PC1 scores were higher in the main cluster of cells, which 
contained the contractile S-L+ subpopulation (Figure 4.11b).  
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Figure 4.11: Highly variable genes identified in S+L+ cells show high levels of co-expression and 
contain a contractile VSMC signature.  
a) Scatterplot showing the relationship between the total expression levels of genes identified as co-
expressed with Myh11, Acta2 and Tagln and the PC1 scores from principal component analysis based 
on these genes. Black points represent individual cells. b, g) Principal component analysis of profiled 
subpopulations of cells, based on 500 most variable genes. Scatterplots show the PC1 and PC2 values 
for individual cells. Cells are colour coded based on their PC1 score summarising the expression levels 
of Myh11, Acta2 and Tagln co-expressed genes (b) or their cVSMC score (g), with blue indicating low 
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and red indicating high overall expression levels. c, d) Network graphs representing the identified 
networks of co-expressed genes, which were identified using WGCNA among the 52 highly variable 
genes detected in S+L+ cells. Correlation strength of gene pairs is encoded by the edge thickness. e) 
Boxplot showing the PC1 scores of WGCNA modules 1 and 2 for the profiled S+L+ (yellow), S+L- (cyan) 
and S-L+ (red) subpopulations of cells. The median is represented by the thick black line and the first 
and third quartiles by the box boundaries. Whiskers show 1.5 of the interquartile range. f) Scatterplot 
showing the relationship between the PC1 scores summarising the overall expression levels of Myh11, 
Acta2 and Tagln co-expressed genes and the cVSMC network, with back points representing individual 
cells. Panels c, d, e and g are adapted from Dobnikar and Taylor et al. 2018 and WGCNA network 
analysis was a collaboration with M. Spivakov. 
 
 
High levels of correlation between highly variable genes suggested that substructure may be 
present among the profiled S+L+ cells. To obtain a more comprehensive picture of the highly 
variable gene co-variability we used network analysis (implemented by M. Spivakov). Network 
analysis performed using the WGCNA approach (Langfelder & Horvath 2008) revealed two 
modules of genes (Figure 4.11c and d, details in Methods). Module 1 contained several 
contractile marker genes, such as Myh11, Acta2, Tagln and Cnn1, and showed strong overlap 
with the genes previously found to be correlated with VSMC markers Myh11, Acta2 and Tagln. 
In total, 20 out of 24 of module 1 genes overlapped with VSMC marker correlated genes. We 
therefore termed this module the contractile VSMC (cVSMC) network. 
 
I next assessed the overall expression levels of the identified gene modules across the profiled 
cells. I performed PCA based on the genes contained within each of the modules and used the 
PC1 scores positively aligned with the total expression levels to summarise the overall 
expression in each cell. Figure 4.11e shows that PC1 scores of module 2 did not vary 
considerably across the profiled subpopulations of cells. In contrast, the cVSMC network was 
expressed highly in the S-L+ population, at low levels in S+L- cells and heterogeneously in S+L+ 
cells (Figure 4.11e). Overall, there was a strong correlation between the PC1 scores across 
cells between the genes correlated with Myh11, Acta2 and Tagln and the cVSMC network 
(Figure 4.11f, R2 = 0.98).  
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4.2.5 Transcriptional signatures of SCA1-positive VSMCs expressing low levels of 
contractile markers 
We were next interested in the transcriptional differences between the S+L+ cells expressing 
low or high levels of the contractile VSMC signature. Figure 4.11g shows that the S+L+ cells, 
which clustered away from the main contractile cluster scored particularly low for the cVSMC 
network expression. To delineate their transcriptional differences, we used negative binomial 
regression to find the genes which correlated positively and negatively with the cVSMC scores 
of individual S+L+ cells. This approach identified 312 positively and 303 negatively correlated 
genes (Figure 4.12a, adjusted p-value < 0.05, collaboration with M. Spivakov, details in 
Methods). 
 
The genes which correlated positively with the cVSMC score (cVSMCpos) showed high 
expression levels in the S-L+ population, low levels in the S+L- cells and variable levels in S+L+ 
cells (Figure 4.12b). Gene ontology analysis identified “muscle system process”, “muscle 
contraction”, “regulation of muscle system process” as the top three overrepresented gene 
ontology terms, which is in agreement with cVSMCpos representing a differentiated 
contractile VSMC signature. In contrast, the top three overrepresented gene ontology terms 
among the genes correlated negatively with the cVSMC network (cVSMCneg) were “positive 
regulation of cell migration”, “angiogenesis” and “wound healing”, which are processes 
associated with the synthetic state of VSMCs. This signature was expressed at particularly high 
levels in a subset of S+L+ cells (Figure 4.12b). This suggested that there may be a subset of 
VSMC-lineage cells in healthy arteries which show a less differentiated and a more activated 
transcriptional signature characteristic of synthetic VSMCs. In agreement with this, the 
cVSMCneg signature contained markers of the VSMC synthetic phenotype, such as Col8a1, 
Vcam1 and Spp1 (Allahverdian et al. 2018). The expression of these genes was sparse but 
overall higher in the S+L+ cells, which expressed lower levels of the cVSMC signature (Figure 
4.12c).  
 
Taken together, the results presented in this chapter suggest that there is a rare 
subpopulation of VSMCs resident in healthy arteries which has a less differentiated 
transcriptional profile and shows some characteristics of a synthetic VSMC phenotype.  
 
94 
 
 
 
Figure 4.12: A subset of S+L+ cells shows characteristics of a synthetic VSMC phenotype.  
a) Heatmap showing the expression levels of cVSMCpos genes (red block) and cVSMCneg genes (blue 
block) in S+L+ cells, with darker blue representing higher expression levels. Cells are ordered according 
to their cVSMC score, which is colour coded from white (low) to purple (high). Identification of genes 
correlated positively and negatively with the cVSMC scores in S+L+ cells was a collaboration with M. 
Spivakov. b) Boxplots show the PC1 scores summarising the expression levels of cVSMCpos genes (left) 
and cVSMCneg genes (right) in profiled S+L+ (yellow), S-L+ (red) and S+L- (cyan) subpopulations of cells. 
The median score is represented by a thick black line, the first and third quartiles by box edges and the 
1.5 interquartile range by the whiskers. c) Scatterplots showing the relationship between the cVSMC 
score and the normalised expression levels of Myh11, Col8a1, Vcam1 and Spp1 in S+L+ cells. Yellow 
dots represent individual S+L+ cells. Figure adapted from Dobnikar and Taylor et al. 2018.  
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4.3 Discussion 
In this chapter I explored whether VSMC heterogeneity in healthy artery walls may underpin 
the observed functional heterogeneity among VSMCs in atherosclerosis and vascular injury. I 
detected a rare subpopulation of medial cells which expressed the progenitor marker SCA1. 
Lineage tracing has enabled us to confirm the VSMC-lineage identity of a subset of medial 
SCA1+ cells and we have combined it with scRNA-seq to profile gene expression in individual 
medial cells from healthy mouse arteries. I found that the SCA1-positive VSMC subpopulation 
is heterogeneous, with some of these cells resembling contractile VSMCs and others showing 
a less differentiated transcriptional profile, devoid of the expression of classic VSMC markers 
and additionally showing some characteristics of the synthetic VSMC state. The existence of 
VSMCs expressing transcriptional signatures characteristic of the synthetic VSMC state in 
healthy arteries is in agreement with a previous hypothesis that VSMCs exist on a spectrum 
between the contractile and synthetic phenotypes (Rensen et al. 2007). 
 
4.3.1 SCA1-positive cells within the adventitial and endothelial layers 
SCA1-positive cells have been previously observed to reside in the endothelial and adventitial 
vascular layers (Psaltis & Simari 2015) and consistent with this, we have observed high levels 
of Ly6a/Sca1 expression among the adventitial and endothelial clusters of cells profiled using 
the 10X Genomics Chromium platform. SCA1-positive subpopulations from both the 
endothelial and adventitial layers were previously observed to have progenitor potential 
(Psaltis & Simari 2015). For example, endothelial cells positive for SCA1 among other markers 
have been shown to have higher potential for clonal expansion than conventional endothelial 
cells, and were capable of forming functional blood vessels in vivo (Fang et al. 2012; Naito et 
al. 2012).  
 
Adventitial SCA1-positive cells have been shown to be capable of differentiating towards 
vascular smooth muscle cells in vitro and to contribute to neointima formation in vivo (Hu et 
al. 2004; Passman et al. 2008; Kramann et al. 2016). Transcriptional profiling of adventitial 
SCA1-positive cells (marked by Gli expression) using single-cell qPCR showed that these cells 
shared some of the transcriptional signatures with S+L+ cells and some of these adventitial 
cells expressed the VSMC marker gene Tagln (Kramann et al. 2016). There were, however, 
some differences in the transcriptional profiles the adventitial cells and S+L+ cells profiled in 
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our study. For example, many of the profiled adventitial cells expressed Cd29, Vegfr2 and Sox2 
(Kramann et al. 2016), which were not expressed by S+L+ cells. Myh11 was not profiled by 
Kramann et al. (2016), therefore it cannot be concluded whether or not these adventitial cells 
would be likely to express the VSMC lineage label and thus potentially overlap with the S+L+ 
population. However, S+L+ cells presented in this chapter appear to be generally distinct from 
adventitial SCA1-positive cells, as highlighted by the flow cytometry and ACTA2 staining 
experiments using Sca1-GFP transgenic mice. The GFP-positive cells we isolated from the 
medial layer had high levels of ACTA2 expression by immunostaining, in contrast to GFP-
positive cells isolated from the adventitia, which stained negative for ACTA2. 
 
Plasticity between adventitial cells and VSMCs has also been suggested in the reverse 
direction, with mature VSMCs described as capable of giving rise to a proportion of SCA1-
positive adventitial cells. Majesky et al. (2017) reported that mature VSMCs migrate to the 
adventitial side of the medial-adventitial layer interface in vivo. These VSMC-derived 
adventitial SCA1-positive cells were then observed to expand following vascular injury 
(Majesky et al. 2017). Using lineage tracing approaches, the authors observed the transition 
of VSMCs towards adventitial SCA1-positive cells within healthy arteries and suggested this 
process helps to maintain the vascular progenitor niche within the vasculature (Majesky et al. 
2017). The extent to which these VSMC-derived adventitial SCA1-positive cells resemble the 
activated S+L+ VSMCs isolated from the medial layer in this project remains to be explored. 
Although we have manually removed the adventitial and endothelial layers during dissection, 
contamination of cells from the neighbouring layers, particularly from cells located at the 
borders, cannot be ruled out. Therefore, given that the VSMC-derived adventitial SCA1-
positive cells were observed to localise on the adventitial side of the adventitial-medial border 
and they would be expected to retain the VSMC lineage label expression, these cells may have 
been included in our study. However, examination of VSMC lineage label expression in the 
adventitial and endothelial layers carried out by A.L. Taylor, showed only very rare expression 
of the VSMC lineage label in the adventitia.  
 
4.3.2 SCA1-positive VSMCs within the medial layer 
A previous study has identified and isolated a subpopulation of cells within the medial layer 
of the aorta, which had progenitor potential and expressed SCA1 (Sainz et al. 2006). Using flow 
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cytometry the authors estimated that the SCA1+ subpopulation of cells represented 6% of all 
medial cells. They observed that after culturing these cells in the presence of TGF-β1 and 
PDGF-BB, these cells acquired a VSMC phenotype whereas an endothelial phenotype was 
acquired after culture with VEGF (Sainz et al. 2006). This SCA1-positive medial subpopulation 
was identified on the basis of reduced Hoechst staining, which is characterised by the 
presence of the ABCG2 transporter. A small number of S+L+ cells profiled in our study (6/92) 
expressed Abcg2, suggesting that there may be some overlap between the previously 
identified medial SCA1+ cells and the S+L+ cells profiled in this project. At the transcriptional 
level we observed expression of the endothelial cell marker Vcam1 in several S+L+ cells and it 
would be interesting to attempt similar in vitro culture experiments with VEGF to assess 
whether S+L+ cells have a potential to differentiate towards endothelial cells. The rarity of 
S+L+ cells, however, presents technical challenges in conducting such experiments, as it would 
be difficult to isolate sufficient numbers of S+L+ cells for successful in vitro culture.  
 
4.3.3 SCA1-positive cells of VSMC lineage within atherosclerotic plaques 
Interestingly, SCA1-positive cells of VSMC lineage were observed previously within 
atherosclerotic lesions, where they were suggested to mark a mesenchymal stem cell-like 
population (Shankman et al. 2015). These SCA1-positive cells downregulated the expression 
of VSMC markers and VSMC-specific lineage tracing has been used to confirm that these cells 
originated from VSMCs (Shankman et al. 2015). These findings suggested that SCA1-positive 
VSMCs may have relevance in disease and prompted us to further investigate S+L+ cells in 
atherosclerosis (see next chapter).  
 
A recent study of VSMCs in healthy and atherosclerotic vessels has confirmed our observation 
of a small proportion of VSMCs in healthy arteries expressing transcriptional signatures 
characteristic of phenotypically switched VSMCs (Wirka et al. 2019). Wirka and colleagues 
profiled the transcriptomes of lineage-traced VSMCs in healthy aortic root as well as in 
atherosclerotic plaques and observed that 1.3% of healthy VSMCs clustered with 
phenotypically modulated VSMCs from the atherosclerotic plaques, some of which expressed 
Ly6a/Sca1 (Wirka et al. 2019).  
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4.3.4 Conclusions 
Overall in this chapter I have identified and characterised a rare subpopulation of VSMCs, 
which expressed Ly6a/Sca1. The scRNA-seq approach has been invaluable in the analysis of 
medial cell heterogeneity, as it enabled the identification of a rare subpopulations of cells, 
which could not have been detected with bulk RNA-seq methods. Combining scRNA-seq with 
VSMC-specific lineage labelling has enabled us to confirm that a proportion of SCA1-positive 
medial cells were of the VSMC lineage and to ensure that profiled cells were not a 
contamination from the neighbouring adventitial and endothelial layers. scRNA-seq has 
further enabled the characterisation of the transcriptional signatures of SCA1-positive VSMCs, 
which indicated that VSMCs showing a less differentiated transcriptional profile and 
expressing transcriptional signatures characteristic of the synthetic VSMC state are present in 
healthy arteries. These observations motivated us to further investigate the expression of 
SCA1 in model systems of VSMC phenotypic switching, which will be discussed in the next 
chapter.  
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5  SCA1-positive VSMCs in model systems of VSMC phenotypic 
switching 
5.1 Introduction 
VSMCs play an important role in the development of atherosclerotic plaques and in neointima 
formation following vascular injury (Bennett et al. 2016). Previous studies observed that 30-
70% of cells within atherosclerotic plaques originate from VSMCs (Shankman et al. 2015; 
Chappell et al. 2016). Despite extensive accumulation of VSMCs within lesions, multicolour 
lineage tracing studies suggested that only a very small proportion of VSMCs proliferate and 
expand during atherosclerotic plaque and neointima formation (Chappell et al. 2016; Jacobsen 
et al. 2017). A possible explanation for this observation is that VSMCs are functionally 
heterogeneous. 
 
In Chapter 4, I presented evidence for a rare subset of SCA1-positive VSMC, which expressed 
transcriptional signatures characteristic of the activated synthetic state of VSMCs. Here, I 
hypothesised that these SCA1-positive VSMCs may be more primed for expansion in 
atherosclerosis and injury. SCA1-positive cells of the VSMC lineage have been previously 
observed within atherosclerotic plaques (Shankman et al. 2015) and the aim of this chapter is 
to investigate whether the transcriptional profiles of Ly6a/Sca1-expressing VSMCs within 
plaques share similarities to healthy S+L+ cells, which expressed transcriptional signatures 
characteristic of synthetic VSMCs. Additionally, I investigated how the transcriptional profiles 
of SCA1-positive VSMCs detected in healthy arteries compare with phenotypically modulated 
VSMCs induced in vivo and in vitro.  
 
To investigate the transcriptional signatures of VSMCs during phenotypic switching I used 
three separate mouse models, in which VSMC phenotypic switching has been extensively 
documented. In vitro culture is a simple but frequently used model system of VSMC 
phenotypic switching, in which some of the hallmarks of the process, such as downregulation 
of VSMC marker protein expression and proliferation, are replicated (Chamley-Campbell et al. 
1979; Rensen et al. 2007). The ApoE-/- mouse atherosclerosis model system provided a 
disease-relevant setting for the investigation of VSMC phenotypic switching (Getz & Reardon 
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2012). Additionally, the carotid ligation injury model (Kumar & Lindner 1997) enabled an in 
vivo investigation of VSMC phenotypic switching in a more acute setting compared with the 
mouse atherosclerosis model. Together, these model systems provided a range of 
environments for the study of VSMC phenotypic switching and additionally enabled the use 
of VSMC-specific genetic lineage tracing, which would not be possible in human 
atherosclerotic plaques. The analysis presented in this chapter revealed that SCA1 and 
Ly6a/Sca1 upregulation marks VSMC phenotypic switching and that the transcriptional 
signatures of SCA1-positive VSMCs in healthy arteries are similar to those observed in model 
systems of VSMC phenotypic switching.  
 
5.2 Results 
5.2.1 SCA1 is upregulated in VSMCs cultured in vitro 
To investigate the gene expression changes that occur in VSMCs during phenotypic switching 
in culture, I used a publicly available single-cell transcriptomics dataset of cultured VSMCs, 
which was generated on the Fluidigm C1 platform (GSE79436, Adhikari et al. 2015). I 
compared the transcriptomes of cultured VSMCs with our profiles of ex vivo VSMCs from the 
AA and DT regions of the aorta, which were generated using the same platform. The ex vivo 
and cultured VSMC transcriptomes were processed in an analogous way and the read counts 
were normalised jointly to account for differences in sequencing depth (details in Methods). 
PCA (originally presented in Section 3.2.1) resulted in separate ex vivo and cultured VSMC 
clusters. VSMC contractile markers, such as Myh11, were downregulated in cultured VSMC, 
as expected. Interestingly, I observed increased levels of Ly6a/Sca1 expression among 
cultured VSMCs (Figure 5.1).  
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Figure 5.1: Ly6a/Sca1 expression levels are increased in cultured compared with ex vivo VSMCs.  
PCA of cultured (squares) and ex vivo (triangles) VSMC transcriptomes with expression levels of Myh11 
(left) and Ly6a/Sca1 (right) colour coded from low (grey) to high (black). PC1 explained 25% of the 
variance and PC2 explained 4%. Transcriptional profiles of cultured VSMCs are publicly available at the 
Gene Expression Omnibus (GSE79436, Adhikari et al. 2015). Ly6a/Sca1 panel was adapted from 
Dobnikar and Taylor et al. 2018. 
 
 
Our next question was whether contractile SCA1-negative VSMCs were capable of 
upregulating SCA1 after stimulus, or whether pre-existing SCA1-positive VSMCs selectively 
expanded in culture. To address this we cultured VSMCs isolated from Sca1-GFP animals (Ma 
et al. 2002) and observed that sorted GFP-negative medial cells upregulated GFP after 10 days 
in culture (Figure 5.2, collaboration with A.L. Taylor). In contrast, we did not observe any GFP-
positive cells after culture of VSMCs from wild-type animals, as expected. Overall, these 
experiments indicated that mature VSMCs have the capacity to upregulate SCA1 during 
phenotypic switching in culture.  
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Figure 5.2: SCA1 is upregulated in sorted GFP-negative medial cells during culture.  
Medial GFP-negative (n=4), adventitial GFP-negative (pooled tissue from four animals) and adventitial 
GFP-positive (pooled tissue from four animals) cells from Sca1-GFP reporter transgenic animals were 
sorted using flow cytometry and cultured in vitro. As a negative control, medial GFP-negative cells from 
a wild type mouse were also isolated and cultured (n=1). a) Images show the GFP expression in isolated 
cell populations after 3 and 10 days in culture. b) Quantitation of the percentages of GFP-positive cells 
among isolated populations after 11 days of culture. Collaboration with A.L. Taylor and the figure is 
from Dobnikar and Taylor et al. 2018. 
 
 
We next investigated whether VSMCs also upregulated SCA1 in vivo using lineage-labelled 
animals. We analysed the proportion of S+L+ VSMCs using flow cytometry after varying time 
periods between tamoxifen injection and flow cytometry analysis in single-colour lineage-
labelled animals (collaboration with A.L. Taylor and M. Spivakov). Logistic regression analysis 
suggested that there was a small but significant increase in the proportion of S+L+ VSMCs with 
longer time periods between the induction of lineage labelling and analysis (Figure 5.3a), and 
this effect did not appear to originate from the confounding factor of varying animal age 
(Figure 5.3b and c). This analysis therefore suggests that VSMCs upregulate SCA1 in vivo, 
although the increase in the proportion of S+L+ VSMC over time is small.  
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Figure 5.3: The proportion of S+L+ VSMCs increases with increased time period between lineage 
labelling and analysis.  
a) Scatterplot showing the relationship between the proportion of S+L+ VSMCs, and the time period 
between tamoxifen injection and flow cytometry analysis. The age of individual animals is colour-
coded, with darker grey dots representing higher age. The trendline was estimated using logistic 
regression, with the proportion of S+L+ VSMCs as the response variable and the labelling time period 
as the explanatory variable (logit-link regression coefficient = 0.016 (mean) ± 0.005 (95% confidence 
interval), Student’s distribution p-value = 2.56e-10). b, c) Bivariate logistic regression analysis using the 
labelling time period and animal age as explanatory variables and the proportion of S+L+ VSMCs as the 
response variable. Blue lines represent the trendline and shaded areas represent 95% confidence 
intervals. b) Effect of labelling time, logit-link regression coefficient = 0.042 ± 0.014, Student’s 
distribution p-value = 2.72e-9. c) Effect of age, logit-link regression coefficient = -0.028 ± 0.015, 
Student’s distribution p-value = 3.07e-5). Partial correlation analysis was used as an alternative 
approach to determine the influence of animal age on the relationship between labelling time and 
proportion of S+L+ VSMCs (pcor function of R package ppcor). While controlling for animal age, there 
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was a positive and significant correlation between the proportion of S+L+ VSMCs and labelling time 
(partial correlation = 0.66, p-value = 0.0069). The correlation between animal age and the proportion 
of S+L+ VSMCs while controlling for labelling time was negative (partial correlation = -0.46). 
Collaboration with A.L. Taylor (experimental work) and M. Spivakov (statistical analysis). The figure is 
adapted from Dobnikar and Taylor et al. 2018.  
 
I next investigated whether the overall transcriptional signatures of cultured VSMCs 
resembled those of the S+L+ cells identified in healthy arteries, which expressed high levels of 
the cVSMCneg transcriptional signature (described in Chapter 4). Figure 5.4 shows that the 
overall expression level of the cVSMCneg signature was markedly higher in cultured VSMCs 
compared with ex vivo VSMCs. This observation prompted us to investigate SCA1 expression 
levels and the transcriptional signatures of VSMCs in models, where VSMC phenotypic 
switching is observed in vivo.  
 
 
 
 
Figure 5.4: Cultured VSMCs express transcriptional signatures of activated S+L+ cells from healthy 
arteries.  
PCA of cultured and ex vivo VSMC transcriptomes with the summarised expression levels of the 
cVSMCneg response signature colour coded from low (blue) to high (red) overall expression levels. To 
summarise the overall gene expression levels, the PC1 score of PCA based on the genes within the 
cVSMCneg signatures has been used (details in Methods). Transcriptional profiles of cultured VSMCs 
are publicly available at the Gene Expression Omnibus (GSE79436, Adhikari et al. 2015) 
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5.2.2 SCA1 is upregulated in VSMCs after carotid ligation injury 
Next we investigated whether SCA1 expression is upregulated in VSMCs after carotid ligation 
injury, which is an in vivo model of VSMC phenotypic switching (Kumar & Lindner 1997). In no 
injury control carotid arteries, we observed a very low proportion of VSMCs positive for both 
the VSMC lineage label and SCA1 (Figure 5.5a), as expected based on previous analysis of 
aortic VSMCs (Chapter 4). After carotid ligation, the proportion of lineage labelled cells which 
also stained positive for SCA1 expression, increased to over 25% on average (Figure 5.5b and 
c, collaboration with J.L. Harman).  
 
 
 
Figure 5.5: SCA1 is upregulated in VSMCs 8 days after carotid ligation injury.  
a,b) Flow cytometry scatter plots showing the expression of the VSMC lineage label (eYFP) on the x 
axis and the expression of SCA1 on the y axis. Whole carotid arteries in no injury control (a) and 8 days 
after carotid ligation (b) were analysed. c) Percentages of eYFP-positive cells, which stained positive 
for expression of SCA1 in no injury controls and 8 days after carotid ligation are shown (5 animals per 
group). Collaboration with J.L. Harman and the figure is from Dobnikar and Taylor et al. 2018.  
 
 
We were next interested in the overall transcriptional changes in VSMCs after carotid ligation 
injury. We used the 10X Genomics Chromium platform to profile the transcriptomes of 
individual VSMC-lineage labelled cells 7 days after carotid ligation (collaboration with A.L. 
Taylor and J. Chappell). In order to capture as many cells involved in phenotypic switching as 
possible, we initially used a reporter inserted into the Mki67 locus to enrich for the cells 
involved in the response to injury. For this experiment we combined the single-colour eYFP 
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VSMC lineage tracing system with the Ki67-RFP reporter allele (Basak et al. 2014, details in 
Methods). Using FACS, we isolated eYFP lineage labelled cells and additionally enriched for 
RFP-positive cells, which also expressed the eYFP lineage label. cDNA libraries were then 
prepared from sorted cells using the 10X Genomics Chromium platform. After sequencing, the 
reads were processed using the 10X Genomics cellranger pipeline, which recovered a total of 
1335 cells (as detailed in Methods).  
 
 
Quality control of captured single-cell transcriptomes showed that the majority of profiled 
cells were of good quality. The remaining cells, which were not profiled to sufficient depth or 
showed a high proportion of mitochondrial reads, were removed from further analysis (Figure 
5.6). To pass quality control, over 5000 UMI counts and over 2000 genes had to be detected 
in a cell. Additionally, cells were required to contain less than 6% of mitochondrial reads in 
order to exclude the cells that may have burst during processing. Cells with particularly high 
total UMI count or high number of detected genes were not removed from this dataset as 
larger differences in these parameters were expected between VSMCs undergoing phenotypic 
switching and contractile VSMCs. Removing such cells could therefore lead to loss of 
interesting cell populations. Additionally, the number of cells captured in this experiment was 
relatively low for the 10X Genomics Chromium platform, which reduced the chances of 
profiling doublets (Zheng et al. 2017). Overall 1126 out of 1335 cells passed quality control 
and the transcriptomes of good quality cells were normalised (details in Methods).  
 
 
 
 
Figure 5.6: Quality control of VSMCs profiled 7 days after carotid ligation injury.  
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Violin plots show the distribution of total UMI count, the number of genes detected and the proportion 
of mitochondrial reads across profiled VSMCs. Red lines represent the filtering thresholds and grey 
dots represent individual cells. Cells with total UMI count over 5000, over 2000 detected genes and 
less that 6% of mitochondrial reads passed quality control.  
 
 
To understand the heterogeneity among the profiled cells I next performed principal 
component analysis. The first principal component separated the cells which expressed 
Ly6a/Sca1 as well as cells showing increased Mki67 expression from the cells expressing the 
contractile VSMC marker Myh11 (Figure 5.7). The second principal component further 
differentiated the cells, which expressed the proliferative marker Mki67 (Figure 5.7).  
 
 
 
 
Figure 5.7: Principal components 1 and 2 separate cells showing lower expression levels of the 
contractile marker Myh11 and higher expression levels of Ly6a/Sca1 and Mki67.  
Top: the log2-transformed normalised expression levels of Ly6a/Sca1 (left), Mki67 (middle) and Myh11 
(right) are colour-coded from grey (low) to red (high) on the PCA plot. The first two principal 
components, which explained the most variance are shown. PC1 explained 25% and PC2 explained 
10% of the variance. Bottom: scatterplots showing the pairwise gene expression relationships between 
Ly6a/Sca1, Myh11 and Mki67. Histograms show the distribution of cells along the x and y axes.  
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To explore the profiled subpopulations of VSMCs and identify the overall differences between 
the cells I performed clustering analysis. Clustering was based on the first 11 principal 
components, all of which explained significantly more variance than expected at random 
(details in Methods). While further principal components also explained significantly more 
variance than expected at random, there was a sharp drop in significance levels after the 11th 
principal component and examination of further principal components did not reveal that they 
highlighted biologically meaningful differences among profiled cells. Overall, clustering 
analysis revealed 7 clusters of cells (Figure 5.8).  
 
Clusters 0, 1, 3 and 5 expressed high levels of contractile VSMC markers, such as Myh11 and 
Acta2 (Figure 5.9). These VSMCs may represent the contractile cells from the non-remodelled 
parts of the carotid artery, as the entire artery was included in scRNA-seq profiling. Cluster 4 
contained the majority of Mki67-positive cells and the majority of Ly6a/Sca1-positive cells 
were located in cluster 2 (Figure 5.10).  
 
 
 
 
Figure 5.8: Clustering analysis of profiled VSMCs after carotid ligation injury.  
Clusters of cells were identified using the graph-based clustering method from the Seurat package 
(Butler et al. 2018) and the clustering analysis was based on the top 11 principal components. In total, 
7 clusters of cells were identified and are colour coded on a t-SNE representation of profiled cells.  
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Figure 5.9: Expression levels of VSMC marker genes Myh11 and Acta2 in VSMCs profiled following 
carotid ligation injury.  
t-SNE plot showing the expression levels of Myh11 and Acta2 in profiled cells following carotid ligation 
injury. The expression levels are colour-coded in individual cells with grey representing low and red 
high log2-transformed normalised expression levels.  
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Figure 5.10: Mki67 and Ly6a/Sca1 expression levels among the cells profiled after carotid ligation 
injury.  
Top: t-SNE plot show the expression levels of Mki67 and Ly6a/Sca1 in profiled cells following carotid 
ligation injury. The expression levels are colour-coded in individual cells with grey representing low 
and red high log2-transformed normalised expression levels. Bottom: scatterplot showing the 
relationship between expression levels if Ly6a/Sca1 and Mki67 in profiled cells. Histograms show the 
distribution of cells along the x and y axes.  
 
 
To obtain a more comprehensive view of the transcriptional differences between the clusters, 
I performed differential gene expression analysis between each of the identified clusters and 
the remaining cells. Cluster 0 showed particularly high levels of expression of VSMC contractile 
markers Myh11 and Acta2, which were identified as significantly upregulated in this cluster 
(Figure 5.11). Cluster 1 expressed higher levels of several genes which we observed to form 
module 2 among highly variable genes identified in healthy S+L+ cells (Section 4.2.4). Examples 
of these genes include Egr1, Fos and Nfkbia, indicating that heterogeneity observed among 
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VSMCs in the healthy arteries was also present following carotid ligation surgery (Figure 5.11). 
Additionally, cluster 1 VSMCs expressed higher level of Klf4, which has previously been shown 
to play a key role in VSMC phenotypic switching (Shankman et al. 2015). This suggests that 
VSMCs in cluster 1 may be in a primed state for the early stages of response to injury compared 
with other contractile VSMCs. Cluster 3 did not express a distinct signature, with only 5 genes 
found to be upregulated in this cluster. Similarly, no genes were found to be significantly 
upregulated in the smallest identified cluster 6 (Figure 5.11).  
 
Interestingly, cluster 5 expressed transcriptional signatures resembling the AA-only cluster 
identified during the application of random forest analysis to the 10X Genomics Chromium 
datasets of VSMCs from healthy aortas. The gene with highest log2 fold change in expression 
in cluster 5 was Rgs5 and additionally this cluster upregulated several other genes, which were 
also observed to be upregulated in the AA only cluster (Section 3.2.8), including Sfrp2 and 
Prxx2 (Figure 5.11).  
 
Cluster 2 showed upregulation of several known markers of VSMC phenotypic switching, such 
as Spp1, Col8a1, Vcam1 and Mgp. Ly6a/Sca1 was also upregulated in cluster 2 (Figure 5.11). 
Cluster 4 showed higher expression levels of the proliferative marker Mki67, which we used 
to enrich for VSMCs undergoing phenotypic switching (Figure 5.11). Additionally this cluster 
showed upregulation of the proliferative markers Pcna and Mcm7 (Juríková et al. 2016) and 
likely represented actively proliferating VSMCs. 
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Figure 5.11: Transcriptional signatures of identified clusters of VSMCs following carotid ligation 
injury.  
Heatmap showing the scaled expression levels of genes, identified as significantly upregulated in at 
least one cluster of cells (adjusted p-value < 0.05 and log2 fold change > 0.5, details in Methods). All 
differentially expressed genes are shown and their scaled expression levels are colour-coded from 
purple (low) to yellow (high). Cells are shown in columns and are grouped by cluster memberships and 
genes are shown in rows. Selected genes are indicated on the right.  
 
 
Evaluation of the quality control metrics in individual clusters showed that VSMCs displaying 
signs of phenotypic switching in clusters 2 and 4 had higher total UMI counts and higher 
numbers of detected genes in individual cells, as would be expected for activated VSMCs 
(Figure 5.12). Thus, removing the cells with high UMI counts and large numbers of detected 
genes during quality control would have removed a significant proportion of cells of interest.  
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Figure 5.12: Quality control metrics in identified clusters of cells following vascular injury.  
Violin plots show the distributions of quality control metrics of total UMI count, number of genes 
detected and the proportion of mitochondrial reads per cell in identified clusters of cells. Individual 
cells are represented as black dots and only the cells, which passed the quality control thresholds, are 
included. 
 
 
I was next interested in understanding whether the cells which showed transcriptional profiles 
characteristic of VSMCs undergoing phenotypic switching resembled the S+L+ cells expressing 
high levels of the cVSMCneg signature in healthy arteries. I visualised the summarised 
expression levels of the cVSMCneg and cVSMCpos transcriptional signatures, which were 
identified as genes which correlated negatively or positively with the cVSMC contractile 
network in healthy S+L+ cells (described in Chapter 4). I used the PC1 values derived from PCA 
based on the cVSMCneg or cVSMCpos signatures to summarise the expression levels of these 
two sets of genes in VSMCs following carotid ligation (details in Methods).  
 
The Ly6a/Sca1-positive cluster of cells (cluster 2) expressed particularly high levels of the 
cVSMCneg signature, which contained genes characteristic of the synthetic state of VSMCs 
(Figure 5.13). In addition, this subset of cells expressed low levels of the contractile cVSMCpos 
signature (Figure 5.13). This suggested that Ly6a/Sca1-positive VSMCs after carotid ligation 
injury shared transcriptional similarities with activated S+L+ cells previously observed in 
healthy arteries.  
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Figure 5.13: Summarised expression levels of the cVSMCneg and cVSMCpos signatures among cells 
profiled after carotid ligation injury.  
t-SNE plots show the summarised expression levels of the cVSMCneg (left) and cVSMCpos (right) 
transcriptional signatures (details in Methods). Summarised expression levels are encoded from blue 
(low) to red (high) in individual cells, which are represented by dots.  
 
 
VSMCs in cluster 2, which contained Ly6a/Sca1-positive cells, also expressed higher levels of 
Col8a1 and Spp1, which are characteristic of the synthetic VSMC state (Figure 5.14). Overall, 
this analysis suggested that Ly6a/Sca1-positive VSMCs were among the phenotypically 
modulated subpopulation of cells following carotid ligation injury.  
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Figure 5.14: Col8a1 and Spp1, which are characteristic of the synthetic state of VSMCs, are expressed 
among the Ly6a/Sca1-positive cells.  
Top: t-SNE representations show the expression levels of Col8a1 and Spp1 in profiled VSMCs following 
carotid ligation injury. The log2-transformed normalised expression levels are colour-coded in 
individual cells with grey representing low and red high expression levels. Bottom: scatterplots show 
the relationship between the expression levels of Ly6a/Sca1, Col8a1 and Spp1. Histograms show the 
distributions of cells along the x and y axes. 
 
 
5.2.3 Transcriptional signatures of VSMCs within the atherosclerotic plaque 
I next investigated the transcriptional signatures of VSMCs undergoing phenotypic switching 
in atherosclerotic plaques. The inflammatory environment of the atherosclerotic plaque has 
been described to drive VSMC phenotypic modulation towards a range of different 
phenotypes, such as calcifying-like cells, macrophage-like cells and mesenchymal stem cell-
like cells, which have been observed to express SCA1 (Shankman et al. 2015; Bennett et al. 
2016; Durham et al. 2018). To understand the transcriptional changes which occur in VSMCs 
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undergoing phenotypic modulation to these states, we profiled the lineage-labelled VSMCs 
isolated from atherosclerotic plaques of ApoE-/- mice, which were fed a high fat diet for either 
14 or 18 weeks (jointly in collaboration with H.F. Jørgensen). 
 
In total we profiled 3346 VSMCs from 14-week plaques and 2757 VSMCs from 18-week 
plaques. The quality of profiled cells was assessed based on their total UMI count, the number 
of genes detected and the proportion of mitochondrial reads. The distribution of the total UMI 
count among the profiled cells was bimodal and closer examination of the relationship 
between the total UMI count and the proportion of mitochondrial reads per cell showed that 
there was a group of cells with relatively low UMI counts and a high proportion of 
mitochondrial reads (Figure 5.15a and b). The lower threshold for acceptable total UMI count 
was therefore set at 5000 UMI counts and cells were required to express less than 9% of 
mitochondrial reads to pass quality control. Cells with particularly high total UMI count (over 
20000) and number of genes detected (over 5000) were removed from this analysis, as the 
higher number of captured cells increased the chances of profiling doublets (Figure 5.15a).  
 
The transcriptomes of good-quality VSMCs were then normalised (details in Methods). I next 
performed principal component analysis to reduce the dimensionality of the dataset prior to 
clustering. Subsequent clustering analysis and t-SNE visualisation initially identified 7 clusters 
of cells (Figure 5.16a, details in Methods). When I performed differential gene expression 
analysis among the identified clusters I noticed that several mitochondrial genes were 
upregulated in cluster 4, which contained VSMCs from both 14- and 18-week atherosclerotic 
plaque stages (Figure 5.16b). Inspection of the quality control metrics for individual clusters 
showed that cluster 4 displayed lower total UMI counts and a higher proportion of 
mitochondrial reads than the other identified clusters (Figure 5.16c). This indicated that 
VSMCs in cluster 4 were of poorer quality and were excluded from further analysis. Clustering 
analysis and t-SNE visualisation was then repeated with remaining VSMCs (Figure 5.16d). 
Although there was some variability in the proportions of VSMCs from different stages of high-
fat diet between the clusters, all clusters contain cells from both the 14- and 18-week stages 
(Figure 5.16e).  
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Figure 5.15: Quality control of single-cell transcriptomes of VSMCs from atherosclerotic plaques.  
a) Violin plots showing the distribution of the quality control metrics of total UMI count, number of 
genes detected and the proportion of mitochondrial reads per cell. Individual cells are represented by 
black dots and the red lines represent the cut offs for good quality cells. b) Scatterplots showing the 
relationship between the total UMI count and the proportion of mitochondrial reads in profiled cells. 
All cells are included on the right, while the left scatterplot shows a zoomed-in view between 0 and 
15000 UMIs and 0 to 0.2 proportion of mitochondrial reads.  
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Figure 5.16: Clustering analysis of VSMCs from atherosclerotic arteries.  
a, b, d, e) t-SNE representation of profiled VSMCs. Individual cells are represented by dots, which are 
colour coded according to cluster membership (a, d) or by the duration of high fat diet prior to analysis 
(b, e). c) Violin plots showing the distribution of total UMI count, the number of genes detected and 
the proportion of mitochondrial reads within identified clusters of VSMCs in panel a. Clusters of cells 
were identified using the graph-based clustering method from the Seurat package (Butler et al. 2018). 
Panel d is adapted from Dobnikar and Taylor et al. 2018. 
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Differential gene expression analysis between the identified clusters of VSMCs showed varying 
levels of transcriptional differences between the clusters. Cluster 9 was transcriptionally the 
most distinct cluster and showed increased expression levels of several macrophage marker 
genes, such as Cd68 and Lgals3 (Figure 5.17). There have been several previous reports of 
VSMC lineage-labelled cells within the plaque co-expressing macrophage markers (Feil et al. 
2014; Shankman et al. 2015; Chappell et al. 2016; Albarrán-Juárez et al. 2016). Differential 
gene expression analysis suggests that the transcriptional profiles of VSMC-derived 
macrophages are substantially different from other plaque VSMCs, beyond the expression of 
a handful of macrophage markers. It is, however, not possible to rule out that observed 
macrophage-like cells could be a contamination from bone marrow-derived macrophages. 
Possible contamination is supported by the fact that Ptprc, which encodes the bone marrow 
marker Cd45, was identified as upregulated in cluster 9 (Figure 5.17), although VSMC lineage-
labelled cells have also been observed to express Ptprc within the plaque previously (Albarrán-
Juárez et al. 2016). Myh11 and Acta2 transcripts were detected at low levels in cluster 9 
(Figure 5.18a), however, this could be explained through background ambient mRNA 
contamination (Macosko et al. 2015), which may be particularly likely for genes expressed at 
high levels by the majority of profiled cells. Due to possible technical factors it is therefore not 
possible to conclusively describe the origin of observed macrophage-like cells.  
 
 
 
120 
 
 
Figure 5.17: Differential gene expression among identified clusters of VSMCs from atherosclerotic 
arteries.  
Heatmap showing the scaled expression levels of genes, identified as significantly upregulated in at 
least one cluster of cells (adjusted p-value < 0.05 and log2 fold change > 0.5, details in Methods). Cells 
are grouped by cluster and represented in columns and the differentially expressed genes are shown 
in rows. Selected upregulated genes are indicated on the right. Scaled expression levels are colour 
coded from purple (low) to yellow (high). 
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Figure 5.18: Contractile VSMC marker and Ly6a/Sca1 expression in profiled cells from atherosclerotic 
arteries.  
t-SNE visualisations of profiled VSMCs with individual cells colour-coded for the log2-transfromed, 
normalised expression levels of Myh11 and Acta2 (a) and Ly6a/Sca1 (b), with light grey representing 
low and dark grey high expression levels. c) Scatterplot showing the relationship between expression 
levels of Myh11 and Ly6a/Sca1. Histograms show the distribution of cells along the x and y axes. Panel 
b is adapted from Dobnikar and Taylor et al. 2018. 
 
 
VSMCs in cluster 7 showed upregulation of Ly6a/Sca1 (Figure 5.18b) as well as several markers 
of VSMC phenotypic switching, such as Vcam1, Col8a1 and Spp1 (Figure 5.17). Cluster 8 shared 
some of the transcriptional signatures of cluster 7 and additionally upregulated several genes 
which mark osteochondrocytes, such as Sox9, Acan and Bglap (Figure 5.17). This cluster of 
VSMCs may therefore be involved in arterial calcification. Clusters 0-6 expressed high levels 
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of VSMC contractile markers such as Myh11 and Acta2 (Figure 5.18a). Differential gene 
expression analysis revealed some differences among the contractile clusters of VSMCs. 
Clusters 2, 4 and 6 showed similar transcriptional signatures, with increased expression of 
several genes including Nfkbia and Klf4. Cluster 0 showed a small increase in expression of 
several genes marking phenotypic activation of VSMCs, such as Vcam1 and Mgp (Figure 5.17). 
These and other genes marking VSMC phenotypic switching were also more strongly 
upregulated in the adjacent cluster 7. Overall, there was a degree of overlap in the 
transcriptional signatures of clusters 0-6 (Figure 5.17), and not all of these clusters showed 
large transcriptional differences. As such, identified clusters likely do not represent distinct 
subpopulations of VSMCs and could be merged. Nevertheless, this analysis did reveal 
interesting heterogeneity within contractile VSMCs, with several biologically relevant genes 
identified as differentially expressed in the identified clusters of cells.  
 
I next investigated the similarity of VSMCs showing transcriptional signatures characteristic of 
phenotypic switching in atherosclerotic plaques to the activated healthy S+L+ cells. Cells in 
clusters 7, 8 and 9 all expressed low levels of the cVSMCpos signature (Figure 5.19), which 
positively correlated with the contractile cVSMC network in healthy S+L+ cells (described in 
Chapter 4). At the same time, the overall expression levels of the negatively correlated 
cVSMCneg signature were higher in clusters 7, 8 and 9 than in the contractile clusters 0-6 
(Figure 5.19). This suggested that Ly6a/Sca1-positive VSMCs, as well as other clusters showing 
signatures of phenotypic modulation shared similarities with healthy S+L+ cells, which 
expressed high levels of the cVSMCneg signature.  
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Figure 5.19: Summarised expression levels of the cVSMCpos and cVSMCneg signatures in plaque 
VSMCs.  
t-SNE representations of VSMCs isolated from atherosclerotic arteries are colour-coded for the 
summarised expression levels of the cVSMCpos (left) and cVSMCneg (right) signatures, which were 
originally identified in healthy S+L+ cells. PC1 values positively aligned with the total expression levels 
of cVSMCpos and cVSMCneg genes were used to summarise the overall expression levels (details in 
Methods), with red representing high and blue low expression. The figure is adapted from Dobnikar 
and Taylor et al. 2018. 
 
 
5.2.4 Alternative marker genes of Ly6a/Sca1-expressing VSMCs in models of 
phenotypic switching 
So far in this chapter I have shown that Ly6a/Sca1-positive VSMCs are present in model 
systems of VSMC phenotypic switching and that the transcriptional signatures of Ly6a/Sca1-
positive VSMCs following in vitro culture, carotid ligation injury and atherosclerosis share 
similarities with healthy S+L+ cells, which express high levels of the cVSMCneg signature. SCA1 
protein, however, has no known human orthologue, which presents challenges for identifying 
a similar population of VSMCs in human atherosclerotic plaques. Knowing the wider 
transcriptional signatures of VSMCs undergoing phenotypic switching in mice is valuable for 
investigating potential analogous VSMC subpopulations in atherosclerotic plaques from other 
organisms using transcriptomics approaches. To further facilitate the isolation of the desired 
subpopulations of VSMCs in other organisms I next aimed to identify a set of alternative 
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marker genes of Ly6a/Sca1-positive VSMCs in model systems of VSMC phenotypic switching. 
To investigate which genes would be suitable candidates for alternative markers of Ly6a/Sca1-
positive VSMCs, I used co-expression analysis to identify a set of genes, which showed a similar 
pattern of expression to Ly6a/Sca1. This analysis identified a set of 708 genes as co-expressed 
with Ly6a/Sca1 in VSMCs following carotid ligation injury (adjusted p-value < 0.01, details in 
Methods). For a gene considered to be a suitable alternative marker of Ly6a/Sca1-positive 
VSMCs, it was also required to be upregulated in cluster 2 of the carotid ligation injury dataset, 
which contained Ly6a/Sca1-positive VSMCs. Additionally, I required suitable alternative 
markers of the Ly6a/Sca1-positive VSMCs to be present in the cVSMCneg signature. This 
approach resulted in a set of 17 genes, which shared expression patterns with Ly6a/Sca1 
(Figure 5.20). The majority of these genes were clearly expressed at higher levels in the 
Ly6a/Sca1 cluster 2 post carotid ligation injury (Figure 5.20).  
 
I next checked the expression levels of these genes in VSMCs isolated from atherosclerotic 
plaques of ApoE-/- mice to ensure that potential alternative markers of Ly6a/Sca1-positive 
VSMCs were representative across different model systems of VSMC phenotypic switching. In 
the atherosclerotic plaque dataset Ly6a/Sca1 was expressed in cluster 7 and while the 
majority of the tested genes were expressed at higher levels in this cluster, only Fbln2 and 
Slco2a1 were specific to VSMCs in this cluster. The majority of other genes were also 
upregulated in clusters 8 or 9 (Figure 5.20).  
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Figure 5.20: Identification of alternative markers of Ly6a/Sca1-positive VSMCs.  
Heatmaps showing the expression levels of genes, which were identified as correlated with Ly6a/Sca1 
in the injury dataset, were upregulated in cluster 2 of post injury VSMCs and were part of the 
cVSMCneg signature. The expression levels in the carotid ligation injury (left) and the atherosclerotic 
plaque (right) datasets are colour-coded with darker red representing higer expression. Genes are 
ordered in rows according to the results of hierarchical clustering and cells are grouped by cluster 
membership in columns.  
 
 
Closer examination of Ly6a/Sca1, Fbln2 and Slco2a1 expression patterns showed that these 
genes were generally expressed in the same subpopulations of VSMCs in model systems of 
VSMC phenotypic switching. However, in the carotid ligation injury model, Fbln2 and Slco2a1 
were expressed in a larger proportion of cluster 2 VSMCs than Ly6a/Sca1, while in cultured 
VSMCs Fbln2 marked a larger proportion of cells than both Ly6a/Sca1 and Slco2a1 (Figure 
5.21). There was a tighter overlap in the expression of Ly6a/Sca1, Fbln2 and Slco2a1 within 
atherosclerotic plaques (Figure 5.21). However, a small proportion of VSMCs located in the 
contractile VSMC clusters in all three models of VSMC phenotypic switching also expressed 
Ly6a/Sca1, Fbln2 or Slco2a1. An alternative and targeted approach for isolation of Ly6a/Sca1-
positive VSMCs would therefore require selecting for reduced expression levels of contractile 
markers alongside higher expression of Fbln2 or Slco2a1. Taken together, Fbln2 or Slco2a1 
may be suitable alternative markers of Ly6a/Sca1-positive VSMCs for the investigation and 
isolation of an analogous population of VSMCs. However, further testing of expression and 
specificity at the protein-level is still required. 
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Figure 5.21: Expression levels of Fbln2 and Slco2a1 overlap with Ly6a/Sca1 expression in model 
systems of VSMC phenotypic switching.  
The expression levels of Ly6a/Sca1, Fbln2 and Slco2a1 are visualised after carotid ligation injury (top), 
in the atherosclerotic plaque (middle) and in cultured VSMCs (bottom). Expression levels are colour-
coded on t-SNE or PCA visualisations and pairwise gene expression relationships between of 
Ly6a/Sca1, Fbln2 and Slco2a1 are shown in scatterplots. Histograms show the distributions of cells 
along the x and y axes of shown scatterplots.  
 
5.3 Discussion 
In this chapter I characterised the transcriptional signatures of phenotypically switching 
VSMCs in three model systems of phenotypic switching. The proportion of VSMCs which 
expressed Ly6a/Sca1 was higher in all three model systems of phenotypic switching compared 
with healthy artery walls. Closer examination of the transcriptional signatures of Ly6a/Sca1-
expressing VSMCs following phenotypic switching revealed similarities with SCA1-positive 
VSMCs from healthy arteries, which expressed transcriptional signatures characteristic of 
synthetic VSMCs. Additionally, I identified a set of putative alternative markers of SCA1-
positive VSMCs to facilitate the investigation of a similar population in human atherosclerosis.  
 
5.3.1 VSMC phenotypic switching in culture 
I initially used in vitro culture as a model system of VSMC phenotypic switching, as single-cell 
transcriptomes of cultured VSMCs were publicly available (GSE79436, Adhikari et al. 2015). As 
expected, I observed downregulation of VSMC marker gene expression in cultured VSMCs 
compared with the ex vivo VSMCs we profiled, which is a hallmark of VSMC phenotypic 
switching. Cultured VSMCs also upregulated Ly6a/Sca1 and showed higher expression of the 
cVSMCneg transcriptional signature. In vitro culture is a simple model system, with clear 
differences to the physiological environment, in which VSMC phenotypic switching occurs in 
vivo (Rensen et al. 2007). However, further in vivo work presented in Sections 5.2.2 and 5.2.3 
showed that these findings were replicated in phenotypically switching VSMCs in the carotid 
ligation injury or atherosclerosis mouse models.  
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5.3.2 Induction of VSMC phenotypic switching after carotid ligation injury 
VSMC proliferation and accumulation in the neointima is reproducibly and acutely induced 
following the cessation of blood flow through carotid ligation surgery (Kumar & Lindner 1997). 
Only a small number of VSMCs were previously observed to expand extensively following 
carotid ligation injury, similar to the observations of clonality in the mouse atherosclerotic 
plaque (Chappell et al. 2016). Consistent with in vitro culture, we observed increased 
frequency of Ly6a/Sca1 transcript expression in VSMCs following carotid ligation injury 
compared with healthy arteries. In addition, we confirmed that SCA1 is upregulated in VSMCs 
at the protein level following carotid ligation using flow cytometry. Similarly to cultured 
VSMCs, Ly6a/Sca1-expressing VSMCs following carotid ligation injury also expressed high 
levels of the cVSMCneg signature originally identified in healthy S+L+ cells. 
 
VSMCs showing signs of phenotypic switching expressed lower levels of contractile VSMC 
genes than other profiled cells. Previous studies have reported extensive downregulation of 
VSMC contractile genes following vascular injury (Regan et al. 2000; Herring et al. 2017). 
Herring et al. (2017) reported a significant decrease in VSMC marker gene expression as early 
as 3 days following carotid ligation injury and Regan et al. (2000) observed nearly complete 
downregulation of VSMC contractile genes in the neointima 7 days after vascular wire injury, 
which is the same time point used for scRNA-seq analysis presented in this chapter. I observed 
downregulation of VSMC contractile marker genes in the transcriptomes of VSMCs showing 
characteristics of phenotypic switching, however, the majority of profiled cells did express 
contractile markers, such as Myh11 and Acta2. The discrepancy in observed contractile gene 
expression levels may be due to different models of vascular injury, as well as the fact that the 
entire carotid artery was profiled in our study, and VSMCs expressing contractile genes may 
have originated from the non-remodelled parts of the artery. Herring et al. (2017) also 
investigated transcriptional changes in carotid arteries following carotid ligation and observed 
upregulation of a number of inflammatory cytokines, such as Il6, Il1b and Ccl2. Herring et al. 
(2017) profiled gene expression changes in the entire carotid artery and not specifically in 
VSMCs. Ccl2 was among the upregulated genes in cluster 2 of our dataset, however Il6 and 
Il1b were only expressed very sparsely and at low expression levels. This observation suggests 
that VSMCs partly contribute to the observed upregulation of inflammatory cytokines 
following injury. Additionally, Spp1 was observed to be upregulated after injury (Herring et al. 
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2017), which is consistent with higher expression levels of Spp1 observed among 
phenotypically modulated VSMCs presented in this chapter. 
 
Carotid ligation injury model (Kumar & Lindner 1997) provided a setting for investigation of 
VSMC phenotypic switching in an alternative and more acute environment to the 
atherosclerotic plaque. Interestingly, I observed a lower level of diversity of VSMC phenotypic 
modulation after injury compared with atherosclerosis. The phenotypically switching VSMCs 
in the carotid ligation dataset showed the transcriptional signatures of both the calcifying and 
the Ly6a/Sca1-positive clusters identified in the atherosclerotic plaque. This may be either due 
to environmental differences or due to the shorter timeframe of lesion development, with 7 
days passing from carotid ligation to scRNA-seq analysis in case of injury and 14-18 weeks of 
high-fat diet duration prior to the analysis of VSMCs within atherosclerotic plaques.  
  
5.3.3 VSMCs are phenotypically modulated towards a variety of phenotypes in 
atherosclerosis 
Single-cell transcriptional profiling of lineage-labelled VSMCs from the atherosclerotic plaques 
revealed distinct subpopulations of phenotypically modulated VSMCs, which expressed low 
levels of contractile VSMC marker genes. This finding is in agreement with previous reports of 
VSMC modulation towards a range of different phenotypes, such as macrophage-like cells and 
calcifying cells (Naik et al. 2012; Nguyen et al. 2013; Feil et al. 2014; Shankman et al. 2015; 
Chappell et al. 2016; Jacobsen et al. 2017). In addition, VSMC-derived mesenchymal stem cell-
like cells, characterised by the expression of Ly6a/Sca1 and Eng, have been observed 
previously within atherosclerotic plaques by Shankman et al. (2015). I detected a cluster of 
Ly6a/Sca1-positive VSMCs showing signs of phenotypic switching within atherosclerotic 
plaques, which is in also agreement with a recent report confirming expression of Ly6a/Sca1 
among phenotypically modulated VSMCs within the plaque (Wirka et al. 2019). Eng was, 
however, expressed sparsely in all detected clusters of cells and was not specific to the 
Ly6a/Sca1 cluster in our dataset.  
 
VSMC involvement in arterial calcification through transition to an osteochondrogenic state 
has been established in recent years (Naik et al. 2012; Nguyen et al. 2013; Durham et al. 2018). 
VSMCs transitioning towards a calcifying phenotype were found to be marked by upregulation 
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of Sox9, Spp1 (encodes osteopontin), Bglap (encodes osteocalcin) and Runx2 among others 
(Durham et al. 2018). In agreement with this, I detected a cluster of VSMCs isolated from the 
atherosclerotic plaques, which showed transcriptional signatures characteristic of VSMCs 
involved in vascular calcification, including differential expression of Sox9, Spp1 and Bglap.  
I also observed a cluster of plaque cells expressing transcriptional signatures characteristic of 
macrophages. VSMC-lineage cells expressing macrophage markers have been documented in 
several studies in mice (Feil et al. 2014; Shankman et al. 2015; Chappell et al. 2016; Albarrán-
Juárez et al. 2016). Additionally, in vitro cholesterol loading experiments have suggested that 
VSMCs can upregulate macrophage markers, as well as a selection of other genes 
characteristic of the macrophage phenotype (Rong et al. 2003; Vengrenyuk et al. 2015). 
Macrophage-like cells detected in our study showed extensive transcriptional differences 
compared with contractile VSMC as well as other phenotypically modulated VSMC 
subpopulations. This may suggest that VSMCs are phenotypically modulated towards a 
macrophage state in atherosclerosis, and that transcriptional changes are global rather than 
confined to the the expression of a handful of macrophage markers. All cells included in the 
atherosclerotic plaque datasets were selected for VSMC lineage label expression by FACS, 
however possible contamination from bone-marrow derived macrophages cannot be ruled 
out. Observed macrophage-like cells expressed low levels of Ptprc, which encodes the bone 
marrow-derived cell marker Cd45. However, low expression levels of Ptprc have been 
previously observed in VSMC lineage-labelled cells within the plaque (Albarrán-Juárez et al. 
2016), therefore expression of Ptprc may not necessarily imply contamination. Observed 
macrophage-like cells did express low levels of VSMC markers, such as Myh11 and Acta2, 
however this may be due to background contamination from cell-free mRNA released from 
damaged cells (Young & Behjati 2018). The fact that the majority of profiled VSMCs expressed 
these genes at high levels would make the presence of cell-free Myh11 and Acta2 transcripts 
particularly likely. A method for removing ambient mRNA from droplet-based scRNA-seq 
datasets has been developed (Young & Behjati 2018), however its requirement for prior 
specification of cluster markers could result in incorrect removal of contractile VSMC markers 
from the phenotypically switching populations. Interestingly, VSMC-derived macrophages 
were not captured in a recent study which characterised mouse atherosclerotic plaques using 
scRNA-seq, although low level lipid uptake was observed in plaque VSMCs (Wirka et al. 2019). 
Wirka and colleagues reported that Lgals3 was the only marker typically used to study 
macrophages which was upregulated in phenotypically switching VSMCs. This is in agreement 
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with our data, where I observed higher Lgals3 expression in non-macrophage phenotypically 
switching VSMCs in atherosclerosis and following injury. Overall, it is difficult to draw 
conclusions about the origins of macrophage-like cells observed in this chapter. Further 
studies will be required to reconcile the discrepancies in the literature on whether VSMCs 
transition to a macrophage-like state within the plaque, and if so, what is the extent of such a 
transition. For example, the list of significantly upregulated genes in the macrophage-like 
cluster 9 could be used to inform further immunostaining experiments in the plaque, where 
co-expression of the VSMC lineage label and previously untested cluster 9 markers could be 
investigated.  
 
In our analysis, we included VSMCs isolated from atherosclerotic arteries of mice fed a high-
fat diet for either 14 or 18 weeks. These time points represent an intermediate and advanced 
stage of atherosclerosis in the ApoE-/- mouse model (Nakashima et al. 1994). We did not 
observe large differences between the samples, however, with all of the clusters containing 
cells from both stages. During dissection we observed a large amount of heterogeneity in the 
sizes of atherosclerotic plaques within a single animal as well as between animals, which were 
fed a high fat diet for the same duration. This may explain the fact that significant differences 
were not present between VSMCs isolated from 14 or 18 week stage plaques. We did observe 
some differences in the proportions of VSMCs from each plaque stage present in certain 
clusters. However further replicates at each time point would be required to substantiate 
these observations.  
 
Studies of the clonality of VSMCs within the atherosclerotic plaque have shown that a single 
VSMC is capable of giving rise to the full range of phenotypes VSMCs adopt within 
atherosclerotic plaques (Feil et al. 2014; Chappell et al. 2016; Jacobsen et al. 2017; Misra et 
al. 2018). One of these studies has investigated VSMC localisation within atherosclerotic 
plaques throughout their early development (Misra et al. 2018). Misra and colleagues 
observed that VSMCs first populated the plaque cap, in which they were highly proliferative. 
They suggested that a currently unknown progenitor expressing contractile VSMC markers 
may initially form the cap and later enter the plaque core where VSMCs would be further 
modulated towards other phenotypes. Wirka et al. (2019) however observed that Lum, which 
marked phenotypically switching VSMCs in their study, was expressed in VSMCs located in the 
132 
 
plaque cap, suggesting that VSMCs in the plaque cap may at least in part show characteristics 
of phenotypically modulated VSMCs.  
 
In light of the observations of the clonality of atherosclerotic plaques, the presence of 
phenotypically switched VSMCs in the plaque and rare S+L+ VSMCs in healthy arteries, which 
share aspects of transcriptional signatures with phenotypically switched VSMCs, it is a 
compelling hypothesis that activated S+L+ cells undergo selective expansion in atherosclerosis 
and following injury. At present, there is however no direct evidence to evaluate this 
hypothesis. Further experimental validation with Myh11 and Sca1 dual lineage tracing is 
required to establish whether it is the healthy S+L+ VSMCs that expand after stimulus.  
 
5.3.4 Alternative markers of Ly6a/Sca1-positive VSMCs 
In order to extend the findings from this chapter to the clinically relevant setting of the human 
atherosclerotic plaque, alternative markers of SCA1-positive VSMCs are required, as there is 
no known human orthologue of SCA1. Knowing the wider transcriptional signatures of 
Ly6a/Sca1-positive VSMCs in healthy as well as atherosclerotic arteries may enable 
identification of analogous subpopulations of VSMCs in human in transcriptome-wide studies. 
Transcriptional signatures of phenotypically switching VSMCs in human plaques have recently 
been established and have been broadly matched to mouse plaque VSMCs (Wirka et al. 2019). 
Ly6a/Sca1 was expressed in a subset of phenotypically switching VSMCs both in our dataset 
as well as in the recent study by Wirka and colleagues (2019), where it appeared to show less 
advanced signatures of phenotypic modulation to VSMCs expressing calcifying signatures. 
Ly6a/Sca1-expressing VSMCs may therefore represent an intermediate state along 
phenotypic modulation of VSMCs. Identifying specific alternative markers of Ly6a/Sca1-
positive VSMCs within the plaque may therefore be valuable to study the heterogeneity of 
phenotypically switching VSMCs in human. In this chapter I have identified Fbln2 and Slco2a1 
as putative alternative markers of Ly6a/Sca1-positive VSMCs. These genes were expressed in 
equivalent subpopulations of VSMCs as Ly6a/Sca1 following in vitro culture, carotid ligation 
injury as well as in atherosclerosis. Experimental validation of co-expression with SCA1 at the 
protein level is ongoing in collaboration with A.L. Taylor.  
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5.3.5 Conclusion 
Overall in this chapter I presented evidence for the existence of Ly6a/Sca1-positive VSMCs 
following induction of phenotypic switching in three separate model systems. I observed a 
higher proportion of Ly6a/Sca1-positive VSMCs in all three models of phenotypic switching 
compared with healthy arteries. Phenotypically switching VSMCs showed similar 
transcriptional profiles to healthy S+L+ VSMCs, which expressed high levels of the cVSMCneg 
signature. These findings, as well as the observation that Ly6a/Sca1-positive VSMCs in 
atherosclerosis appear to represent an intermediate state of phenotypic switching, are in 
support of the hypothesis that Ly6a/Sca1-positive VSMCs may be responsible for clonal 
expansion of VSMCs in atherosclerosis and following injury. However, further validation using 
dual Sca1 and Myh11 lineage tracing systems is required to test this hypothesis 
experimentally.  
 
Recent work by Wirka and colleagues (2019) has confirmed our observation of Ly6a/Sca1-
positive VSMCs within the atherosclerotic plaque and additionally identified a population of 
phenotypically modulated VSMCs in human atherosclerotic plaques. To overcome the lack of 
human SCA1 orthologue, I have identified two alternative markers of Ly6a/Sca1-positive 
VSMCs, which may aid in further understanding of VSMC heterogeneity in human plaques. 
Despite the challenges in translating the findings from this chapter to human VSMCs due to 
lack of a SCA1 orthologue, the use of mouse models has been invaluable in this study. Genetic 
VSMC-specific lineage tracing systems, which could not have been used in human, have 
enabled us to identify the transcriptional signatures of phenotypically switching VSMCs, which 
have lost the expression of VSMC marker genes. 
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6 General Discussion 
In this thesis I explored the heterogeneity of VSMCs and their transcriptional profiles in 
disease. I found that VSMCs located in the atherosclerosis-prone AA and atherosclerosis-
resistant DT regions have distinct transcriptional signatures at the single-cell level and 
additionally identified the heterogeneous expression of several disease-relevant genes within 
both vascular beds. I also identified and characterised a rare subset of VSMCs in healthy 
arteries which expressed the progenitor marker SCA1 and showed that these cells express 
transcriptional signatures characteristic of the synthetic state of VSMCs. Examination of the 
VSMC response to in vitro culture and injury suggested that SCA1 upregulation marks the 
process of VSMC phenotypic switching. Furthermore, the transcriptional profiles of 
Ly6a/Sca1-positive VSMCs in atherosclerotic plaques were similar to those of SCA1-positive 
VSMCs detected in healthy arteries. I therefore hypothesise that SCA1-positive VSMCs may be 
the rare subset of cells which undergoes clonal expansion of VSMCs in atherosclerosis, which 
would have clinical implications for specific targeting of clonally expanding VSMCs and earlier 
detection of the disease in the future.  
 
VSMCs were previously proposed to exist on a spectrum of contractile and synthetic states 
(reviewed in Rensen et al. 2007). In line with this hypothesis, I observed diverse VSMC 
transcriptional profiles both in healthy arteries and after response to stimulus. In healthy 
arteries the phenotypic spectrum was heavily biased towards the contractile state, with the 
vast majority of VSMCs expressing the contractile transcriptional signature. S+L+ VSMCs, 
however, showed progressively higher expression levels of transcriptional signatures 
associated with the synthetic state. Following stimulus in the form of vascular injury or 
induction of atherosclerosis, the proportion of VSMCs expressing signatures characteristic of 
phenotypic switching increased, even though the majority of VSMCs in profiled arteries 
retained the expression of contractile VSMC genes. Previous studies have described distinct 
subpopulations of VSMC-derived cells within atherosclerotic plaques (Feil et al. 2014; 
Shankman et al. 2015; Bennett et al. 2016; Durham et al. 2018). However, our data suggested 
that the transcriptional signatures of Ly6a/Sca1-positive VSMCs and calcifying-like VSMCs 
share a degree of similarity. A very recent study by Wirka et al. (2019) observed a continuous 
axis of phenotypic modulation of VSMCs within the plaque, which suggests that there may be 
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a continuity in the transcriptional profiles of phenotypically modulated VSMCs within the 
plaque rather than distinct subpopulations of cells.  
 
The findings presented in this thesis have shed light on the transcriptional signatures of VSMCs 
located within the atherosclerotic plaques. Atherosclerosis is a complex disease and many 
different cell types are involved in plaque formation. scRNA-seq approaches are particularly 
well suited to the exploration of cellular heterogeneity within a complex environment, where 
population-level analysis would obscure the diversity of cells involved. The power of scRNA-
seq for studying the atherosclerotic plaque is illustrated by recent studies of macrophages, 
which have revealed heterogeneity among this population in the plaque (Winkels et al. 2018; 
Cochain et al. 2018). Characterisation of the transcriptional profiles of identified macrophage 
subpopulations also shed light on the putative functions of different macrophage 
subpopulations identified within the plaque (Winkels et al. 2018; Cochain et al. 2018). 
Increased understanding of VSMC and macrophage heterogeneity in atherosclerosis highlights 
that the composition of atherosclerotic plaques may be even more complex than previously 
thought, with not only several cell types involved but there also being significant 
heterogeneity within each cell type. Further studies will be required to understand the role of 
different subpopulations of VSMCs in the plaque and to understand how different 
subpopulations of cells interact with one another. If it is confirmed that the diversity of VSMCs 
in the plaque is generated from SCA1-positive VSMCs, it will be important to understand how 
potential elimination of plaque-accumulating VSMCs would impact disease progression, given 
that VSMCs are currently thought to possess both protective and destabilising properties 
within the plaque (Bennett et al. 2016; Basatemur et al. 2019).  
 
Our study used dissociated tissue for analysis, however recent advances in spatial 
transcriptomics have made high-resolution measurements possible within intact tissue 
samples at transcriptome-wide or near transcriptome-wide coverage (Eng et al. 2019; Vickovic 
et al. 2019). The spatial architecture of the atherosclerotic plaque is disrupted during 
dissociation of tissue to a single-cell suspension, which leads to loss of spatial positioning 
information for individual cells. Availability of spatial information from the atherosclerotic 
plaques would enable a detailed characterisation of plaque architecture and characterisation 
of any subpopulations of cells, which may localise or co-localise in specific areas of the plaque. 
Additionally, applying spatial transcriptomics to healthy arteries may shed light on whether 
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VSMCs showing signs of phenotypic switching in healthy arteries localise in areas of increased 
atherosclerotic risk, such as near branch sites. Another advantage of using spatial 
transcriptomics as a complementary approach to scRNA-seq would be that any artefacts 
induced during tissue dissociation could be eliminated. A recent study observed that 
dissociation of tissue could induce a stress response in cells, which included upregulation of 
several genes identified as heterogeneously expressed in several analyses in this thesis, such 
as Egr1, Nfkbia, Fos and Atf3 (O’flanagan et al. 2019). O’flanagan et al. (2019) further observed 
that the precise effects of dissociation-induced stress response on transcriptional profiles 
varied between different cell types. Since VSMCs were not included in the analysis there is still 
the need to understand the specific effects that the tissue dissociation approach used in our 
study had on the transcriptomes of profiled VSMCs. However, I cannot rule out the possibility 
that some of the observed heterogeneity may have originated from a dissociation-induced 
stress response. Any dissociation-induced gene expression changes may also impact future 
investigations of early transcriptional changes during VSMC phenotypic switching using 
scRNA-seq. Dissociation-induced transcriptional changes would likely be similar to early 
changes induced by in vitro culture, which is a model system for VSMC phenotypic switching. 
Spatial transcriptomics approaches, which would enable investigation of gene expression 
directly in primary tissues, would therefore provide a valuable alternative in such studies.  
 
It is currently not possible to determine whether healthy VSMCs showing signs of phenotypic 
switching in healthy arteries are primed for response to stimulus and subsequently expand, 
or whether phenotypic switching is a homeostatic process, which happens to a lesser extent 
in healthy than stimulated arteries and does not impact on clonal expansion. To validate 
whether SCA1-positive VSMCs in healthy arteries expand in atherosclerosis and after vascular 
injury, dual VSMC/Sca1 lineage tracing systems would be required. A tamoxifen-inducible 
Sca1-Cre tracing approach for tracking SCA1-positive cells has been developed (Vagnozzi et al. 
2018). However, since the Cre approaches used in Myh11-Cre and Sca1-Cre lineage tracing 
systems are not independent, it would not be possible to use a combined Sca1-Cre and 
Myh11-Cre tracing system for such validation. This is because the induction of Cre expression 
under the control of either the Myh11 or Sca1 promoter would in both cases trigger the 
recombination at a Cre-reporter allele. A potential way around this problem would be to 
combine the Sca1-Cre (Vagnozzi et al. 2018) and Myh11-Dre (available from Shanghai Model 
Organisms) mouse lines, where the Cre-loxp and Dre-rox recombination systems would act 
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independently upon tamoxifen induction (Anastassiadis et al. 2009). This approach would 
require characterisation of the specificity and efficiency of the Myh11-Dre system and 
subsequent establishment of a dual Myh11-Dre/Sca1-Cre mouse line. Such a model could be 
used in conjunction with the Ai66 reporter, which requires recombination at both the rox and 
loxp sites to induce expression of the fluorescent reporter (Rosa26-rox-stop-rox-loxp-stop-
loxp-tdTomato) (Madisen et al. 2015).  
 
In order to avoid the extensive crossing required to establish the dual lineage tracing system, 
an alternative approach could be taken to substantiate the hypothesis that SCA1-positive 
VSMCs may expand after stimulus. Independent animals traced through the Myh11-Cre or 
Sca1-Cre systems coupled with fluorescent reporters could be used in conjunction with the 
carotid ligation model, which would not require the establishment of a Sca1-Cre/ApoE-/- 
model. This experiment would involve scRNA-seq profiling of four samples; the entire carotid 
arteries from both Myh11-Cre and Sca1-Cre mice serving as reference points, as well as 
isolated lineage-labelled cells from each of the Myh11-Cre and Sca1-Cre mice. Joint analysis 
of profiled cells could then reveal whether the phenotypically switching VSMC population is 
found within both the Myh11-traced and Sca1-traced samples. However, for unambiguous 
validation, dual lineage tracing experiments would likely be required in the future. 
 
Myh11-Cre used throughout chapters 4 and 5 of this thesis was inserted into the Y 
chromosome (Wirth et al. 2008). A limitation of this work is therefore that only male mice 
were studied. However, there are some differences in the presentation and risk factors of 
atherosclerosis between men and women (Han et al. 2008; Yahagi et al. 2015) and inclusion 
of both sexes is important for reducing the sex bias of research findings and potential future 
clinical implications. Studies have shown that there are widespread gene expression 
differences between female and male mice (Yang et al. 2006) and that sex bias in biomedical 
research may result in poorer clinical outcomes for women (Beery & Zucker 2011). The 
tamoxifen-inducible Myh11-Dre mouse line mentioned above is not linked through the Y 
chromosome, and the use of this model would enable investigation of whether the findings in 
this thesis can be extended to female mice and to generate future findings by investigating 
both sexes. Due to the Y-linked Myh11-Cre, only male mice were also used in the recent study 
by Wirka et al. (2019), which confirmed our observations of a population of VSMCs in healthy 
arteries showing characteristics of phenotypic switching, as well as of Ly6a/Sca1-positive 
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VSMCs with similar transcriptional signatures within atherosclerotic plaques. Wirka and 
colleagues have extended their observations to human VSMCs by jointly analysing their 
transcriptomes with those of mouse VSMCs, which enabled the lineage-traced mouse VSMCs 
to act as a guide in interpreting human atherosclerotic cells. One of the four human 
atherosclerotic samples used by the authors was female, however they have not reported on 
whether the conclusions were supported by each individual sample (Wirka et al. 2019). 
Inclusion of more female samples and a specific comparison between male and female 
samples would have enabled an assessment of whether the findings applied to both sexes. A 
similar strategy of joint data analysis to that employed by Wirka et al (2019) could also be used 
to test the existence of Ly6a/Sca1-positive VSMCs in healthy as well as diseased arteries in 
unlabelled female mice in absence of the Myh11-Dre system in the future.  
 
Advances in scRNA-seq and lineage tracing approaches have enabled investigations of cellular 
heterogeneity and plasticity in many different tissues. Investigations at the single-cell level are 
highlighting the extent of cellular heterogeneity within tissues. It is becoming apparent that 
numerous cell types, which were previously thought to be relatively homogeneous, are in fact 
heterogeneous and are composed of many different subtypes of cells (Zeisel et al. 2015; Villani 
et al. 2017; Chen et al. 2017; Papalexi & Satija 2018; Guo et al. 2019), which is consistent with 
observed heterogeneity in VSMCs. In addition, it is becoming clear that plasticity of resident 
differentiated cells in response to injury is common to many different tissues (Merrell & 
Stanger 2016). De-differentiation of mature cells under such circumstances is thought to have 
the function of tissue repair (Merrell & Stanger 2016). Transitioning of contractile VSMCs to 
the synthetic state can be seen as de-differentiation and the observation of VSMC-lineage cells 
expressing transcriptional signatures associated with synthetic VSMCs in healthy arteries 
suggests that this process may also occur during tissue homeostasis, albeit to a lesser extent.  
 
Overall the findings presented in this thesis highlight that the heterogeneity of VSMCs at the 
single-cell level is a widespread phenomenon, both in healthy arteries as well as in disease. 
Additionally, the transcriptional signatures expressed by VSMCs appear to be dynamic both in 
healthy arteries and following stimulus, suggesting VSMC plasticity may be observed both 
during homeostasis and after injury or in disease. Future investigations will further the 
understanding of the role that the heterogeneity and plasticity of VSMCs play in cardiovascular 
disease. 
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